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Pain is a major symptom of patients with advanced cancer21. Tetrahydrobiopterin 
(BH4) has been found to be a key modulator of cancer pain.23,30 Two enzymes GTP 
cyclohydrolase I (EC 3.5.4.16; GTPCH1) and sepiapterin reductase (EC 1.1.1.153; 
SR) are required for the biosynthesis of BH4.18,19,20,23 This link between BH4 synthesis 
and pain provides a new approach for treating neuropathic and other forms of chronic 
pain24. GTPCH1 and SPR enzymes are drug targets based on active site 
characterization of these two enzymes. Therefore, we wish to develop inhibitors of 
GTPCH1, SPR key enzymes in the synthesis of BH4 that could potentially be targeted 
in the treatment of cancer pain. Our work will be focused on the inhibition of GTPCH1 
by thiopurines.30 8-(alkylthio) guanine and an extensive range of 8-(substituted benzyl 
thio) guanines were synthesised using traditional reactions of purine chemistry in 13-
98% yields. The target compounds are accessible from readily available nucleosides. 
This part of thesis describes research towards the synthesis of amino acids via [1,2]-
Stevens rearrangements of benzylic ammonium ylids and [2,3]-sigmatropic 
rearrangements of allylic heteroatoms. Firstly, [1,2]-Stevens rearrangements using 
camphorsultam as the chiral auxiliary, it was found that yields were improved when 
BTPP, 5 Å molecular serves and DMSO as solvent were used. We have reported 12 
examples of [1,2]-Stevens rearrangement of benzylic ammonium ylids with different 
benzyl substituted (61-89% total yields) as well as three examples of non-coded amino 
acids (32-39%). Finally, we have reported the metal catalysed [2,3]-sigmatropic 
rearrangements of allylic heteroatoms (N,I,S). The investigation was done via using 
diazo attached to a chiral auxiliary (camphorsultam and benzyl oxazolidinone), allyl 
heteroatoms and catalysts (5,10,15,20-Tetrakis(pentafluorophenyl)-21H,23H-
porphyrin iron(III) chloride and rhodium(II) acetate). Reactions of the diazo 
oxazolidinone and the diazo chiral benzyl oxazolidinone worked well with highly 
reactive iron(III) porphyrin catalyst in the presence of the N,N dimethylallylamine and 
gave high yields (70%, 86% respectively), although diastereoselectivity was poor 
(1:1.5). Rhodium(II) acetate catalysed decomposition of the diazoaceyl 
camphorsultam in the presence of the ally iodide and produced high yield (>90%) and 
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1.  Introduction 
In recent years, there has been an increased interest in the synthesis of purine 
compounds for many reasons. One reason is that they act as neurotransmitters and 
hormones. The second is that they often have therapeutic activity. Lastly, they are 
subunits of some molecules, for instance DNA and RNA, which are essential in 
biological processes. Purine compounds have several applications for example as 
inducers of interferon and, for the treatment of virus infection and AIDS. 
1.1 Purine 
In 1899, Emil Fischer synthesized a colourless, crystalline weak base for first time and 
named it purine.1 He synthesised purine from uric acid (1), which was reacted with 
PCl5 to give 2,6,8-trichloropurine (2), and was then converted to 2,6-diiodopurine (3) 
by reaction with HI and PH4+I-. Finally, this compound was reduced with zinc to give 
purine (Scheme 1).1  
 
Scheme 1. Original synthesis of purine from uric acid. 
 
Purine is a heterocyclic compound which contains four nitrogen atoms within a 
skeleton of two fused rings, an imidazole and a pyrimidine as shown in Figure 1.  
 
Figure 1. Purine (imidazole [4, 5-d] pyrimidine) ring. 
 





The imidazole ring of purine can undergo nucleophilic (c) and electrophilic (b) 
reactions whereas the pyrimidine ring only undergoes nucleophilic (d) reactions. This 
is due to the possible prototropic tautomerism as illustrated in Figure 2 (a).2      
  
Figure 2. a) The possible tautomerism of purine. b) Electrophilic reaction on imidazole ring.               
c) Nucleophilic reaction on imidazole ring. d) Nucleophilic reaction on pyrimidine ring. 
1.1.1 Classification of purines 
There are many purine derivatives, which may be classified into three groups 
according to the following descriptions: 2,3 
a) Hydroxy or oxy purines which contain a carbonyl or enol form, such as uric acid, 
xanthine 16 and 17 (Figure 3). 
 
Figure 2. Chemical structure:  Uric acid (16). b) Xanthine (17). 





b) Amino purines: 
These contain an amine group at positions 2-, 6- or 8- of the purine skeleton. 
An example of an amino purine is adenine (18) (Figure 4). 
 
Figure 4. Chemical structure of adenine. 
c) Amino and oxo purines: 
These contain an amino and carbonyl group at positions 2, 6- or 8- of purine, for 
instance guanine (19) (Figure 5). 
 
             Figure 5. Chemical structure of guanine. 
1.1.2 Biochemistry of purines 
As mentioned above, purine derivatives are essential in biological processes because 
they are basic units in the composition of DNA and RNA. In addition, purines are 
cofactors associated with many enzymes and receptors, such as ATP, GTP, GDP, 
GMP, cAMP, ADP, NAD and NADP, which play important roles in the cell cycle.4 To 
explain further, some basic points will be illustrated.  
1.1.2.1 Nucleosides and nucleotides 
A nucleoside is a nitrogenous base, in this case purine compounds, attached to a 
sugar (ribose) but without the phosphate group. A nucleotide consists of a nitrogenous 
base, a sugar (ribose) and one to three phosphate groups, as shown in (Figure 6). 
 
Figure 6. Nucleoside and nucleotide. 
Base= Adenine, Guanine. 
Nucleoside= Ribose + Base 
Nucleotide=Ribose + Base + Phosphate. 
Or Nucleoside + Phosphate. 





To further explain what has been described above, we will use Guanine, which has a 
structure as shown in Figure 5, and as a basis for further explanation about the role of 
purine compounds in biological processes Figure 7.2 
 
Figure 7. Guanine nucleotide. 
1.1.3 Biological activity of purine analogues 
The purine rings have biological importance for example Heteromines were isolated 
from the Chinese climber Heterostemma brownii. These plants are used in Taiwan as 
a folk medicine for the treatment of certain tumors (Figure 8).5  
 
Figure 8. Chemical structure of Heteromines. 
In 1980, Fuhrman has reported that 1-methylguanosine (dordosine, 21), which was 
isolated from marine sponges, reduced heart rate in anesthetized mice by 50% for 






Figure 9. Chemical structure of Dordosine. 





There is a class of plant growth substances (Phytohormones) called cytokinins. One 
of them is zeatin (22), which is isolated from Zea mays. Zeatin in the E configuration 
shows phytohormone activity. Isopentenyl adenine (23) is present as a component 
part of isopentenyl adenosine (24). It has strong antimetabolic and anti-cancer 
activities (Figure 9a).7, 8  
 
Figure 9a. Chemical structures of cytokinins. 
In 1998, Kashman and co-worker found that asmarines (25, 26, 27), which are tricyclic 
purine derivatives, have cyotoxic activity against cell cultures of leukemia, lung 
carcinoma and colon carcinoma (Figure 10).9  
 
Figure 10. Chemical structures of asmarines. 
There are a large number of examples which are represented use of purine and its 
derivatives in biological activity and the table 1 shows some purines derivatives 




























































1.2 Tetrahydrobiopterin (BH4) 
 
Tetrahydrobiopterin (BH4) is essential for different processes and is present in all 
tissues of higher organisms. It has found to play a role as an enzymatic cofactor. BH4 
is the natural cofactor required for the hydroxylation of the aromatic amino acids 
phenylalanine, tyrosine, and tryptophan. 
 





1.2.1 Biosynthesis of BH4 
BH4 is biosynthesized from several pathways, including the de novo synthesis 
pathway, salvage and the recycling pathway. The de novo pathway is a common form 
of BH4 biosynthesis which is carried out by three enzymes as shown in Scheme 2. 
1.2.2 GTP reaction mechanism of de novo pathway 
In the de novo pathway (Scheme 1), three enzymes GTP cyclohydrolase (I) (EC 
3.5.4.16; GTPCH), pyruvoyl tetrahydropterin synthase (EC 4.6.1.10; PTPS), and 
sepiapterin reductase (EC 1.1.1.153; SPR) are required to form BH4. The first part of 
the pathway is carried out by GTP cyclohydrolase (I), which is responsible for the 
hydrolysis of guanosine triphosphate (GTP)(28) to form dihydroneopterin triphosphate 
(29). GTP cyclohydrolase (I) contains a single zinc ion, which present in the active 
site. The mechanism of GTP cyclohydrolase (I) on GTP (28) requires that the zinc ion 
acting as a Lewis acid and polarizing water ligand, thus forming a hydroxyl nucleophile 
which attacks carbon 8 of the GTP substrate, while His-210 can donate a proton and 
acts as a proton donor at position 7 of GTP. This leads to the opening of the imidazole 
ring at carbon 8; in addition, protonation of the ribose ring by His-143 leads to the 
formation of a Schiff base at the N9-glycoside. Next, cleavage of the formamide bond 
occurs, catalyzed by zinc. After that comes the opening of the sugar ring and the 
formation of an Amadori product, (via a re-arrangement of the Schiff base), and the 
creation of an enol tautomerises to the ketone. Finally, condensation (the amino group 
at position 7 attacks the carbonyl, before loss of a molecule of water) which leads to 
the formation of the final product (29) (Scheme 3).17, 18, 19, 20 
 
 







Scheme 2. BH4 pathways. 
 






Scheme 3. GTP reaction mechanism of De novo pathway. 
 





1.3 Tetrahydrobiopterin (BH4) and cancer pain 
From pharmacological viewpoints, chronic pain exists in two forms. One of them is 
inflammatory pain and the second is neuropathic pain. Cancer derived neuropathic 
pain is common in cancer patients as a direct result of the effect of the cancer on 
peripheral nerves (e.g. compression by a tumour), or as a side effect of chemotherapy, 
radiation injury or surgery.  
Lötsch et al have reported21 that most of cancer patients with advanced cancer suffer 
pain. Genetically, the results obtained in their study suggest that the reduction of GTP 
cyclohydrolase 1, which is responsible for the first step of biosynthesis of BH4, leads 
to a decrease in the need for opioid therapy in cancer patients. They analysed data of 













Figure 11. Consequences of the GCH1 ‘‘pain protective” haplotype in 251 patients treated for 
chronic cancer pain in tertiary care (Taken out of ref 21 without permission). 
 
In the same context, Nasser has pointed out22 that GCH1 variants or GCH1 gene 
mutations are the most important factors for decrease pain sensitivity and chronic pain. 
Perhaps this linkage may provide potential new targets for analgesic drugs. 
Tegeder et al. have enhanced and indicated that blocking the increased BH4 
tetrahydrobiopterin synthesis by inhibiting both GCH1 and SPR might reduce 
neuropathic pain. They have demonstrated that 2,4-diamino-6-hydroxypyrimidine 
(DAHP) has shown great promise as GTPCH1 inhibitor.23  





Naylor et al. have stated that the discovered relationship between BH4 and pain 
provide new insights for treating neuropathic pain and that reducing the action of two 
enzymes (GCH1 and SPR) makes them a target for drugs according to the active site 
of two enzymes. Small molecules which include guanine and its derivatives or those 
which have a similar structure to guanine are capable inhibition of GCH1 in high 
efficiency. In other words, these molecules bind to the active site in the enzyme, which 
contains zinc, and inhibits the action of the enzyme (Table 2).24 
Table 2.  































Table 2 shows that both 8-azaguanine and 8-mercaptoguanine are competitive 
inhibitors. They are molecules with similar shape to the substrate (GTP) therefore 
inhibitors and substrate compete to react with the enzyme through active sites. 
Some of the first examples of GTPCH1 inhibitors are 7-deazaguanine derivatives 
which have been prepared using a novel two steps synthesis, starting from 
diaminopyrimidinones and -halooximes to give (46). In the second step 
transoximation (cleavage oxime which reacts with aldehyde) occurs, to give 7-
deazaguanine derivatives in 41-65 % yield (Scheme 4).27 






Scheme 4. Synthesis of 7-deazaguanine derivatives. 
 
The second example of a GTPCH1 inhibitor is diaminohydroxypyrimidine (DAHP) 
which has been reported as a selective inhibitor of GCH1 in the de novo pathway with 
an IC50 in the range of 0.3-1 mM. DAHP has been reported to have a dual activity, 
binding at GTP site/GFRP interaction site at low concentrations but directly inhibiting 
the GTP binding site at high concentrations. DAHP can be prepared from reaction of 
guanidine and ethyl cyanoacetate in the presence of sodium ethoxide (Scheme 5).28 
 
 
Scheme 5. Synthesis of diaminohydroxypyrimidine. 
Firstly, considering the previously mentioned biological activity of purine compounds 
and due to the similarity between the purine skeleton and GTP substrate (see scheme 
2) which is the starting point of BH4 biosynthesis. Secondly, according to many studies 
about cancer pain, tetrahydrobiopterin (BH4) has been found to be a key modulator of 
cancer pain.  Therefore, our attention turned to find out whether the purine compounds 
have activity against or reduce chronic pain which is associated with cancer patients.  
 
 






The aim of this project is therefore to explore the relationship between biosynthesis of 
BH4 and cancer pain and develop inhibitors of GTPCH1, the key enzyme in the 
production of BH4 that could potentially be targeted in the treatment of cancer pain 
and could reduce the need for opioids. In the first stage, efforts will be focused on the 
synthesis of 8-mercaptoguanine derivatives as inhibitors for GTPCH1 enzyme. In 
parallel, pharmaceutical testing (in collaboration with Dr. McHugh at the University of 
Huddersfield) will be carried out. 
2. Organic synthesis of GTPCH1 inhibitors 
2.1 Methodology 
The chemical starting points chosen were guanine (51), 2-amino-4-chloro-6–hydroxy 
pyrimidine (62), 5-amino-1H-imidazol-4-carboxamide hydrochloride (65) and 
guanosine (69). The introduction of sulfur at the 8- position, where the GTPCH1 
enzyme reacts with GTP, of guanine is thought to improve the therapeutic effect and 
block the reaction at this position (Figure 12).29  
 

















2.2 Results and discussion 
2.2.1 Towards 9-methyl-8-mercaptoguanine derivatives 
2.2.1.1 First approach: guanine route (plan A) 
Original efforts were focused on the synthesis of 9-methyl-8-mercaptoguanine (53) 
using guanine (51) as starting material. A retrosynthesis is presented in Scheme 6. 
The key steps of the retrosynthesis are the introduction of a directing group, enabling 
the methylation of the correct nitrogen, and the introduction of sulfur using thiourea. 
Once 9-methyl-8-mercaptoguanine (53) would be obtained, it would serve as the 
starting material for derivatisation. 
 
Scheme 6. General strategy for the synthesis of 54 
Several points have to be considered for the synthesis of 53 when using guanine as 
starting material. These are: 
 Protection of the amino group.  
 The insertion of a methyl group at N9 is essential for successful bromination at 
C-8 in order to facilitate the introduction of a sulfur-function by nucleophilic 
displacement. 
Direct methylation of guanine produces N7, N9 isomeric mixtures that are difficult to 
separate, due to the limited solubility of these compounds in organic solvents. 
Therefore, the selective N9 methylation of guanine is important and this may be 
achieved by using a steric shield at position 6 to give enhancement of N9 methyl. 
The protection of amino group was done as reported by Zou [30]. Three different 
solvents were evaluated (55) as shown in table 3. 






Start material Conditions % yield 
Chemical shifts (in ppm) 
2NAc N9Ac C8-H 
Guanine Ac2O, DMAc, 160 °C, 7 h 79% 2.21 2.81 8.44 
Guanine Ac2O, NMP, 160 °C, 7 h 75% 2.20 2.79 8.44 
Guanine Ac2O, AcOH, 135 °C, 7.5 h 77% 2.18 2.79 8.41 
 
Subsequently, amide group was protected by formation of the N,N-diphenyl carbamate 
(56) in 89% yield. We have assumed that there were many advantages to introduce 
N, N-diphenyl carbamate, one of them was to block the methylation at the N7 position. 
Secondly, to increase solubility of guanine derivatives via increase polarity.30 Next, 
deprotecton of N9 using mixture of EtOH/H2O. N-methylation of 56 was done via 
methyl iodide and NaH as base.  
 
Scheme 7. Proposed preparation of the target compounds via guanine. 
Unfortunately, all attempts to produce single desired N9 methyl guanine product (52a) 
failed. The reaction produced the mixture of N7 and N9 methyl guanine 52a and 52b 





which were difficult to separate using column chromatography especially because 
these compounds are insoluble in organic solvents. It was supposed to carry on with 
bromination C8-H of 52a or 52b by Br2 and AcOH mixture to give (57), thiolation using 
thiourea and the target compounds (54) using sodium hydroxide (0.5M) and haloalkyl 
(Scheme 7). 
2.2.1.2 Second approach: guanine route (plan A) 
Compound (58) obtained from (55) using benzyl bromide (69% yield) and was 
subsequently treated with base in the presence of diphenyl disulfide. However, no 
desired product (59) was observed. Due to the poor solubility of 58, the counter ion 
was switched from bromide (-Br) to tetraphenylborate (-BPh4) using reported 
procedure60 within our group (Scheme 8), nonetheless reaction with diphenyl disulfide 
failed to provide the desired product (59). 
 
Scheme 8. Proposed preparation of the target compounds via guaninium salts (58 and 60).  
2.2.1.3 Pyrimidine route (plan B) 
To solve the problem, which was the production of the mixture of N7 and N9 methyl 
guanine (Scheme 7), we turned to another route (plan B), which was reported by 
Blagg,29 to synthesis N9 methyl guanine (Scheme 9). In plan B, the formation of N9 
methyl guanine was accomplished in 20% yield by introducing the methylamino group 





to pyrimidine ring via SNAr of chloropyrimidine (62) followed by nitrosylation (72% 
yield), reduction and cyclization of the imidazole ring, was performed using a mixture 
of formamide and formic acid.30, 31 
 
Scheme 9. Plan B: Proposed formation of N9-methyl guanine by cyclization of the imidazole ring. 
2.2.1.4 Imidazole route (plan C) 
The yield of N9 methyl guanine (52a) obtained by the previous route was low, therefore 
our attention turned to plan C (Scheme 10), which was reported by Alhede,32 where 
methylation of the N-imidazole ring occurs before formation of the pyrimidine ring. 
Preparation of the potassium salt of 65 in DMF using KOH powder followed by addition 
of iodomethane allowed the introduction of the N-Me substituent in 41% yield. 
Subsequently, It was supposed to carry on with bromination C8-H of 52a by Br2 and 
AcOH mixture and the introduction of sulfur using thiourea to give 53. 
 
 






Scheme 10. Plan C: Proposed formation of N9-methyl guanine via cyclization of the pyrimidine ring. 
Next, the treatment of N1-methyl imidazole (66) with benzoyl isothiocyanate in acetone 
afforded the corresponding thiourea (67), 65% yield. Finally, the cyclization catalysed 
by copper(II) acetate, allowed construction of the pyrimidine ring, and compound (52a) 
was obtained in 76% yield.32  
2.2.1.5 Guanosine route (plan D) 
Other methods to prepare 9-methyl guanine having proved unsatisfying a pathway 
using guanosine (69) was chosen, using to our advantage the regioselective 
benzylation on N7 on guanosine (69). Acid hydrolysis of the sugar ring afforded (70) in 
94% yield, protection of the amino group using acetic anhydride gave (71) in 77% 
yield33 and treatment of N7 benzyl guanine with methyl iodide gave guaninium salt (72) 
in 86% yield. The last in turn, dissolved in DMSO then tBuOK was added as base 
which presumably resulted in the formation of carbanion that was reacted with S-S 
bond and getting the target compounds (Scheme 11). Guaninium salt (72) was reacted 
with the base but the desired product was not observed. 






Scheme 11. Proposed preparation of the target compounds via guaninium salt. 
Attempts to transform guaninium salts (72), (and as previously presented 58 and 60) 
to 9-methyl-8-mercaptoguanine derivatives using base and diphenyl disulfide were 
unsuccessful. After adding the base (tBuOK), the colour changed from colourless to 
yellow. In order to understand the colour change, NMR analysis was performed for the 
reaction mixture which contained the salt (72) and the base (tBuOK). The 1H NMR 
spectrum of the reaction mixture showed the absence of the proton at position 8 (at 
9.6 ppm) in the starting material (72), but no reaction with Ph-S-S-Ph (Figure 13). Mass 
spectrometry also support this observation (Figure13a). Mass spectrometry data 
analysis for guaninium salt (72) [M]+ = 298.1296, while mass spectrometry data 
analysis for the product was [M+H]+ = 298.1292 corresponding to loss of one proton. 
We assumed that either N-H of amide or C8-H was deprotonated. In case C8-H was 































Product + D2O 





2.2.2 Synthesis of 8-mercaptoguanine 
Finally, the target compounds were obtained in four steps using guanosine (69). The 
presence of sugar group at N9 is essential for successful bromination at C8 by NBS 
and DMF as solvent, 34 and compound (73) was obtained in good (66%) yield. Then, 
guanosine bromide (73) underwent nucleophilic substitution with thiourea and after 
acid hydrolysis of the sugar ring by HCl, 8-mercaptoguanine (75) was obtained in 56% 
yield (Scheme 12). 
 
Scheme 12. Preparation of the target compounds via guanosine. 
2.2.3 Synthesis of 8-mercaptoguanine derivatives 
The target compounds, represented by formula (76), were prepared by the reaction of 
compound (75) with several alkyl bromides and chlorides using sodium hydroxide 


























2 h 44 15 
 
76o 98 17 h 31 
2 
 
76b 64 3 h 43 16 
 
76p 44 20 h 44 
3 
 
76c 62 15 h 9 17 
 
76q 13 16 h 7 
4 
 
76d 72 2 h 52 18 
 
76r 58 16 h 28 
5 
 
76e 75 5 h 33 19 
 
76u 58 3 days 48 
6 
 
76f 65 17 h 59 20 
 
76v 73 18 h 41 
7 
 




76w 95 20 h 52 
8 
 
76h 82 4 h 35 22 
 
76x 82 3 days 52 
9 
 
76i 81 6 h 30 23 
 
76y 37 3 days 41 
10 
 
76j 57 6 h 37 24 
 
76z 60 3 days 44 
11 
 




23a  5 h 67 
12 
 




37a 19 h 70 
13 
 
76m 69b 18 h 41 27 
 
76ac 30 1 day - b 
14 
 
76n 98 15 h 31 
a 
Using chloride derivatives. 
b No biological test for this compound. 
 
The difference in the physical and chemical properties of halo compounds led to the 
use of different procedures for the preparation of the target compounds. The sulfur 
atom was substituted successfully with alkyl and benzyl groups bearing a wide range 





of functionalities (ketone, ether, amide, cyano, hydroxyl, ester, ketal). From the 
previous table it is not easy to explain the reason of the high yield and there are no 
obvious trends. Generally, α-bromoacetophenone derivatives (Entry 8, 9, 14 and 15) 
gave good yields and this is due to the benzoyl group (as withdrawing group) 
increasing the electrophilicity of the carbon neighbour. Secondly, bromide derivatives 
gave better than chlorides derivatives (entry 7, 27 and 29) and this is due to the 
bromide (Br−) is good leaving group than chloride (Cl−).   
All 8-mercaptoguanine derivatives 76a-76ab were subjected to biological testing in 
THP-1 monocyte cell line (in vitro) performed using ELISA experiments. Neopterin, 
which is first product in the BH4 pathway, can be used as a marker of GTP 
cyclohydrolase (I) enzyme activity (Scheme 2). Biological experiments were run using 
the Neopterin ELISA kit (total n=9 for stimulated/ stimulated+ DAHP/non-stimulated 
samples and n=6 for all other 26 compounds at 10 μM concentration in stimulation 
media). Neopterin concentrations increased from non-stimulated THP-1 cell lysates of 
2.75 ± 2.19 nM to 64.63 ± 10.77 nM in stimulated THP-1 lysates. 
Figure 14. Data obtained from biological testing. 
Figure 14 presents preliminary data obtained for subjecting compounds 76a-76ab to 
THP-1 monocyte cell line and monitoring the formation of Neopterin. It represents 
Neopterin concentration when the target compounds were subjected, the biological 
method described above were obtained from Dr. Patrick McHugh and Ben Moore at 
the University of Huddersfield. It can be seen that the target compounds have shown 
inhibition activity against the formation of Neopterin which represents the activity of 
GTPCH1 enzyme. The compound (76ab) has showed the best activity against the 
formation of Neopterin which means the reduction of biosynthesis of BH4. 
Compounds number 






Summing up the results, toward the target compounds, the initial attempts were to 
prepare N9 methyl guanine. The latter in turn, was synthesised by three different plans 
(Scheme 14). The problem with the plan (A) was in that the reaction produced a 
mixture of N7/N9 methyl guanine which were difficult to separate them. On the other 
hand, plans (B) and (C), which involved the cyclisation of pyrimidine and imidazole 
rings, took 3 and 4 steps to prepare N9 methyl guanine which additionally will take 3 
steps to produce the target compounds. Finally, instead of use N9 methyl guanine, our 









In conclusion, a library of 8-mercaptoguanine derivatives (76a-76ab) were 
successfully synthesised in four-steps using traditional purine chemistry reactions in 
moderate to high yields (13-98%). The target compounds are accessible from readily 











Towards amino acids: asymmetric [1,2]-Stevens 
rearrangements and [2,3]-sigmatropic rearrangements 
















Our group has been interested in [1,2]-Stevens rearrangement of benzyl ammonium 
and [2,3]-sigmatropic rearrangement for many reasons, firstly that it is a good strategy 
for construction of carbon-carbon bonds, quickly converting accessible C-N bonds into 
a new C-C bonds. For example, the rearrangement of benzyl ammonium salts might 
be an efficient way to generate α-benzylated chiral amino acid derivatives, by using 
chiral auxiliaries such as camphorsultam (Scheme 15). In the case of allyl onium ylids 
(Scheme 16), the [2,3]-sigmatropic rearrangement affording α-allylated chiral amino 
acid in which the double bond could be converted into many other functional groups. 
Moreover, the presence of the dialkyl phenyl alanine skeleton in many natural 
bioactive cyclopeptides such as Sanjoinine and Lasiodine which are isolated from 


















Figure 16. (a) Structure of Sanjoinine. (b) Structure of Lasiodine. 




4.1 Amino acids 
Amino acids are a class of organic compounds, which contain carboxyl and amine 
group and a side chain, which is specific to each amino acid (Figure 17). 
 
Figure 17. 
Amino acids can be classified according to the position of the amino group, which may 
be attached to carbon alpha- (α-), beta- (β-) or gamma- (γ-) to the carboxylic acid 
(Figure 18).  About 700 amino acids are known in nature and some of them exist in 
free form or bound into large molecules. Although, there are so many amino acids, 
only 20 appear in the genetic code (proteinogenic) and under control of genes for 
synthesis of proteins in human body.36  
 
Figure 18 
4.1.1 Examples of -amino acids 
Shown below the chemical structures and names for 20 coded amino acids 
(proteinogenic). Except for glycine (93), all amino acids have at least one asymmetric 
carbon, which leads to the presence of amino acids in two isomeric forms, because of 
the possibility of forming two different enantiomers (stereoisomers) around the central 
carbon atom. In addition, all amino acids have a primary amino group (except for 
proline, 108) and a carboxylic acid group attached to -carbon atom (Figure 19). 






4.1.2 Peptide linkage 
As mentioned earlier, proteins are built by amino acids, which are linked together. The 
carboxylic acid group of one amino acid is linked to the basic amino group of another 
with elimination of water (Scheme 20).37  
 
Scheme 17 
4.1.3 The synthesis of amino acids 
There is a lot of interest in the synthesis of coded and non-coded amino acids because 
of their importance in biosynthesis and their medicinal properties. In the past, 
synthesis of amino acids produced amino acids as racemic mixture. There are many 




methods for synthesis of -amino acids. One of them is amination, in which the amino 
group is introduced into -bromocarboxylic acids (114), as illustrated in scheme 18.38  
 
Scheme 18 
4.1.3.1 Gabriel synthesis 
Traditionally, Gabriel synthesis of -amino acid begins with potassium phthalimide 
(116), which is the source of the amino group and serves as nucleophile, and diethyl 
bromomalonate (117). The phthalimide substituted malonic ester 118 has an acidic 
hydrogen, (activated by two ester groups), this compound can be deprotonated and 
reacted in nucleophilic substitution (SN2) fashion with electrophiles to install the side 
chain of the amino acid. Finally, base hydrolysis of the phthalimide derivatives (119) 
followed by acid catalysed decarboxylation, produces an amino acid (Scheme 19). 
 
Scheme 19 
4.1.3.2 Strecker synthesis  
By this method, amino acids are produced from an aldehyde (120), which is reacted 
with ammonium chloride (the amine precursor) in the presence of potassium cyanide 
(the carboxyl precursor) to form -aminonitrile (121) which can be subsequently, 
hydrolysed to an amino acid (Scheme 20).39 






Unfortunately, using Strecker synthesis in this manner, only gives a racemic mixture 
of amino acids. Therefore, there has been extensive attention developed towards an 
asymmetric Strecker reaction that would be used to produce optically pure non-
proteinogenic amino acids. There are several methods in this context, for instance, 
enantioselective Strecker reaction using organocatalysts and metal catalysts (Scheme 
21).39  
 
Scheme 21  
In 2012, Woong Lee and co-worker have reported an organcatalytic asymmetric 
Strecker reactions using oligoethylene glycol (1a) as catalyst and KCN. They were 
able to transform various -amido sulphone substrates (128) (alkyl, aryl and 
heteroaryl) into optically active amino nitriles, which were hydrolysed to afford amino 
acids, with enantionselectivities and excellent yields (Scheme 22).40 





Scheme 22  
In 2011, Li and co-workers found that chiral N-phosphonylimines (131) were good 
electrophiles for reaction with diethylaluminium cyanide. The reaction gives chiral -
aminonitriles (132) in excellent yield (94-98 %) and diastereoselectivity (95:5 to > 99:1 
d.r.). The N-phosphonyl group was cleaved by HCl in methanol, which was followed 
by treatment with Boc anhydride to give Boc-- aminonitrile (133) that can be 
hydrolysed to amino acids (Scheme 21).41  
 
Scheme 21  
The limited benefit of Strecker reaction might be due to many factors. The most 
important factor is the use of hazardous cyanide sources in high stoichiometric 
amounts, which reduce application to large-scale. 
4.1.3.3 Total synthesis of L-azatyrosine 
 
Figure 20 
As an example of -amino acids, L-azatyrosine (Figure 20) was obtained from a 
fermentation broth of Streptomyces chibanesis, which was isolated from soil in Japan. 




It is an antibiotic which has showed anti-cancer activity. Many total syntheses of L-
azatyrosine have been achieved since its discovery.  
In 1994, Schow and co-workers have reported a distereoselective synthesis of L-
azatyrosine (134). They started with the silyl protection of 5-hydroxy-2-methyl pyridine 
(135), which is commercially available. Subsequent bromination of the methyl group 
using NBS followed by SN2 displacement of the bromide by the enolate of chiral glycine 
derivative 13842 produced azatyrosine precursor 139. Next, deprotection of silyl group 
using TBAF and hydrogenation over Pearlman’s catalyst to remove diphenylethylene 
and gave mixture of azatyrosine (141) and side product 142. To solve this problem, 
the mixture was treated with HCl and continued hydrogenation in water over 5 % Pd/C 
to yield azatyrosine.HCl (Scheme 22).43  
 
Scheme 22 




One year later, Westwell published a total synthesis of L-azatyrosine in three steps, 
starting with 3-hydroxypyridine (143) which was converted to 2-iodo-5-hydroxypyridine 
(144) using NaI, NaOCl, NaOH. The next step was a Negishi coupling with organozinc 
14644 followed by deprotection to give the desired amino acid 134 (Scheme 23).45 
 
Scheme 23 
Myers et al. described a practical synthesis of L-azatyrosine and showed that it can 
be prepared from pseudoephedrine glycinamide (149), (which is produced from 
pseudo ephedrine (148) using base and LiCl in the presence of GlyOMe).  
 
Scheme 24 




Alkylation of 149 with iodo derivative 150 gave protected L-azatyrosine 151, which 
was deprodected using NaOH affording sulfonate 152 (Scheme 24).46 
4.2 Rearrangement reaction 
As mentioned previously, our group is interested in the [1,2]-Stevens rearrangement 
and the [2,3]-sigmatropic rearrangement of ammonium ylids (often referred to as the 
[2,3]-Stevens rearrangement) because they offer an efficient way to generate α- chiral 
amino acid therefore our attention will focus on them. 
A rearrangement reaction is a type reaction where bonds are changed of order to 
produce a structural isomer. 
4.2.1 Pericyclic reactions  
Pericyclic reactions are rearrangement reactions where the order of bonds change. 
This reaction includes mechanism through cyclic geometry of the transition state 
where flow of electrons occurs through a cyclic transition state and according to 
Woodward–Hoffmann rules, which can predict the stereochemical outcome of 
pericyclic reactions. They can be classified into following four categories: 
Sigmatropic rearrangements, cycloaddition, electrocyclic reactions and group transfer 
reactions    
4.2.2 Sigmatropic rearrangements 
Sigmatropic rearrangement is a type of pericyclic reaction where the number of  and 
π bonds in the product and the starting material is unchanged and a σ-bond migrates 
with rearrangement of the π-framework. The Woodward–Hoffmann notation describe 
sigmatropic rearrangement by an order term [i,j] which means -bond moves to one 
or more π bonds for example [1,3]-shift which means -bond moves from position 1 to 
position 3. There are many types of this rearrangement, includes [1,2]- and [2,3]-
rearrangements (Scheme 25). 
 
Scheme 25 




4.2.2.1 [1,2]-Stevens rearrangement  
In 1928, the [1,2]-rearrangement of benzyl ammonium salts was first reported by T. S. 
Stevens who observed the 1,2-shift of quaternary ammonium salt while attempting 
amine protection. Ammonium salt 155 was converted to 1-benzoyl-2-




A few years later, Stevens reported an analogous reaction with sulfonium salt 157 and 
sodium methoxide as base to get the corresponding sulfide 158 (Scheme 27).                                                                
 
Scheme 27 
4.2.2.1.1 [1,2]-Stevens rearrangement mechanism  
To produce [1,2]-Stevens rearrangement products, ammonium salts must be prepared 
first. Then, addition of base allows for deprotonation of the most acidic proton and 
forms the ammonium ylides (160). As the σ*-orbitals of C-N bond have little 
stabilization by the negative charge adjacent to the onium centre, ammonium ylides 









To explain the [1,2]-Stevens rearrangement mechanism, we will use a chiral auxiliary 




There are two proposed mechanisms for the [1,2]-Stevens rearrangement, whether 
the reaction proceeds via an ion-pair or a radical-pair. A number of views and 
evidence48 support the [1,2]-shift occurs through radical mechanism which includes 
homolytic cleavage of C-N bond to stable carbon a radical and forming a radical pair 
that is held tightly together by a solvent cage. Next, rapid recombination of a radical 
pair to provide the Stevens [1,2]-shift products. Stereoselectivity should be considered 
when a radical pair recombine (Scheme 30).49  
 
Scheme 30 




In 1975, Ollis and co-workers reported the influence of solvent and reaction 
temperature on the stereoselectivity and intramolecularity of the Stevens [1,2] 
rearrangement. They investigated the stereoselectivity using different solvents and 
temperature. The results led to the following conclusion: firstly, the stereoselectivity 
and intramolecularity of the Stevens [1,2] rearrangement decreases when the solvent 
used has low viscosity; secondly, at high temperature, intramolecularity of the Stevens 
[1,2] rearrangement decreases. These results seem to indicate that the high viscosity 
of the solvent favours the solvent cage effect.50  
4.2.2.1.2 Previous work 
In 1952, Stevens reported the [1,2]-rearrangement of benzyl fluorenyl dimethyl 
ammonium salt (166) in the presence of base to give 9-benzyl-9-dimethylamine 




In the same context and using cyclic ammonium salts, West and coworkers obtained 
chirality transfer from heteroatom to carbon. They used ammonium salts of proline 
(169), which was treated with base to yield [1,2] or [2,3]-rearrangement depending on 
R group attached to nitrogen. The products were obtained in 73 and 95% yield and 
good enantioselectivity (Scheme 32).52   
 
Scheme 32 




Diastereoselectivity of [1,2]-shift of cyclic ammonium salts reaction was low (3:1), 
which was due to the rate of the diffusion was competitive with the rate of 
recombination (Scheme 33).52 
 
Scheme 33 
Tayama investigated [1,2]- rearrangement of proline ammonium salt (175), which was 
treated with CsOH in 1,2-dichloroethane as solvent to form the desired products with 
high enantiopurities and high yield (Scheme 34).53 
 
Scheme 34 
The [1,2]- rearrangement of proline derivatives can be promoted by Lewis acids. 
Treatment of N-benzyl proline amide (177) with BBr3 produces an intermediate where 
BBr3 coordinates to the oxygen and nitrogen on the same side (cis). Subsequent 
deprotonation with Et3N, homolytic cleavage of the C-N bond, recombination of 
radicals, and finally hydrolysis gives the desired product (178) in excellent yield and 
enantioselectivities (Scheme 35).54     
 
Scheme 35 




Tomooka and co-workers achieved the first example of [1,2]-Stevens rearrangement 
using D-glucose-derived lithium alkoxide as a chiral promoter. The reactions were 
carried out in the presence of chiral alkoxides at 0 °C to room temperature to give 
enantiomerically enriched products (4-61 % ee) (Scheme 36).55 
 
Scheme 36 
4.2.2.1.3 Synthetic applications of the Stevens rearrangement of 
ammonium ylides 
Towards the synthesis of functionalized isopavines, which are morphinomimetics, 
Hanessian has reported highly distereoselective intermolecular [1,2]-rearrangement of 
ammonium salt (182) (Scheme 37). The salt 182 was prepared from amine 181 with 
methyl iodide then subsequently it was reacted in basic conditions to form desired 
[1,2]-product 183.  
 
Scheme 37 
Hanessian proposed two possible pathways as resulting from deprotonation at two 
different benzylic positions (Scheme 38). Pathway a (giving 184) is a favoured over 
pathway b (giving 187) due to 1,2 allylic strain.56  






4.2.2.1.4 Previous work in the Sweeney group 
The asymmetric [1,2]-Stevens rearrangement of N-benzylic ammonium salts has been 
of prime interest in the Sweeney group. Initial investigation from the Sweeney group 
was conducted by Neil Garrido, who tested [1,2]-Stevens rearrangement using the 









The stereochemistry of the major diastereoisomer, which was (2R), was confirmed by 
X-ray crystallography (Figure 21). An X-ray (crystal) structure of the camphorsultam 
ammonium salt 192 was also obtained (Figure 22).58   




The crystallographic data (Figure 21) suggested that the carbonyl C=O double bond 
is anti-parallel to the nitrogen-sulfonamide bond and is vertical to N,N dimethyl amine 
group in the product, so as to minimize dipole interactions. An ammonium salt 189 did 
not fully dissolve in DME therefore Garrido changed the base to LiHDMS and used 
DMF as solvent (Scheme 40). He reported 11 examples using different substituents 









Entry R 2R (%)a 2S (%)a 
1 4-OMe 6 - 
2 4-F 8 4 
3 4-CF3 34 6 
4 4-NO2 43 - 
5 3-OMe 8 - 
6 2-Me 9 - 
7 4-Me 13 - 
8 2-NO2 44 - 
9 3-NO2 9 - 
10 3-F 6 - 
11 3-CF3 25 - 
                         a Isolated yield. 
The results showed that the presence of electron withdrawing groups (CF3, NO2) on 
the aromatic ring gave best results (entries 3, 4, 8, 11), albeit low yields where 
obtained. In addition, these experiments showed that the cleavage of the chiral 
auxiliary was a competitive side reaction. To solve this problem, they continued to 














Entry Xc Yield (%) d.r (R):(S) Cleaved Xc 
1 
 
64 3:1 33 
2 
 
25 nd 63 
3 
 
60 1:1 traces 
4 
 
51 1:2 traces 
5 
 
60 9:1 6 
 
From table above, it is clear that camphorsultam gave a good yield in rearrangement, 
whereas oxazolidinone gave low yield with maximal auxiliary cleavage. Menthol and 
phenyl menthol showed only a trace of cleavage product with decreased stereocontrol. 
Camphene-derived auxiliary (entry 5) gave the best selectivity (9:1 d.r.) with minimal 
auxiliary cleavage (6%) and good yield (60%). Therefore, camphorsultam and 
camphene-derived as a chiral auxiliary were used for further investigation. Our group 
moved to test a number of bases, which were applied to camphene-derived 
ammonium salt (Scheme 42 and Table 7).59,60  







Entry Base eq. Yield (%) d.r (R):(S) Cleaved Xc 
1 LiHMDS 1.05 60 9:1 6 
2 BTPP 1.05 38 19:1 13 
3 BTPP 2.00 66 8:1 traces 
4 BTPP 2.00 44 5:1 10 
5 BTPP 2.00 22 10:1 22 
6 BTPP 1.75 64 12:1 36 
7 P2-tBu 1.05 21 2:1 Traces 
8 P2-tBu 2.00 0 n/a 39 
 
The table lists four types of bases with different number of equivalents. Overall, it can 
be seen that the best results obtained when BTPP is used (highest yield 66% entry 3, 
8:1 d.r.), however, the reaction yield dropped (Entry 7, 8) when stronger phosphazene 
bases (Figure 23) were used.  
 
Figure 23. Phosphazene bases. 




Further studies were conducted to explain the mechanism behind the cleavage of 
chiral auxiliary. They used optimised conditions with camphorsultam N-trimethyl 
ammonium salt 201, which is unstable and yielded cleaved camphorsultam in good 





The reaction in scheme 43 allowed to us to suggest two possible mechanisms for the 
cleavage of the camphorsultam unit through anionic or hydrolysis cleavage (Figure 
24). If there is a trace of water in the reaction mixture as well as base, hydroxide anions 
could be produced that lead to cleavage camphorsultam.59,60 
In order to assess the hypothesis of hydroxide mediated cleavage of the auxiliary 
several desiccants were used in the reaction of the p-nitro camphorsultam ammonium 
salt (203) as shown in (Scheme 44 and Table 8).59 
 
Scheme 44 





Desiccants Yield (%) d.r (R):(S) Cleaved Xc 
- 41 3:1 22 
3 Å MS 50 5:1 8 
4 Å MS 53 4:1 5 
5 Å MS 65 5.5:1 10 
Na2SO4 55 4:1 12 
CuSO4 0 n/a 71 
 
The results showed decrease of the camphorsultam cleavage and increase in yield in 
most cases (except when CuSO4 was used). It can be noted that 5 Å molecular sieves 
gave the best result with 65% yield and 5.5:1 ratio of diastereoisomers. It is worth 
noting that copper sulfate, which is powerful desiccant, did not give any of the desired 
products. This may be because it acts as a Lewis acid and thus favours the cleavage 
of camphorsultam.    
4.2.1.2 [2,3]-Sigmatropic rearrangement  
The [2,3]-sigmatropic rearrangement is a type of sigmatropic rearrangement and can 
be categorized into two types, neutral and anionic (Scheme 45). Moreover, the scaffold 
always contains at least one heteroatom (N, O, S).  
 
Scheme 45 
The [2,3]-sigmatropic rearrangement is an important reaction in organic synthesis 
because it can form carbon-carbon bonds diastero- and enantioselectively. Most 
stereoselective [2,3]-rearrangements involve the presence of either a stereocentre 
within the starting material, chiral catalysts, chiral ligands or chiral auxiliaries. The most 




widely reported [2,3]-sigmatropic rearrangements are either base catalysed or metal 
catalysed.61   
In the 1960s, Stevens discovered the [2,3]-sigmatropic rearrangement of allyl 
ammonium salts (allylic analogues to the [1,2]-Stevens rearrangement of benzyl 
ammonium salts); this rearrangement will be referred to as the [2,3]-Stevens 
rearrangement in the following parts of the thesis (Scheme 46).62 
 
Scheme 46 
When he warmed cinnamyl (R = Ph) ammonium salt with NaOH and he observed the 
production of a mixture of [1,2] and [2,3]-rearrangement product, while the crotyl 
analogue (R=Me) gave only [2,3]-rearrangement. Years later, Ollis and Rautenstrauch 
examined the reaction and showed that the [2,3]-rearrangement dominates at low 
temperature.63,64 
4.2.1.2.1 Generation of allylic onium ylides  
There are two important strategies to form onium ylides. One of them is alkylation of 
the heteroatom using allyl halides followed deprotonation by base (Scheme 47). On 
the other hand, an alternative approach that shows a great promise is trapping metal 
carbenoids will allylic nucleophiles (Scheme 48). However, the last strategy can 
sometime be associated with cyclopropanation issues.61 
 
Scheme 47. Onium ylides from quaternary salts 





Scheme 48. Onium ylides from metal carbenoids 
4.2.1.2.2 [2,3]-Rearrangement mechanism 
To explain the mechanism, ammonium ylides will be used as an example. The reaction 
mechanism occurs through a six-electron and five-membered transition state. The 
process involves breaking of heteroatom-carbon σ bond and formation of a new 
carbon-carbon σ bond. In addition, new stereocentres (at least one) are generated 





From a molecular orbitals viewpoint, the rearrangement can be explained through 
overlap between the HOMO of the allyl anion and the LUMO of carbon-nitrogen double 
bond (or opposite). The maximized overlap can be obtained when bonds are parallel 
as shown in the transition state structure (Figure 25).61,65,66   
4.2.1.2.3 Diastereoselectivity in the rearrangement 
As mentioned earlier, in [2,3]-rearrangements new stereocentres can be formed (at 
least one). In the case of two stereocentres, the formation and stereoselectivity of the 




two new stereocentres (syn and anti) is determined by the conformation of the 
transition state (Exo-TS and Endo-TS), R group on alkene and geometric isomerism 




4.2.1.2.4 Stereochemistry of the newly formed double bond 
Generally, [2,3]-rearrangements of allyl salts with substituents at the vinyl position 
occur to give (E)- selectivity for the new formed double bond (Scheme 51). From the 
five-membered transition state, one can observe that the pseudo-equatorial 
orientation is preferred to the pseudo-axial orientation to minimise 1,3-allylic strain 
which is the strain energy arises from interaction between a substituent on one end of 
an alkene with an allylic substituent.61  






4.2.1.2.5 Base-mediated [2,3]-rearrangement 
Coldham et al. developed a one-pot procedure using K2CO3, DBU and DMF, where 
N-alkylation of N-allyl -amino esters was followed by [2,3]-rearrangement (Scheme 




Entry R1 R2 R3X Yield 
(%) 
Ratio (anti:syn) 
(anti:syn) 1 H  Me MeI 48 - 
2 Me  Me MeI 53 60:40 
3 H Me PhCH2Br 52 - 
4 Me Me PhCH2Br 65 60:40 
5 H PhCH2Br MeI 51 - 
6 Me PhCH2Br MeI 63 60:40 
 




Another example of [2,3]-rearrangement which is catalysed by base, is the 
rearrangement of 1,2,5,6-tetrahydropyrdinium salt in the presence of NaOH. The 
reaction afforded highly syn-selective rearrangement and with concomitant formation 
of the pyrrolidine ring. Ollis suggested that this selectivity occurs due to interaction 




In the same context, Kaiser and co-worker have reported the stereospecific alkylation 
of a penicillin at C6 using [2,3]-rearrangement (Scheme 54). The reaction was carried 
out with 1.5 eq of sodium hydride in DMF-benzene (2:5) at room temperature for 30 
min, affording 248 in 75 % yield, as the single rearrangement product.69 
   
Scheme 54 
4.2.1.2.6 Metal-catalysed rearrangements 
An alternative methodology to base-mediated [2,3]-rearrangement has been reported, 
where a metal catalyst promotes the generation of onium ylides which in turn undergo 
rapid [2,3]-rearrangement. Rhodium(II) and copper(II) are common catalysts used to 
generate onium ylides. Firstly, the metal catalyst reacts with the carbene precursor (in 
this case diazo compound 249), to form metal carbenoid 252, which is a reactive 
electrophilic carbene complex (Scheme 55). 






Subsequently, the reactive electrophilic carbenoid (252 or 253) is reacted with a 
nucleophile (for example hetero-allyl nuclephiles) leading to regeneration of the metal 
catalyst as well as formation of onium ylid 256 which undergoes the [2,3]-
rearrangement (Scheme 56). 
 
Scheme 56 
As reported by Doyle et al., rhodium and copper catalysts catalyse the decomposition 
of ethyl diazoacetate in the presence of methyl allyl sulfide, allylic tertiary amines and 
allyl halides to give the [2,3]-rearrangement and cyclopropanation products (Schemes 
57 and 58, Tables 10 and 11).70 







X R1 R2 Catalyst (mol %) Yield (%) 
((9(%)(%) SMe H  H Rh2(CO)16 (0.5) 96 
SMe H  H Rh2(OAc)4 (0.5) 91 
NMe2 H H Rh2(CO)16 (0.5) 82 
NMe2 H H Rh2(OAc)4 (1.0) 60 
NMe2 CH3 CH3 Rh2(CO)16 (0.4) 49 
NMe2 CH3 CH3 Rh2(OAc)4 (1.0) 37 
NMe2 CH3 H Rh2(CO)16 (0.2) 36 (77:23)a 
NMe2 CH3 H Rh2(OAc)4 (0.5) 79 (75:25)a 
NMe2 C6H5 H Rh2(CO)16 (0.5) 78 (72:28)a 
NMe2 C6H5 H Rh2(OAc)4 (0.5) 59 (75:25)a 




Allyl halide Catalyst (0.5 mol %)  
Yield (%)a 
of 260 
Ratio of 260/262  
trans/cis b 
CH2=CHCH2I Rh2(CO)16  89 100:0 
CH2=CHCH2I Rh2(OAc)4  98 100:0 
CH2=CHCH2Br Rh2(CO)16  41 27:73 (1.13) 
CH2=CHCH2Br Rh2(OAc)4  76 28:72 (1.12) 
CH2=CHCH2Cl Rh2(CO)16  26 7:93 (1.22) 
CH2=CHCH2Cl Rh2(OAc)4  95 5:95 (1.16) 
                        a Isolated product yield. 
                        b Ratio of cyclopropane geometrical isomers 
 




From the results obtained by Doyle, it can be observed that cyclopropanation is a side 
reaction when allyl bromide and chloride are used. Allyl iodide and methyl allyl sulfide 
are similar in ability to react with carbenoid intermediates. In like manner, Gross 
reported the unique, fast and efficient [2,3]-rearrangement of dimethyl allylamine and 
ethyl diazoacetate (EDA) catalysed by iron(III) porphyrins affording products in 
excellent yields (Scheme 59 and Table 12). In addition to allylamine, this reaction 




X Catalyst Time Yield (%) 
NMe2 A 1 min 96a 
NMe2 B 24 h 92a 
SMe A 1 h 91b 
[a] Catalyst/EDA/substrate 1:500:500. 
[b] Catalyst/EDA/substrate 1:100:100.  
All of these reactions reported by Gross were faster and used lower catalyst loadings 
than other metal catalysed [2,3]-rearrangements. 
Another example of carbenoid mediated [2,3]-rearrangements, complementary to the 
work of Kaiser on penicillin salts (Scheme 54), was reported by Giddings, who 
investigated intermolecular [2,3]-rearrangement of diazopenicilliin (Scheme 60). 
Copper(II) acetylacetonate (Cu(acac)2) catalysed formation of the ylide using allylic 
sulphides and selenides followed by [2,3]-rearrangement afforded products in good 
yields.72   







X dr (ratio) Yield (%) 
PhS 87:13 65 
MeS 80:20 60 
PhSe 50:50 64 
 
4.2.1.2.7 Previous work in the Sweeney group 
Following Stevenson’s work,76,77 who reported that the reaction of didehydro- 
piperidinium salt 282 with base in an alcohol solvent gave elimination product 284 
rather than [2,3] rearrangement (Scheme 61), our group optimised the reaction to 
favour [2,3] rearrangement over elimination processes. Reaction optimisation was 




















THF NaH Reflux 30 0 
THF BuLi -78 °C to reflux 46 0 
THF DBU Reflux 73 0 
DME NaH Reflux 57 0 
DME DBU Reflux 79 0 
 
One year later, Sweeney’s group continued to investigate the [2,3]-rearrangement 
(metal-catalysed rearrangements) of tetrahydropyridine derivatives 289 with diazo 
malonate compounds 288 in the presence of copper catalysts and reported many 
examples proceeding in high yields, using different substituents (R1 and R2) on N-
methyl tetrahydropyridine (Scheme 63).79 In addition, they examined the reaction 





Highly diastereo-enantioselective [2,3]-rearrangements of simple allylic ammonium 
ylides in excellent yields were reported by the Sweeney group. The reaction catalysed 
by NaH produces the [2,3] rearrangement of allylic sultam ammonium salts using DME 
as solvent. A range of substituents have been used to generate allyl glycine derivatives 
294 (Scheme 64 and Table 15).81 
 
Scheme 64 





R1 R2 R3 R4 Yield (%) Anti:syn dr (R:S) 
H H Me Me 99 - 2:98 
H H Me Allyl 99 - 97:3 
H H Allyl allyl 86 - 97:3 
H H Bn allyl 80 - >99:1 
Me H Me Me 86 >99:1 96:4 
Me Me Me Me 70 - 97:3 
MeO2C H Me Me 64 >99:1 >99:1 
 
The previous method can be used to prepare (R)-allyl glycine simply using triallyl 
ammonium salt 295 (Scheme 65).81  
 
Scheme 65 
As reported by Doyle who examined the reaction of dimethyl allyl amine with ethyl 
diazoacetate, our group proposed to further study this reaction using a chiral diazo 
camphorsultam. The reaction was optimised using different solvents, catalysts, 













Entry Solvent Catalyst °C Addition rate (ml h-1) Yield 
(%) 
d.r. (2S:2R) 
1 PhMe Cu(acac)2 90 0.397 44 84:16 
2 DCE Cu(acac)2 reflux 0.397 <5 100:0 
3 DME Cu(acac)2 90 0.397 <5 100:0 
4 PhMe Cu(acac)2 90 120 38 76:24 
5 PhMe Cu(OTF)2 90 0.397 57 88:12 
6 PhMe Cu(OTF)2 90 120 52 73:27 
7 PhMe Rh2(OAc)4 90 0.397 58 84:16 
8 PhMe Rh2(OAc)4 90 120 47 83:17 
 
As shown in table 16, high temperature is required to accelerate the reaction and 
activate the diazo compound. Secondly, the best yields were obtained by using 
toluene as solvent and Rh2(OAc)4 as catalyst (Entry 7, Table 16) with very good 
diastereoselectivity (84:16). In contrast 1,2-dichloroethene (DCE, Entry 2, Table 16) 
and dimethoxyethane (DME, Entry 3, Table 16) gave very low yields but with excellent 
diastereoselectivity. Next, our group turned attention to examine the reaction of cyclic 
amines with a chiral diazocamphorsultam which would allow to compare the results 
obtained in the carbenoid pathway with previously obtained base mediated ones. The 
results show that both approaches were similar, giving syn products with low 
diastereoselectivity (Scheme 67).58 
Scheme 67 
4.2.1.3 Competion between [1,2]- and [2,3]-processes 
In the case of benzyl ammonium salts, which normally undergo [1,2]-Stevens 
rearrangements, a competing [2,3]-rearrangement known as the Sommerlet-Hauser 
rearrangement can occur. This [2,3]-rearrangement competes with [1,2]-Stevens 




rearrangement depending on the reaction conditions and the steric and electronic 
properties of the substrates. For example, Tayama has shown that either 
rearrangements can be obtained by carefully tuning the reaction conditions. N-Benzyl 
proline ammonium salt 267, underwent both rearrangements depending on the 
reaction conditions chosen (Scheme 68).73  
 
Scheme 68 
The [1,2]-Stevens rearrangement mechanism proceeds, as mentioned previously, via  
a radical-pair which formed through homolytic cleavage of the C-N bond followed fast 
recombination of the radical-pair to give [1,2] products. On the other hand, from the 
ylide, the [2,3]-rearrangement proceeds via an anionic mechanism where concomitant 
nucleophilic attack of the negatively charged carbon of the ylide on the benzene ring 
and cleavage of the carbon-nitrogen bond (affording a rearranged product with an exo 
double bond) followed by rearomatisation of the benzene ring afford the rearranged 
product (Scheme 69).73 
 
Scheme 69 




Tayama extended the study of the [2,3]-rearrangement to benzylammonium ylides 
bearing a (-)-8-phenylmenthol chiral auxiliary and various para substituents on the 
benzene ring. The reaction proceeded in excellent yields and high stereoselectivity 
(Scheme 70 and Table 17). In addition, electron withdrawing substituents were shown 
to be essential for the reaction to proceed as no desired product was formed when 




Entry R T (°C) Time Yield (%) d.r. ratio (S:R) 
1 CO2tBu -40 4 h 95 >98:2 
2 CN -60 4 h 82 97:3 
3 CO2CH3 -60 8 h 85 >98:2 
4 COPh -60 8 h 82 >98:2 
5 CF3 -60 15 h 93 >98:2 
6 H -40 15 h 46 >98:2 
7 OCH3 -40 15 h 0 - 
 
In the same publication, the authors also carried out the reaction with meta substituted 
benzylammonium salts (CN and CF3) obtaining almost completely selectively 
ortho/para substituted products 275 (Scheme 71 and Table 18).73 
 
Scheme 71 





R T (°C) 
Yield (%) (275)  
d.r. 
Yield (%) (276)  
d.r. 
CN -60 63 (>98:2) 6 (>98:2) 
CF3 -40 90 (>98:2) 0 
 
The explanation given for the regioselectivity of the transformation (Scheme 72) was 
based on the favourable formation of less sterically hindered intermediate 277.73 
 
Scheme 72 
A switch in selectivity from [2,3] to [1,2] metal catalysed carbenoid rearrangement of 
iodonium ylide from metal carbenoid was reported by Tamber. The selectivity of the 
rearrangement of allylic iodonium ylides was controlled by the choice of ligand using 
the same metal catalyst. The reaction afforded either of the products in high yield and 




The aim of the work described in this chapter is to highlight and expand the scope of 
the [1,2]-Stevens rearrangement of benzylic ammonium salts and of the [2,3]-Stevens 
rearrangement of allylic onium ylids. This work should provide access towards novel 
amino acids and is complementary to other work done within our group. 




5. Results and discussion  
5.1 Asymmetric [1,2]-Stevens rearrangement 
In general, our synthetic strategy toward α-benzylated amino acids is shown in scheme 
74. 
Scheme 74 
5.1.1 Synthesis of Oppolzer’s chiral auxiliary 
The synthesis outlined in Scheme 74 (as reported by Davis)82 began with (1S)-(+)-10-
camphorsulfonyl chloride (303), which was treated with an ammonia solution to give 
camphorsulfonamide (304) in 85% isolated yield. Without any purification 304 was 
used in the next step, where Amberlyst 15 ion-exchange resin was used as acid 
catalyst for the imine formation using Dean-Stark conditions and affording 
camphorsulfonimine (305) in excellent yield (95%). The latter in turn, underwent 
reduction with LiAlH4 in THF to afford camphorsultam (306), also known as Oppolzer’s 
chiral auxiliary. 




5.1.2 Synthesis of benzylic ammonium salts 
Subsequently, reaction of camphorsultam 306 with bromoacetyl bromide gave 
compound 307, which was reacted with N,N-dimethylamine to produce amine 308. 
Ammonium salts 309 can be synthesized efficiently in high yield by treatment of 308 
with benzyl bromide derivatives at 50 °C for 75 h. After such time, the salt, which is 














5.1.3 [1,2]-Stevens rearrangement of benzylic ammonium salts 
As described in the introduction of this chapter, the optimized conditions towards the 
[1,2]-Stevens rearrangement of benzylic ammonium salts were obtained within our 
group, and use BTPP as base, DMF as solvent, and 5 Å molecular sieves as a water 
scavenger in order to avoid cleavage of the chiral auxiliary (Scheme 76).59  
Entry R Yield (%) Product No 
1 H 95 309a 
2 4-OMe 98 309b 
3 4-COMe 75 309c 









7 2,4-diF 96 309g 
8 3,5-diF 82 309h 
9 2,4,6-triF 95 309i 
10 3-F 98 309j 
11 4-Ph 72 309k 
12 2-CN 96 309l 






Moreover, the results obtained by Ollis and co-workers on the influence of solvent and 
reaction temperature on the stereoselectivity and intramolecularity of the [1,2]-Stevens 
rearrangement, suggested that the high viscosity of the solvent favours the solvent 
cage effect. The latter in turn, might increase yield. For next stage, we chose to limit 
our initial focus to improve the yield. For that purpose, we hypothesized that the use 
of a high viscosity solvent, could lead to increased yield (Table 20). 
Table 20 
Solvent Viscosity at 20 °C 
DMF 0.92 cP 
DMSO 1.996 cP 
 
Furthermore, in order to further understand the effect of solvent on the [1,2]-Stevens 
rearrangement it is worth looking at the solvent’s chemical structure (Figure 26). When 
considering DMF and DMSO, it is clear that DMF has a partial negative charge on 
oxygen and partial positive on nitrogen, whereas DMSO has negative charge on 
oxygen and positive on sulfur. 
 
Figure 26 
According to intermediate 162, which is formed during the [1,2]-Stevens 
rearrangement (as shown in Scheme 30), it can be observed that the structure of 
DMSO, where the delocalisation of the charge is increased, stabilises further the 
formation of ylide 162 thus should allow to improve the yield (Figure 27). 






Therefore, we carried out [1,2]-Stevens rearrangement of benzylic ammonium salts 
using the previous conditions except for the use of DMSO as solvent instead of DMF 
(Scheme 77).  
Scheme 77 
The results obtained show that the reaction’s efficiency was increased and products 
were obtained in high yields compared with those obtained with DMF. We expanded 
the scope of the [1,2]-rearrangement to different substituted benzylic ammonium salts. 
Products were generated in 61-89 yields and with a degree of diastereoselectivity in 
the presence of several functional groups on the aromatic ring (methoxy, ketone, ester, 
phenyl, cyano, haloalkyl) and using various substitution patterns (Scheme 78 and 
Table 21, Appendix 9, Pages 122-138). 
 
Scheme 78 






a   The ratio determined from 1H NMR spectrum of the crude, by integration of N- dimethyl resonances for two diastereoisomers. 
b   The ratio determined from HPLC spectrum of the crude by calculation of peak area for two diastereoisomers. 
c  (2R)-[1,2]-product and camphorsultam as an inseparable mixture. 
d  (2S)-[1,2]-product and [2,3]-product as an inseparable mixture. 
e 16 % [2,3]-rearrangement. 
f  18 % [2,3]-rearrangement. 
 
 
The ratio of diastereoisomers was calculated by 1H NMR and HPLC analysis of the 
crude product. Generally, the best results were obtained with fluorine substituted 
compounds. The presence of competing [2,3]-rearrangement products was possible 
for all compounds, however, noticeably just one example, (2-CN, Entry 12), gave [2,3]- 
rearrangement along with [1,2]-Stevens rearrangement. Furthermore, camphorsultam 
was recovered in most reactions in 1-5% showing little hydrolysis had occurred.  
The stereochemistry of the major product was confirmed by X-ray of single-crystal (a, 
Figure 28). The X-ray data showed that the carbonyl C=O double bond is opposite to 
sulfonamide (N-S) bond in the product, to minimize dipole interactions. In addition, C-








Entry R % of [1,2] pure products  (dr) ratio (2S:2R) 
(2S) (2R) Total yield 1H NMR a  HPLC b 
1 H 54% 
54% 
 
  11% c 65% 83:17 81:19 
2 4-OMe 50% 15% 65% 79:21 79:21 
3 4-COMe 57  11% 68% 75:25 78:22 
4 2,5-diF 60% 29% 89% 78:22 71:29 
5 4-COPh 
 
43% 17% 60% 38:62 44:56 
6 4-CO2Me 
 
41% 22% 63% 78:22 75:25 
7 2,4-diF 42% 19% 61% 80:20 79:21 
8 3,5-diF 55% 32% 87% 80:20 72:28 



















23% c 88% 71:29 67:33 
11 4-Ph 41% 22% c 63% 80:20 77:23 
12 2-CN 47% d 30% 77% 66:18e 63:19f 





a) Our work (BTPP as base and DMSO as solvent, Appendix 9, Pages 122) 
 
 
                                  
 
 
b) Previous work within Sweeney group (NaH as base and DME as solvent) 
                  
Figure 28 
Based on the configuration of the product, we can provide an explanation for 
diastereocontrol of this reaction. Presumably, the benzyl radical recombines from the 
upper face, leading to the observed stereoselectivity. We assume that recombination 
is faster when the NMe2 group is anti to S=O bonds (Scheme 79). Surprisingly, our X-
ray structure shows that there is the difference in an absolute configuration of the major 
product which prepared by two methods (Figure 28) (two different conditions). In other 
words the major product, which was prepared by the previous work within our group 
using NaH as base and DME as solvent, has absolute configuration (2R) whereas the 
major product, which was prepared by this work using BTPP as base and DMSO as 
solvent has absolute configuration (2S). 
 






5.1.4 Cleavage of the auxiliary 
[1,2]-Stevens rearrangement products can be hydrolysed to give the corresponding 
amino acids. The hydrolysis reactions were performed according to a known 
procedure (with minor modifications), which was previously reported by the Sweeney 
group.83 The reaction was carried out using lithium hydroxide monohydrate in 
THF/H2O (4:1) giving amino acids in 311a-c (Scheme 80 and Table 22, Appendix 9, 
Pages 139-140).   
 
Scheme 80 





Entry R Yield (%) 
1 H 32 
2 2,4-diF 39 
3 4-Ph 35 
 
5.2 [2,3]-Rearrangement of allylic onium ylids 
Regarding the [2,3]-rearrangement, we reported earlier that the Sweeney group had 
previously obtained excellent results in the case of base-mediated allyl ammonium salt 
rearrangements (Scheme 71). Our goal was to further examine the rearrangement 
reaction but using metal-catalysed rearrangements instead, which is expected to 
obviate the need to use of the base and hygroscopic salts. Optimization of the [2,3]-
rearrangements of allylic ylids using metal catalysts and diazo compounds (carbene 
precursors) can be challenging because many different species compete for addition 
to the metal carbenoid (Scheme 81). 
 
Scheme 81 
The metal carbenoid species (322) can react with the allylic heteroatom to produce 
allylic onium ylids, which undergo [2,3]-rearrangements (Scheme 56 and Scheme 81). 




On the other hand, the metal carbenoid species (322) can also react with the double 
bond giving a cyclopropanation, which is concerted addition of the metal carbene to 
the alkene to form cyclopropane ring, species side reaction (formation of 324)(Scheme 
81a). Moreover, the electron-deficient carbon, which is attached to metal, can undergo 
to the nucleophilic attack by another diazo to form dimerization compound 
325)(Scheme 81b). Finally, [2,3]-products might react with metal carbenoid species as 










5.2.1 Synthesis of the diazoacetyl camphor sultam 
As outlined in Scheme 82, glyoxylic acid chloride p-toluenesulfonyl hydrazone (330) 
was prepared by procedure reported by Atkinson.84 The synthesis started with 
glyoxylic acid (327) which was reacted with p-toluenesulfonyl hydrazide (328) to 
produce glyoxylic acid p-toluenesulfonyl hydrazone (329) in 98% yield. Subsequently, 
329 was converted into glyoxylic acid chloride p-toluenesulfonyl hydrazone (330) using 
freshly distilled thionyl chloride. Finally, the desired diazo compound 297 was prepared 
in 60% yield using a modified procedure from Myers.58,85  






5.2.2 Synthesis of N--diazoacyl oxazolidinones 
Different diazo oxazolidinones were synthesized according to reported 
procedures.86,87 The synthesis began with the conversion of N-hydroxyphthalimide 
into diazo phthalimide obtained in 71% yield followed by addition of oxazolidinone or 




Entry R Yield (%) 
1 H 75 
2 Benzyl  57 
3 Isopropyl  55 
 




5.5.3 [2,3]-Rearrangements of allylic onium ylids 
The example reported by Gross (Scheme 59), suggested it was worth investigating 
[2,3]-rearrangements of allylic ammonium ylides using iron(III) porphyrin catalysts and 
a diazoacyl moiety attached to a chiral auxiliary. The use of the auxiliary, might allow 
access to range of products with high diastereoselectivity. 
5.5.3.1 [2,3]-rearrangements of allylic ammonium ylids 
Our initial idea was to examine [2,3]-rearrangements using dimethyl allylamine and 
diazoacyl group attached to different chiral auxiliaries in the presence of a highly 
reactive iron(III) porphyrin catalyst 337 (Scheme 84).   
 
Scheme 84 
[2,3]-Rearrangements using dimethyl allylamine and diazoacyl camphorsultam 297 in 
the presence iron(III) porphyrins were initially studied (Scheme 85).  The reaction was 
carried out according to reported procedures.71 The first reaction was carried out using 
low catalyst loading (0.2 mol%), one equivalent of N,N dimethylallylamine and CDCl3 
as the reaction solvent. The reaction mixture was monitored by 1H NMR and TLC 
analysis.  
Scheme 85 




The conversion from diazoacyl camphorsultam to [2,3]-rearrangement products was 
determined at a series of time points from the 1H NMR spectrum of the reaction mixture 
recorded in CDCl3 by integration of N,N-dimethyl resonances for each isomer product 
and -proton (substrate) (Figure 29). 
 
 
Figure 29. 1H NMR for the reaction mixture.  
The results showed that the reaction provided the desired product albeit very slowly. 
In order to optimise the reaction, a combination of catalyst loading (1, 5, 10, 20, 40 
























































From the previous chart, it is clear that increasing the amount of catalyst 
(Stoichiometry) led to increased conversion. After two days and using 40 mol% of 
catalyst loading at room temperature, 90% of starting material was consumed and the 
product was obtained as diastereoisomers in a 3:1 ratio. Secondly, increasing number 
of equivalents of N,N dimethyl allyl amine (1eq, 5 eq, 10 eq) gave the same results. 
Generally, the reaction worked slowly and requires a high loading of catalyst. The 
reason for this might be the steric hindrance between the catalyst and diazo 
camphorsultam. Therefore, our focus turned to other iron catalysts as shown scheme 
86 and table 24. 
 
Scheme 86 
Table 24   
Entry Catalyst Time (h) Conversiona 












5 DPPF 50 0 
            
a
 According to the consumption of diazo and alkene peaks (1H NMR for crude). 




The results of this investigation (Table 24) show that there is no conversion to the 
desired products and only starting materials were recovered from all reactions. Based 
on this, we did not continue the investigation of the [2,3]-rearrangement with diazo- 
camphorsultam, and we moved to examine another chiral auxiliary.  
Our next goal was to test iron(III) porphyrin catalyst with diazoacyl oxazolidinones in 
the presence of N,N dimethylallylamine (Scheme 87). The reaction was carried out 
using 1 mol% of iron(III) porphyrin catalyst, one equivalent of N,N-dimethylallylamine 
and CH2Cl2 as solvent at room temperature. The initial reaction worked efficiently 




affording the desired product in 70% yield. The reaction was performed by addition of 
a solution of diazo 339 and allylamine into a solution of catalyst in one portion and it 
took 20 min for the nitrogen bubbles to stop (showing no more diazo compound was 
consumed).    
 
Scheme 87 
This was a promising start and led to further investigation using different substrates. 
Next, the chiral diazo-oxazolidinone 341 was used in the reaction (Scheme 88). 
 
Scheme 88 
Iron (III) porphyrin catalysed the decomposition of diazo benzyl oxazolidinone 341 in 
the presence of N,N-dimethylallylamine to produce [2,3]-products 342a and 342b in 
high 86% yield (Appendix 9, Pages 145-146), although diastereoselectivity was poor 
(2:3). The reaction was carried out at room temperature, 0 °C and -78 °C as a means 
to improving the diastereoselectivity. Unfortunately, all the reactions gave the same 
ratio of diastereoisomers. Next, the reaction was carried out using another chiral 
oxazolidinone, which employed (R)-isopropyl oxazolidinone, and N,N-
dimethylallylamine to give the product in poor diastereoselectivity (1:1.7, see appendix 
9, Page 263, Crude 20). In addition, the reaction was done using cyclic allyl amines 
and the obtained results are shown in scheme 89 and table 25. 






Table 25  
Entry Ally amine [2,3] (dr) ratio Ratio ([2,3]:dimer) Total yield (%) 
1  1:1.5









b 2:1a 62 
                       a The ratio determined from 1H NMR spectrum of the crude, by integration of one proton of CH2Ph resonances  
                   for [2,3]-products and dimer.                    
                          b The ratio determined from HPLC spectrum of the crude by calculation of peak area for two diastereoisomers. 
                c Could not estimate yield. 
 
We assume that the steric hindrance around nitrogen atom affects its ability to 
nucleophilically attack to the metal carbenoid. As result of this, dimerization of the 
diazo compound occurred (Entry 3, Table 25) when N-allylpiperidine was used in 
reaction. Perhaps due to the high reactivity of the iron catalyst and the steric effect 
around the nitrogen reaction the formation of the dimerized product competed with the 
[2,3]-rearrangement (Scheme 90). 
 
Scheme 90 




To shine some light on the previous reaction, we hypothesised that improvement of 
diastereoselectivity of the iron(III) porphyrin catalysed rearrangement could be 
achieved by using Lewis acids that would bind to both carbonyl oxygens and therefore 
force the rearrangement to proceed in a “more asymmetric” environment as illustrated 
in transition state (345) (Scheme 91).  
 
Scheme 91 
Before employing a Lewis acid within the reaction, it was necessary to test a range of 









Entry   Solvent [2,3]:Dimer  
1 EtOH 0:1 
2 DMSO - 
3 MeCN 3:1 
4 CHCl3 2:1 
It is worth noting that acetonitrile (Entry 3, Table 26) reduces the formation of dimer 
and supports the formation of [2,3]-rearrangement whereas ethanol did not give any 
[2,3]-products. Next, a range of Lewis acids were used the reaction along with iron 




Entry Lewis acid solvent [2,3]-products 
1 MgCl2 CHCl3 - 
2 AlCl3 CHCl3 - 
3 FeCl3 CHCl3 - 
4 Bu2BOTf CHCl3 - 
5 Mg(ClO4)2 MeCN - 
6 MgBr2.OEt2 MeCN - 
 
According to 1H NMR for all the previous reactions, it was clear there were no [2,3]-
rearrangement products. However, diazo benzyl oxazolidinone (341) was fully 
consumed in all reactions.  
As another possible means to improve the diastereoselectivity of the reaction we 
thought of using chiral allylamines. N,α-Dimethylbenzylallylamine (347) was therefore 
examined in the reaction with the chiral diazo benzyl oxazolidinone (341) in the 
presence of the iron(III) porphyrin catalyst (Scheme 94). 






Unexpectedly, when diazo compound (341) was treated with one equivalent of chiral 
amine 347 (in chloroform at room temperature), [2,3]-rearrangement products were 
not observed. 
We were also interested in testing whether the reaction of N,N-dimethylbenzylamine 
(348) with diazo benzyl oxazolidinone would undergo the [1,2]-Stevens rearrangement 
or not. The reaction was carried out using iron porphyrin catalyst at room temperature 
and gave desired compound 349 in 21% yield, in a 5:4 ratio of diastereoisomers 
(Scheme 95).      
 
Scheme 95 
5.5.3.2 [2,3]-rearrangements of allylic onium ylids 
To increase the coverage of the study of chiral diazo oxazolidinones, we proposed to 
carry out the reaction of diazo benzyl oxazolidinone 341 with other allylic nucleophiles 
as illustrated in scheme 96 and table 28.  






Table 28  
Entry X [2,3]: Dimer 
1 OH 0:1 
2 OCH3 0:1 
3 I 0:1 
 
Based on the results shown in table 28, the formation of the dimerization product 
overcame the formation of [2,3]-rearrangement products. The high reactivity of iron(III) 
porphyrin catalyst with diazo compounds would make dimerization occur faster than 
nucleophilic attack of allylic nucleophiles on the metal carbenoid compound. These 
findings may be explained by the increased nucleophilicity of nitrogen than oxygen 
and iodine. To tune the balance between the reactivity of catalyst and the ability of 
nucleophilic attack, firstly we proposed to use a less activating catalyst such as 
Rh2(OAc)4, which is used widely in metal carbenoid chemistry. Secondly, the rate of 
addition of the diazo precursor to solution mixture of catalyst and allylic nucleophiles 
should affect the production of the dimer (diazo solution can be added slowly, and 
allylic nucleophiles can be used in excess). The next idea was to test if Rh2(OAc)4 
catalyse decomposition of diazo chiral oxazolidinone in the presence of excess allyl 
iodide (Scheme 97). 
 
Scheme 97 




Various reagents addition order were evaluated. Firstly, the solution of diazo 
compound was dropwise to a solution of catalyst and allyl iodide (5 eq.). Secondly, the 
solution of catalyst was dropwise to a solution of diazo (341) and allyl iodide (5 eq.). 
Unfortunately, attempts to produce desired [2,3]-products failed. To solve this problem, 
we examined the use diazocamphorsultam with the Rh(II) catalyst in the presence of 
excess allyl iodide and toluene as solvent at room temperature (Scheme 98). The 
initial reaction afforded products in 50% yield with 85:15 diastereoselectivity. 
 
Scheme 98 
This reaction was done with slow addition of the diazocamphorsultam solution (0.1g 
in 10 mL solvent over 24 h) to the solution of Rh2(OAc)4 and five equivalents of allyl 
iodide. Next, we focued on improving the yield by tuning the reaction conditions. To 
optimise the reaction, various factors were investigated. Firstly, the reaction was 
carried out using different solvents and the results are shown in table 29.  
 
Scheme 99 
Table 29. Solvent screen. 
Entry Solvent Addition time (mL.h-1)d Conversiona Total yield (%) d.r.b,c 
1 Toluene 0.397 100 50 85:15 
2 DCM 0.397 100 73 85:15 
3 THF 0.397 100 55 85:15 
4 MeCN 0.397 44 -e 85:15 
5 DMF 0.397 0 - - 
6 DME 0.397 100 >90 85:15 
 a






A solution of diazo (100 mg) in solvent 
(10 mL).
 e 
Analytical reaction carried out without purification. 




As can be seen from table 29, the best results were obtained in DME, as 352 was 
obtained in 90% yield and 5.6:1 d.r (Appendix 9, Pages 243-245). In contrast DMF did 
not give any desired products. In addition, acetonitrile (MeCN) gave 40% conversion 
in the same reaction time. 
The second factor that might affect the diastereoselectivity is the reaction temperature 





Solvent Temp (°C) Addition time (mL.h-1) dr ratioa,b Total yield (%) 
DME 0 0.397 85:15 >90 
DME -20 0.397 85:15 >90 
DME -40 0.397 85:15 >90 
          a Calculated by HPLC.
  b
 Approximate ratio. 
 
Clearly, the results above show that lowering the temperature did not affect the 
diastereoselectivity and conversion of the reaction. 
Stability of 352 at room temperature  
The carbon-iodine bond (C-I) is weak (bond dissociation energy = 57.6 kcal/mol). In 
other words, iodide is very good leaving group and iodide compounds are light 
sensitive. Therefore, iodide compounds have to be stored in a dark bottle, which 
prevent light from reaching to sample, and in the fridge.  
Method  
To monitor the stability of camphorsultam iodide (352), a quantity (solid) of 
camphorsultam iodide (352) was divided into 6 vials each one containing 10 mg. All 
vials were covered with aluminium foil to protect them from the light. Monitoring of 
stability was done by 1H NMR of the mixture of two diastereoisomers during 24 days 
(24 h, 48 h, 5, 6, 7 and 24 days) (Figure 30).  






In the meantime, one of these samples, left in solution in CDCl3 was monitored by 1H 




Figure 31. (In CDCl3). 
This study has demonstrated that 352 (solid) is stable at room temperature (at least 
for 24 days) (Figure 30), whereas it started to decompose after 48 h when stored at 
r.t. in a CDCl3 solution (Figure 31). This can be more simply noticed from the colour of 




the solution that turned to pink, and the colour intensity increased dramatically over 
the 7 days. 
To further expand the scope of the [2,3]-rearrangements of iodonium ylides, we carried 
out the reaction with substituted allyl iodides (Scheme 101). Products were generated 





R1 Ratio (dr) Total yield (%) 
H 85:15a 95 
Me   84:16a,b 90 
                                                                                             a Calculated by HPLC. 
                                                                                             b Calculated by 1H NMR and HPLC. 
  
As mentioned above, iodide is very good leaving group and it should be easy to 
transform the newly made iodide rearrangement product into amino acids. For this, 




The reaction was carried out using the crude mixture of the two diastereoisomers of 
352 directly with sodium azide (1 eq.) at 60 °C and room temperature. According to 
the 1H NMR spectrum for the crude product, we observed the corresponding peaks of 




the cleaved chiral auxiliary (Scheme 102 and Table 32), therefore reaction had to be 
carried out carefully. We were pleased to see that a 4 h reaction at room temperature 
afforded desired compound 354 in 70% yield. 
Table 32 
Tem (°C) Time  Ratio (354:306)a 
Total yield (%)  
354 
60 Overnight 1:1 41 
RT Overnight 5:1 - 
RT 4 h 8:1 70 
 
                          a  The ratio determined from 1H NMR spectrum of the crude, by integration of CH2CH=CH2 for azide products and CH2SO2 for the cleaved sultam. 
Finally, we turned to examine another allylic nucleophile with diazocamphorsultam and 
Rh2(OAc)4 catalyst. The next reactions carried out using two examples of allyl sulfide 
with diazocamphorsultam in the presence of a Rh(II) catalyst at room temperature 
gave [2,3]-rearrangement products in low to good yield but with low 




Entry R  d.r. Total yield (%)  
1 Ph 1:1a 80 
2 CH2CO2Et 1:1b 28 
                                                         a  The ratio determined from 1H NMR spectrum of the crude.
 b  The ratio determined from HPLC of the crude 
In the case of phenyl allyl sulfide we have done the reaction with two solvents, DCM 









6. Conclusion  
We have shown that the [1,2]-Stevens rearrangement of benzylic ammonium ylids can 
carried out in excellent yield and diastereoselectivity. We have reported 12 examples 
with the [1,2]-Stevens rearrangement of benzylic ammonium ylids in good to excellent 
yields (61-89%). These results can be achieved by using phosphazene base (BTPP) 
in DMSO in the presence of 5 Å molecular sieves to decrease product hydrolysis. As 
expected, the use of DMSO as the reaction solvent improved the [1,2]-Stevens 
rearrangement yield by at least 19% compared to DMF (results previously obtained 
within our group). Finally, the [2,3]-sigmatropic rearrangement of allylic onium ylids 
catalysed by metal catalysts has been investigated and applied successfully to 
allylamines, allyl iodides and allyl sulfides. 5,10,15,20-Tetrakis(pentafluorophenyl)-
21H,23H-porphyrin iron(III) chloride catalyst showed high reactivity with a chiral diazo 
oxazolidinone towards [2,3]-rearrangement while diazocamphorsultam worked slowly. 
Rhodium(II) acetate [Rh2(OAc)4] worked well with diazocamphorsultam and allyl 












7. General experimental methods 
Spectrometry: 
The NMR spectra were recorded with a Bruker 400 MHz spectrometer using CDCl3, 
DMSO-d6 and D2O as the solvents. Chemical shifts (δ) in 1H NMR are reported in ppm, 
downfield from TMS, and as in 13C NMR, are referenced to the residual solvent peak. 
Multiplicities are reported as a singlet (s), doublet (d), triplet (t), quartet (q) and 
combinations thereof, or multiplet (m). Coupling constants (J) are quoted in Hertz. All 
melting points were obtained using a Stuart SMP10 melting point apparatus. The 
Infrared spectra were recorded on Thermo Electron Corporation FT-IR Nicolet 380 and 
Omnic software. Mass spectrometry was performed using a Agilent 6210 TOF MS 
instrument with electrospray ionisation in the positive mode. 
Reagents 
All the solvents and reagents used were supplied by Sigma–Aldrich, Fisher Scientific 
and Tokyo Chemical Industry. 
Chromatography 
Thin layer chromatography (TLC) was carried out using silica gel 60 F254 aluminium 
sheets. Spots were visualised by quenching UV irradiation at 254 nm, and by staining 
with solution of KMnO4 (3.0 g), K2CO3 (20.0 g) and NaOH (0.2 g in 5 mL water) in 250 
mL water. Flash column chromatography was carried out using silica gel 60 A, 70-230 
mesh, 63-200 µm obtained from Sigma–Aldrich. The HPLC analysis was conducted 
on a Chiralpack IB-3, IF-3 columns (Dimensions: 4.6 mm×250 mm; particle size: 3 
µm). The UV detection was at wavelengths of 200, 210, 220, 230 and 254. Solvents 














2-N, 9-diacetyl guanine (55).29 
 
Guanine (3.75 g, 25 mmol), 60 mL of dry DMAc and 13 mL of Ac2O were stirred at 160 
°C for 7 h. After this time, the solution was left to cool. The precipitated solid was 
filtrated and washed by acetone to give (4.6 g, 79%). m.p.= 262-264 °C (lit 251-256). 
H1 NMR (400 MHz, DMSO-d6)H: 2.21 (s, 3H, 2NCOCH3), 2.81 (s, 3H, N9COCH3), 
8.44 (s, 1H, C8H), 11.75 (s, 1H, exchange with D2O, AcNH), 12.21 (s, 1H, exchange 
with D2O, NH). 13C NMR (100 MHz, DMSO-d6)C: 24.3 (CH3CO), 25.1 (N9COCH3), 
121.9 (C5), 137.9 (C8), 148.3 (C4), 148.9 (C2), 155.1 (C6), 168.5 (N9-CO), 174.2 
(N2CO). IR max /cm-1: 3148 (NH), 3113 (NH), 1742 (CO), 1702 (CO), 1675 (CO).  
MS m/z (ESI+) calculated for (C9H9N5O3) [M+H]+;  236.0778 found 236.0785. 
2-acetamido-9H-purin-6-yl diphenylcarbamate (56).29 
 
(4.5 g, 19 mmol) of 2-N, 9-diacetylguanine in (7 mL, 40 mmol) of EtN(i-Pr)2 and 100 
mL of dry pyridine was treated with (4.9 g, 21 mmol) of diphenyl carbamoyl chloride 
for 1 hour at room temperature. Water (7 mL) was added and stirring for 20 min. The 
solvents were evaporated in vacuo and coevaporation (3 x 20 mL of PhCH3). The 
residue was heating at 100 °C with 300 mL of EtOH/H2O (1:1) for 1.5 hours. After this 
it was left to cool for 24 h, followed by filtration, washing (EtOH), and drying to give 
(6.5 g, 89%). m.p.= 241-242 °C. 1H NMR (400 MHz, DMSO-d6) H: 2.14 (s, 3H, 
2NCOCH3), 7.32-7.49 (10H, ArCH), 8.40 (s, 1H, C8H), 10.63 (s, 1H, exchange with 
D2O, N-H), 13.57 (s, 1H, exchange with D2O, N-H). 13C NMR (100 MHz, DMSO-d6) C: 
24.8 (CH3CO), 117.3 (C5), 127.7-129.8 (10×ArCH), 142.1 (2×ArC), 144.4 (C8), 150.7 
(C6), 152.4 (C4), 155.4 (C2), 156.4 (OCON), 169.0 (CH3CO). IR max /cm-1: 3327 (NH), 




3161 (NH), 1714 (CO), 1629 (CO). MS m/z (ESI+); calculated for (C20H16N6O3) [M+H]+; 
389.1357 found 389.1359.  
N9 and N7-methyl guanine (52a and 52b) 
 
To cold mixture of NaH (1.1 eq) in 30 mL DMF was added (56) (1 g, 2.5 mmol). After 
30 min iodomethane (1.2 eq) was added and the mixture was stirred at room 
temperature for 3 days under nitrogen. The solvent was evaporated under reduced 
pressure. Next, 50 mL EtOAc and 50 mL H2O were poured to the residue. The organic 
layer was separated, washed with brine (50 ml × 2), dried over MgSO4 and 
concentrated under pressure. Deprotection step was done by adding 60 mL (1:1) 
NH3/MeOH to the product, reflux overnight. The solvent was removed under reduced 
pressure, and the residue was suspended in DCM (20 mL) and stirred for 30 min. Then 
the solid was filtered and washed with DCM to obtain the mixture of (52a and 52b) 
(0.18 g, 43%).  
52a 1H NMR (400 MHz, DMSO-d6) H: 3.50 (s, 3H, N9CH3), 6.07 (s, 2H, NH2), 7.61(s, 
1H imidazole, C8H).  
52b 1H NMR (400 MHz, DMSO-d6) H: 3.80 (s, 3H, N7CH3), 6.40 (s, 2H, NH2), 7.80 (s, 
1H imidazole, C8H). 
N2acetyl-7,9-dibenzylguaninium bromide (58).33  
 
2-N,9-diacetyl guanine (1.54 g, 6.5 mmol), DMAc (5 ml) and benzyl bromide (1.6 ml, 
13.3 mmol) were added respectively. The reaction mixture was heated at 120 °C for 3 
hours. The solution was poured into hot EtOAc (50 mL) with stirring. After cooling of 
the mixture, the solid began to separate after 2 hours then filtered and washed by 
acetone to give (2.0 g, 69%) of (58). m.p.= 213-214 °C. 1H NMR (400 MHz, DMSO-
d6) H: 2.19 (s, 3H, CH3CO), 5.47 (s, 2H, NCH2 ), 5.68 (s, 2H, NCH2 ), 7.21-7.48 (10H, 




ArCH ), 9.75 (s, 1H, C8H ), 12.11 (s, 1H, ,exchange with D2O, NH), 12.60 (s, 1H, 
exchange with D2O, AcNH ) .13C NMR (100 MHz, DMSO-d6) C : 24.4 (CH3CO), 48.9 
(CH2Ph), 52.1 (CH2Ph), 110.9 (C5), 128.0-134.6 (10×ArCH and 2×ArC), 140.3 (C8), 
148.0 (C4), 151.1 (C2), 151.8 (C6), 174.6 (CH3CON). IR max /cm-1: 3034 (NH), 1717 





To a stirred solution of N2acetyl-7,9-dibenzylguaninium bromide (1.0 g, 2.2 mmol) in 
10 mL water was added a solution of sodium tetraphenylborate (0.75 g, 2.2 mmol) in 
10 mL water, then filtration and drying in oven at 50 °C overnight to give (1.28g, 85%) 
of (60). m.p. = 174-175 °C (dec). 1H NMR (400 MHz, DMSO-d6) H: 2.19 (s, 3H, 
CH3CO), 5.45 (s, 2H, NCH2 ), 5.67(s, 2H, NCH2 ), 6.74-7.47  (30H, ArCH), 9.7 (s, 1H,  
C8H), 12.09 (br, s, 1H, exchange with D2O, NH ), 12.59 (br, s, 1H, exchange with D2O, 
NH).  13C NMR (100 MHz, DMSO-d6) C: 24.4 (CH3CO), 48.9 (CH2Ph), 52.2 (CH2Ph), 
110.9 (C5), 121.9 (4× tetraphenylborate ArCH), 125.9 (8× tetraphenylborate ArCH), 
127.0-134.9 (ArCH), 135.9 (8× tetraphenylborate ArCH), 140.3 (C8), 148.0 (C2), 151.2 
(C4), 151.9 (tetraphenylborate ArC), 163.0 (tetraphenylborate ArC), 163.5 
(tetraphenylborate ArC), 164.0 (tetraphenylborate ArC), 164.5 (C6), 174.2 (CH3CON). 
IR max /cm-1: 3281(N-H), 3052 (CH), 1698 (CO). 
2-amino-6-hydroxy-4-methylamine pyrimidine (63).30 
 
2-amino-6-chloro-4-hydroxy pyrimidine (1.0 g, 6.87 mmol) and ethanolic methylamine 
(5 mL) were heated in sealed tube at 120 °C for 5 hours. The solution was cooled, and 
precipitate was collected to give (0.74 g, 77%) of (63). m.p.= 255-256 °C (lit 255-257).  




1H NMR (400 MHz, DMSO-d6) H: 2.65 (s, 3H, NCH3), 4.34 (s, exchange with D2O, 
NH), 6.10 (s, 2H, exchange with D2O, NH2), 6.26 (s, 1H, CH), 9.63 (s, 1H, exchange 
with D2O, NH). 13C NMR (100 MHz, DMSO-d6) C: 28.3 (NCH3), 75.0 (C5H), 155.1 
(C4), 163.5 (C2), 165.3 (C6O). IR max /cm-1: 3345 (NH), 3112 (NH), 2909 (CH). MS 
m/z (ESI+); calculated for (C5H8N4O) [M+H]+;141.0771 found 141.0774.  
2-amino-6-hydroxy-4-methylamine -5-nitros pyrimidine (64).30 
 
(0.75 g, 5.3 mmol) of (63) in 1:1 mixture of H2O/AcOH (20 mL) was added NaNO2 
(0.73 g, 10.6 mmol) in H2O (10 mL) at 0 °C. After that, the mixture was stirred to room 
temperature for 1.5 hour. After such time, the reaction flask was put in ice to cool to 0 
°C and the precipitated was collected by filtration and washed by ethanol to give (0.65 
g, 72%) of (64). m.p.>300 °C. 1H NMR (400 MHz, DMSO-d6) H: 2.86 (d, J 4.8 Hz, 3H, 
NCH3), 6.86 (s, 2H, exchange with D2O, NH2), 10.78 (s, exchange with D2O, NH), 
12.27 (s, 1H, exchange with D2O, NH). 13C NMR (100 MHz, DMSO-d6) C: 26.9 (CH3), 
141.1 (C5), 153.3 (C4), 156.6 (C2), 161.8 (C6O). IR max /cm-1: 3524 (N-H), 3322 (NH), 
2991 (CH), 1727 (CO), 1582 (str, N=O). MS m/z (ESI+); calculated for (C5H7N5O2) 
[M+H]+ ;170.0673 found 170.0673. 
N9 methyl guanine (52a).30 
 
To mixture of (64) (0.9 g, 5.3 mmol), HCONH2 (4.5 mL) and 90% HCO2H (3.5 mL) was 
heated for 1 h. Next, Na2S2O4 (1.0 g, 5.7 mmol) was added then the mixture was 
heated to 70 °C for 3 hours. After such time, the mixture was left to cool to room 
temperature and cooled to 0 °C. The precipitated was collected by filtration. Then it 
was dissolved in 1N HCl and neutralized with NH4OH. The precipitated solid was 
collected by filtration to give (0.17 g, 20%) of (52a). m.p.>300 °C. 1H NMR (400 MHz, 
DMSO-d6) H: 3.50 (s, 3H, NCH3), 6.43 (s, 2H, exchange with D2O, NH2), 7.61 (s, 1H, 
C8H), 10.53 (s, 1H, exchange with D2O, NH). 13C NMR (100 MHz, DMSO-d6) C: 26.7 
(CH3), 116.8 (C5), 138.5 (C8), 151.9 (C4), 153.9 (C2), 157.2 (C6O). MS m/z (ESI+); 




calculated for (C6H7N5O) [M+H]+;166.0723 found 166.0724. IR max /cm-1: 3315 (NH), 
3160 (CH), 1618 (CO). 
5-amino-1-methyl -1H- imidazol-4-carboxamide (66).32 
 
90 % KOH powder (0.88 g, 15.8 mmol) was added to solution of 5-amino- 1H- 
imidazol-4-carbobamide. HCl (65) (1 g, 7.92 mmol) in 10 mL DMF. At 0 °C on ice bath, 
the mixture was stirred for 5 hours. Next, iodomethane (0.5 mL, 7.92 mmol) was added 
dropwise over 2 hours at 0 °C. The precipitated product was separated by filtration 
and washed with MeOH to give (0.45 g, 41%) of (66). m.p.= 258-259 (lit 251-255) °C. 
1H NMR (400 MHz, DMSO-d6) H: 3.36 (s, 3H, NCH3), 5.70 (s, 2H, exchange with D2O, 
NH2), 6.56 (s, 2H exchange with D2O, NH2), 7.04 (s, 1H, CH). MS m/z (ESI+); 
calculated for (C5H8N4O) [M+H]+;141.0771 found 141.0769. IR max /cm-1: 3355 (NH), 
3191 (CH), 1607 (CO).  
5-(3-benzoylthioureido)-1-methyl-1H-imidazole-4-carboxamide (67).32 
 
The mixture of (66) (0.43 g, 3.0 mmol), benzoyl isothiocyanate (0.5 mL, 3.7 mmol) and 
acetone (7 mL) were refluxed for 6 hours. After such time, the mixture was cooled on 
ice bath and the precipitated solid was filtrated and washed with acetone to give (0.56 
g, 61%) of (67). m.p.= 198-200 °C (lit 194-6). 1H NMR (400 MHz, DMSO-d6) H: 3.53 
(s, 3H, NCH3), 7.07 (s, 2H, exchange with D2O, NH2), 7.52-7.69 (5H, ArCH), 7.97(d, J 
7.3 Hz, 1H, CH), 11.97 (s, 1H, exchange with D2O, N-H), 12.05 (s, 1H, exchange with 
D2O, NH). 13C NMR (100 MHz, DMSO-d6) C: 31.7 (CH3N), 127 (C4, imidazole), 129.0, 
129.2, (ArCH), 129.8 (ArC), 132.3 (C5, imidazole), 133.8, 135.9 (ArCH), 135.9 (CH, 
imidazole), 164.1 (CO), 168.6 (CO), 183.0 (C=S). MS m/z (ESI+); calculated for 
(C13H13N5O2S) [M+H]+; 304.0863 found 304.0861. IR max/cm-1: 3353 (NH), 3148 (CH), 
1667 (CO), 1599 (CO). 
 




 1-methyl-5-thioureido-1H-imidazole-4-carboxamide (68).32 
 
Potassium carbonate (0.11 g, 0.83 mmol) in water 2 mL was added to 5-(3-
benzoylthioureido)-1-methyl-1H-imidazole-4-carboxamide (67) (0.5 g,1.64 mmol) in 
acetone – methanol (1:1, 8 mL). The reaction mixture was heated at 70 °C to reflux 
under nitrogen for 5 hours. After this time, 0.1 mL of acetic acid was added, cooling 
on ice bath, filtration and washing by acetone to give (0.21 g, 65%) of (68). m.p.= 254 
°C (dec). 1H NMR (400 MHz, DMSO-d6) H: 3.45 (s, 3 H, NCH3), 7.03 (s, 2H, NH2), 
7.18 (s, 2H, NH2), 7.57 (s, 1H, CH), 9.19 (s, 1H, NH). MS m/z (ESI+); calculated for 
(C6H9N5OS) [M+H]+; 200.0601 found 200.0600. IR max /cm-1: 3268 (NH), 3154 (CH), 
1659 (CO).  




Copper (II) acetate monohydrate (0.3 g, 1.5 mmol) was added to 1-methyl-5-
thioureido-1H-imidazole-4-carboxamide (68) (0.2 g, 1 mmol) in 1N NaOH (50 mL). The 
reaction mixture was heated to reflux for 1.5 h. After this time, the mixture cooled to 
50 °C then filtered and the solid residue was washed by 1N NaOH. The filtrate was 
acidified with acetic acid to pH 5 and the precipitated product was filtered and dried in 
oven at 50 °C to give (0.12 g, 76%) of (52a). m.p.>300 °C. 1H NMR (400 MHz, DMSO-
d6) H: 3.50 (s, 3H, NCH3), 6.42 (s, 2H, exchange with D2O, NH2), 7.61 (s, 1H, C8H), 
10.51 (s, 1H, exchange with D2O, NH). 13C NMR (100 MHz, DMSO-d6) C: 29.7 (CH3), 
116.9 (C5), 138.5 (C8), 151.9 (C4), 153.9 (C2), 157.3 (C6O). IR max /cm-1: 3348 (NH), 










N7- Benzyl guanine (70).33 
 
In 100 mL flask, guanosine (5 g, 17.6 mmol) was dissolved in 50 mL DMSO. After that, 
benzyl bromide (5 mL, 21 mmol) was added dropwise. The reaction was stirred 
overnight at room temperature. Then, 15 mL of HCl 37% was added in one portion at 
60 °C. After stirring for 1 hour, the solution was poured into 300 mL methanol and was 
left one day for crystallization then the solid was collected by filtration. The product 
was dissolved in HCl (6M) and neutralized by 6M NaOH to give (4.0 g, 94%) of (70). 
m.p.>300 °C. 1H NMR (400 MHz, DMSO-d6) H: 5.38 (s, 2H, NCH2), 6.11 (s, 2H, 
exchange with D2O, NH2), 7.25-7.33 (5H, ArCH), 8.05 (s, 1H, C8H), 10.71 (s, 1H, 
exchange with D2O, NH). MS m/z (ESI+); calculated for (C12H11N5O) [M+H]+; 242.1036 
found 242.1035. IRmax /cm-1: 3401 (NH), 3126 (CH), 1706 (CO). 
N2-Acethyl - 7- benzyl guanine (71).33 
 
To suspension of (70) (1g, 4.1 mmol) in DMAc (10 mL) was added of Ac2O (0.6 mL, 
6.3 mmol). The reaction mixture was heated at 150 °C for 2 hours. The solvent was 
removed under reduced pressure and EtOAc (10 mL) was added to residue followed 
by filtration and washing by acetone to give (0.9 g, 77%) of (71). m.p.= 238-239 °C (lit 
236-238). 1H NMR (400 MHz, DMSO-d6) H: 2.13 (s, 3H, CH3CO), 5.48 (s, 2H, NCH2), 
7.26-7.33 (5H, ArCH), 8.33 (s, 1H, C8-H), 11.56 (s, 1H, exchange with D2O, N-H), 
12.09 (s, 1H, exchange with D2O, AcNH). 13C NMR (100 MHz, DMSO-d6) C: 24.2 
(CH3CO), 49.6 (CH2Ph), 111.6 (C5), 128.0 (2×ArCH), 129.1 (2×ArCH), 137.8 (ArC), 
144.6 (C8), 147.7 (C2), 157.7 (C6O), 173.6 (NHCOCH3). MS m/z (ESI+); calculated 
for (C14H13N5O2) [M+H]+; 284.1142 found 284.1139. IR max /cm-1: 3138 (NH), 1713 








2-acetamido-7-benzyl-9-methyl-6-oxo-6,9-dihydro-1H-purin-7-ium bromide (72).  
 
To a suspension of (71) (0.85 g, 3.0 mmol) in DMF (5 mL) was added iodomethane 
(0.18 mL, 3.0 mmol). The reaction mixture was heated 40 °C and stirred for 3 days. 
After this time the solvent was removed in vacuo and the solid was washed by acetone 
to give (0.97 g, 86%) of (72). m.p.= 264 °C (dec). 1H NMR (400 MHz, DMSO-d6) H: 
2.19 (s, 3H, CH3CO), 3.808 (s, 3H, NCH3), 5.67 (s, 2H, NCH2), 7.19-7.47 (5H, ArCH), 
9.58 (s, 1H, C8H), 12.19 (s, 1H, exchange with D2O, NH), 12.57 (s, 1H, exchange with 
D2O, AcNH). 13C NMR (100 MHz, DMSO-d6) C: 24.4 (CH3CO), 31.1 (N9CH3), 51.9 
(CH2Ph), 110.4 (C5), 128.7 (2×ArCH), 129.3 (2×ArCH), 134.7 (ArC), 140.9 (C8), 148.4 
(C4), 151.0 (C2), 151.8 (CO), 174.5 (CH3CO). IR max /cm-1:  3130 (NH), 3017 (CH), 




To suspension of guanosine (2.0 g, 7.0 mmol) in 30 mL of dry DMF was added N-
bromosuccinimide (1.4 g, 7.8 mmol) and the reaction mixture was stirred over the 3 
days at room temperature. After such time. The mixture was concentrated in vacuo, 
then cold water added to the mixture and the precipitated solid was filtered and washed 
by acetone to give (1.64 g, 66%) of (73). m.p.= 210-211 °C (dec), (lit 201-203). 1H 
NMR (400 MHz, DMSO-d6) H: 3.49 (m, 1H, CH2), 3.63 (m, 1H, CH2), 3.83 (m, 1H, 
CH), 4.11 (m, 1H, CH), 4.93 (t, J 5.5 Hz, 1H, OH), 4.99 (m, 1H, CH), 5.1 (d, J 5.2 Hz, 
1H, OH ), 5.45 ( d, J 6.2 Hz, 1H, OH), 5.66 ( d, J 6.0 Hz., 1H, CH) , 6.49 (s, 2H, NH2), 
10.82 (s, 1H, NH ). 13C NMR (100 MHz, DMSO-d6) C: 62.4 (CH2), 70.7 (CH), 70.9 
(CH), 86.3 (CH), 90.1 (CH), 117.9 (C5), 121.6 (C8), 152.5 (C4), 153.9 (C2), 155.9 




(C6O). MS m/z (ESI+); calculated for (C10H12BrN5O5) [M+H]+; 362.0095 found 
362.0091. IR max /cm-1: 3118 (NH), 2933 (CH), 1680 (CO). 
8-mercaptoguanine (75). 
 
A mixture of 8-bromoguanosine (73) (1.0 g, 2.7 mmol) and thiourea (0.5 g, 6.5 mmol) 
in anhydrous ethanol (15 mL) was refluxed for 24 h. The mixture was cooled to room 
temperature; the solid was filtered, dried to give (0.4 g, 47%) of (74). 
A mixture of 8-mercaptoguanosine (74) (0.4 g, 1.2 mmol) and 15 mL of 3N HCl was 
heated to 100 °C for 1.5 hours. The precipitated solid was filtrated and washed by 
acetone to give (0.11 g, 56%) of (75). m.p.>300 °C. 1H NMR (400 MHz, DMSO-d6) H: 
6.49 (s, 2H, NH2), 10.8 (s, 1H, NH), 12.34 (s, 1H, NH), 12.52 (s, 1H, NH). 13C NMR 
(100 MHz, DMSO-d6) C: 105.3 (C5), 151.1 (C4), 151.2 (C2), 154.4 (C6), 164.5 (C8). 
IR max /cm-1: 3407 (NH). MS m/z (ESI+); calculated for (C5H5N5OS) [M+H]+; 184.0288 
found 184.0281. 
Preparation of compounds from 76a to 76ac.  
General procedure (A): 76a-76g, 76q, 76t, 76u, 76w and 76x. 
To a solution of 8-mercaptoguanine (0.1 g, 0.54 mmol) in 0.5N NaOH (3 mL) was 
added bromide derivative (0.61 mmol). The reaction mixture was stirred for time at 
room temperature. At this time, the solution was acidified by acetic acid and the 
precipitated solid was filtrated and washed by water then acetone to give product.  
General procedure (B): 76h-76o, 76r, 76y and 76ac. 
To a solution of 8-mercaptoguanine (0.1 g, 0.54 mmol) in 0.5N NaOH (3 mL) was 
added bromide derivative (0.61 mmol) in ethanol or acetone (0.8 mL). The reaction 
mixture was stirred for time at room temperature. At this time, the solution was acidified 
by acetic acid and the precipitated solid was filtrated and washed by water then 
acetone to give product.  
General procedure (C): 76s, 76v, 76z and 76aa. 
To a stirred solution of sodium hydride (1.1 eq) in DMF (3 mL) was added via syringe  
a solution of 8-mercaptoguanine (0.1 g, 0.54 mmol)  in DMF (3 mL) and the reaction 
was stirred for 30 min. Bromide derivative (0.61 mmol) was added dropwise, and after 
complete addition the reaction was stirred for time at room temperature. At this time, 




the solvent was removed by vacuum and the residue was quenched by water, the solid 
was filtered and washed by acetone. 
2-amino-8-((3-fluorobenzyl)thio)-1,9-dihydro-6H-purin-6-one (76a).  
 
Following procedure (A) outlined above, the product (76a) was isolated as solid (69 
mg, 44%, Table 4, Entry 1). m.p.= 229 °C (dec). 1H NMR (400 MHz, DMSO-d6) H: 
4.37 (s, 2H, SCH2), 6.32 (s, 2H, exchange with D2O, NH2), 7.03-7.34 (4H, ArCH), 10.54 
(br, 1H exchange with D2O, NH), 12.54 (s, exchange with D2O, NH). 13C NMR (100 
MHz, DMSO-d6) C: 35.5 (SCH2), 114.4 (d, J 20.5 Hz, ArCH), 115.8 (d, J 21.5 Hz, 
ArCH), 117.7 (C5), 125.3 (ArCH), 130.7 (d, J 8.5 Hz, ArCH), 141.2 (d, J 7.5 Hz, ArC), 
148.7 (C8), 153.7 (C4), 154.0 (C2), 156.2 (C6O), 162.4 (d, J 242.0 Hz, ArCF). 19F 
NMR (376.5 MHz, DMSO-d6) F -113.3 (Ar-F). IR max /cm-1: 3315(NH), 3099 (CH), 




Following procedure (A) outlined above, the product (76b) was isolated as solid (100 
mg, 64%, Table 4, Entry 2). m.p.= 280 °C (dec). H1 NMR (400 MHz, DMSO-d6)H: 
2.23 (s, 3H, CH3Ar), 4.33 (s, 2H, CH2Ar), 6.50 (s, 2H, NH2), 7.02-7.17 (m, 4H, ArCH), 
11.09 (s, br ,1H, NH). 13C NMR (100 MHz, DMSO-d6) C: 21.3 (CH3Ar), 36.1 (CH2Ar), 
115.6 (C5), 126.3 (ArCH), 128.3 (ArCH), 128.8 (ArCH), 129.8 (ArCH), 137.9 (ArC), 
138.0 (ArC), 143.5 (C8), 153.7 (C4), 155.7 (C2, C6O). MS m/z (ESI+); calculated for 
(C13H13N5OS) [M+H]+; 288.0914 found 288.0913. IR max /cm-1: 3311 (NH), 3072 (CH), 











Following procedure (A) outlined above, the product (76c) was isolated as solid (107 
mg, 62%, Table 4, Entry 3). m.p.= 275 °C (dec). H1 NMR (400 MHz, DMSO-d6)H: 
4.45 (s, 2H, CH2Ar), 6.30 (s, 2H, NH2), 7.51-7.71 (m, 4H, ArCH), 10.63 (s, br, 1H, NH), 
12.59 (s, br, 1H, NH). MS m/z (ESI+); calculated for (C13H10 F3N5OS) [M+H]+; 342.0631 
found 342.0626. IR max /cm-1: 3308 (NH), 3136 (CH), 2873 (CH), 1651 (CO), 1329 
(ArCF3), 1115 (CF). 
2-amino-8-((2-methylbenzyl)thio)-1,9-dihydro-6H-purin-6-one (76d). 
 
Following procedure (A) outlined above, the product (76d) was isolated as solid (103 
mg, 72%, Table 4, Entry 4). m.p.= 290 °C (dec). H1 NMR (400 MHz, DMSO-d6)H: 
2.34 (s, 3H, CH3), 4.37 (s, 2H, CH2), 6.38 (s, br, 2H, NH2), 7.09-7.28 (m, 4H, ArCH), 
10.81 (s, br, 1H, NH), 12.66 (s, br, 1H, NH). 13C NMR (100MHz, DMSO-d6) C: 19.2 
(CH3Ar), 34.6 (CH2Ar), 115.9 (C5), 126.4 (ArCH), 128.0 (ArCH), 130.1 (ArCH), 130.7 
(ArCH), 135.5 (ArC), 137.0 (C4), 143.5 (C8), 153.8 (C2), 155.9 (C6O). MS m/z (ESI+); 
calculated for (C13H13N5OS) [M+H]+; 288.0914 found 288.0914. IR max /cm-1: 3304 
(NH), 3066 (CH), 2856 (CH), 1658 (CO). 
2-amino-8-((3,5-difluorobenzyl)thio)-1,9-dihydro-6H-purin-6-one (76e). 
 
Following procedure (A) outlined above, the product (76e) was isolated as solid (116 
mg, 75%, Table 4, Entry 5). m.p.= 293 °C (dec). H1 NMR (400 MHz, DMSO-d6)H: 
4.38 (s, 2H, CH2Ar), 6.63 (s, br, 2H, NH2), 7.07-7.10 (m, 3H, ArCH), 11.01 (s, br, 1H, 
NH), 12.65 (s, br, 1H, NH). 13C NMR (100 MHz, DMSO-d6) C: 35.0 (CH2Ar), 103.1 (t, 
J 25.5 Hz, ArCH), 112.2 (d, J 6.5 Hz, ArCH), 112.4 (d, J 6.5 Hz, ArCH), 116.3 (C5), 




143.2 (ArC), 143.3 (C4), 143.4 (C8), 153.9 (C2), 155.6 (C6O), 161.2 (d, J 13.5 Hz, 
CF), 163.7 (d, J 13.5 Hz CF). 19F NMR (376.5 MHz, DMSO-d6) F: -110.03 (Ar-F). MS 
m/z (ESI+); calculated for (C12H9F2N5OS) [M+H]+; 310.0569 found 310.0558. IR max 
/cm-1: 3322 (NH), 3164 (CH), 2858 (CH), 1658 (CO), 1113 (C-F). 
2-amino-8-(benzylthio)-1,9-dihydro-6H-purin-6-one (76f). 
 
Following procedure (A) outlined above, the product (76f) was isolated as solid (92 
mg, 65%, Table 4, Entry 6). m.p.= 295 °C (dec). H1 NMR (400 MHz, DMSO-d6)H: 
4.36 (s, 2H, CH2), 6.33 (s, br, 2H, NH2), 7.24-7.34 ( 5H, ArCH), 10.71 (s,, br, 1H, NH), 
12.55 (br, 1H, NH). 13C NMR (100 MHz, DMSO-d6) C: 36.1 (SCH2), 116.8 (C5), 127.7 
(ArCH), 128.9 (ArCH), 129.2 (ArCH), 138.1 (ArC), 142.0 (C8), 153.6 (C2), 155.5 
(C6O). MS m/z (ESI+); calculated for (C12H11N5OS) [M+H]+; 274.0757 found 274.0755. 
IR max /cm-1: 3306 (NH), 3027 (CH), 2684 (CH), 1651 (CO). 
2-amino-8-((4-methoxybenzyl)thio)-1,9-dihydro-6H-purin-6-one (76g). 
 
Following procedure (A) outlined above, the product (76g) was isolated as solid (33 
mg, 20%, Table 4, Entry 7). m.p.= 242 °C (dec). 1H NMR (400 MHz, DMSO-d6)H: 
3.69 (s, 3H, OCH3), 4.29 (s, 2H, CH2), 6.51 (s, br, 2H, NH2), 6.83 (d, J 8.2 Hz, 2H, 
ArCH), 7.26 (d, J 8.1 Hz, 2H, ArCH), 10.97 (s, br, 1H, NH), 12.07 (br, 1H, NH). MS 
m/z (ESI+); calculated for (C13H13N5O2S) [M+H]+; 304.0863 found 304.0863. IR max 




Following procedure (B) outlined above, the product (76h) was isolated as solid (146 
mg, 82%, Table 4, Entry 8). m.p.= 280 °C (dec). 1H NMR (400 MHz, DMSO-d6)H: 




3.83 (s, 3H, OCH3), 4.78 (s, 2H, CH2), 6.26 (s, br, 2H, NH2), 7.04 (d, J 8.7 Hz, 2H, 
ArCH), 8.00 (d, J 8.6 Hz, 2H, ArCH), 10.66 (br, 1H, N-H), 12.49 (br, 1H, N-H). 13C 
NMR (100 MHz, DMSO-d6) C: 31.1 (S-CH2), 56.0 (OCH3), 114.6 (ArCH), 114.7 
(ArCH), 115.6 (C5), 128.6 (ArC), 131.2 (2×ArCH), 140.7 (C8), 151.3 (C2), 154.4 
(C6O), 163.7 (ArC), 192.3 (CO). MS m/z (ESI+); calculated for (C14H13N5O3S) [M+H]+; 
332.0812 found 332.0808. IR max /cm-1: 3322 (NH), 3081(CH), 2923 (CH), 1651 (CO), 
1700 (CO), 1021 (OMe). 
2-amino-8-((2-oxo-2-(p-tolyl)ethyl)thio)-1,9-dihydro-6H-purin-6-one (76i). 
 
Following procedure (B) outlined above, the product (76i) was isolated as solid (137 
mg, 81%, Table 4, Entry 9). m.p.= 271 °C (dec). 1H NMR (400 MHz, DMSO-d6)H: 
2.37 (s, 3H, ArCH3), 4.83 (s, 2H, CH2), 6.26 (s, br, 2H, NH2), 7.34 (d, J 8.0 Hz, 2H, 
ArCH), 7.90 (d, J 8.0 Hz, 2H, ArCH), 10.52 (br, 1H, N-H), 12.51 (br, 1H, N-H). ). 13C 
NMR (100 MHz, DMSO-d6) C: 21.6 (ArCH3), 39.9 (S-CH2), 117.5 (C5), 128.9 
(2×ArCH), 129.5 (2×ArCH), 133.2 (ArC), 140.7 (C8), 144.6 (ArC), 153.7 (C2), 156.0 
(C6O), 193.5 (CO). MS m/z (ESI+); calculated for (C16H13N5O2S) [M+H]+; 316.0863 





Following procedure (B) outlined above, the product (76j) was isolated as solid (98 
mg, 57%, Table 4, Entry 10). m.p.= 263 °C (dec). 1H NMR (400 MHz, DMSO-d6)H: 
4.80 (s, 2H, CH2), 6.57 (s, br, 2H, NH2), 7.36 (t, J 8.8 Hz, 2H, ArCH), 8.1 (dd, J 5.6 Hz, 
8.6 Hz, 2H, ArCH), 10.51 (br, 1H, NH), 12.53 (br, 1H, NH). 13C NMR (100 MHz, DMSO-
d6) C: 31.1 (SCH2), 105.3 (C5), 116.3 (d, J 22.0, 2×ArCH), 131.9 (d, J 9.5, 2×ArCH), 
132.6 (ArC), 151.1 (C8), 153.6 (C2), 154.6 (C6O), 164.4 (d, J 3.5, CF), 192.6 (CO). 




19F NMR (376.5 MHz, DMSO-d6) F: -105.2 (Ar-F). MS m/z (ESI+); calculated for 
(C13H10FN5O2S) [M+H]+; 320.0612 found 320.0617. IR max /cm-1: 3324 (NH), 3078 
(CH), 2923 (CH), 1650 (CO), 1156 (C-F). 
S-(2-amino-6-oxo-6,9-dihydro-1H-purin-8-yl) 2-hydroxyethanethioate (76k). 
 
Following procedure (B) outlined above, the product (76k) was isolated as solid (114 
mg, 88%, Table 4, Entry 11). m.p.>300 °C. 1H NMR (400 MHz, DMSO-d6)H: 3.96 (s, 
2H, CH2), 6.24 (s, br, 2H, NH2), 10.51 (s, br, 1H, N-H), 12.88 (br, 1H, N-H). 13C NMR 
(100 MHz, DMSO-d6) C: 34.1 (S-CH2), 115.4 (C5), 143.2 (C8), 153.6 (C2), 155.4 
(C6O), 170.2 (CO). MS m/z (ESI+); calculated for (C7H7 N5O3S) [M+H]+; 242.03 found  




Following procedure (B) outlined above, the product (76l) was isolated as solid (117 
mg, 62%, Table 4, Entry 12). m.p.= 241 °C (dec). 1H NMR (400 MHz, DMSO-d6)H: 
4.97 (s, 2H, CH2), 6.11 (s, br, 2H, NH2), 7.59-8.69 (2H, ArCH), 7.98-8.03 (3H, ArCH), 
8.09-8.11 (1H, ArCH), 8.80 (s, 1H, ArCHa), 10.38 (s, 1H, N-H), 12.48 (1H, NH). 13C 
NMR (100 MHz, DMSO-d6) C: 39.9 (SCH2), 115.8 (C5), 124.1 (ArCH), 127.5 (ArCH), 
128.1 (ArCH), 128.8 (ArCH), 129.3 (ArCH), 130.1 (ArCH), 131.1 (ArCH), 132.5 (ArC), 
133.1 (ArC), 135.6 (ArC), 143.7 (C8), 153.5 (C4), 155.6 (C2), 156.5 (C6O), 194.1 
(CO). MS m/z (ESI+); calculated for (C17H13N5O2S) [M+H]+; 352.0863 found 352.0864. 












Following procedure (B) outlined above, the product (76m) was isolated as solid (141 
mg, 69%, Table 4, Entry 13). m.p.= 261 °C (dec). 1H NMR (400 MHz, DMSO-d6)H: 
4.83 (s, 2H, CH2), 6.18 (s, 2H, NH2), 7.40-7.44 (m, 3H, ArCH), 7.52 (d, J 7.8 Hz, 2H, 
ArCH), 7.76 (d, J 8 Hz, 2H, ArCH), 8.11 (d, J 8 Hz, 2H, ArCH), 10.53 (s, br,1H, NH), 
12.63 (s, br,1H, NH). 13C NMR (100 MHz, DMSO-d6) C: 39.7 (SCH2), 117.4 (C5), 
127.1 (ArCH), 127.3 (2×ArCH), 127.5 (2×ArCH), 129.5 (2×ArCH), 129.6 (2×ArCH), 
130.1 (ArC), 134.7 (ArC), 139.3 (ArC), 145.2 (C8), 152.6 (C4), 156.4 (C2), 158.8 
(C6O), 194.5 (CO). MS m/z (ESI+); calculated for (C19H15N5O2S) [M+H]+; 378.1019 




Following procedure (B) outlined above, the product (76n) was isolated as solid (159 
mg, 98%, Table 4, Entry 14). m.p.= 265 °C (dec). 1H NMR (400 MHz, DMSO-d6)H: 
4.84 (s, 2H, CH2), 6.35 (s, 2H, NH2), 7.51-7.55 (2H, ArCH), 7.64-7.68 (1H, ArCH), 
8.00-8.02 (2H, ArCH), 10.84 (s, br, 1H, NH), 12.39 (s, br, 1H, NH). 13C NMR (100 MHz, 
DMSO-d6) C: 39.9 (S-CH2), 117.0 (C5), 128.8 (2×ArCH), 129.2 (2×ArCH), 134.1 
(ArCH), 135.8 (ArC), 144.1 (C8), 153.6 (C4 and C2), 155.6 (C6O), 194.0 (CO). MS 
m/z (ESI+); calculated for (C13H11N5O2S) [M+H]+; 302.0706 found 302.0711. IR max 











Following procedure (B) outlined above, the product (76o) was isolated as solid (167 
mg, 98%, Table 4, Entry 15). m.p.= 234 °C (dec). 1H NMR (400 MHz, DMSO-d6)H: 
4.77 (s, 2H, CH2), 6.26 (s, 2H,  NH2), 6.85 (d, J 8.1 Hz, 2H, ArCH), 7.88 (d, J 8.1 Hz, 
2H, ArCH), 10.47 (s, 1H, NH), 10.53 (s, 1H, OH), 12.51 (s, br, 1H, NH). 13C NMR (100 
MHz, DMSO-d6) C: 39.7 (SCH2), 115.8 (2×ArCH), 116.0 (C5), 127.2 (ArC), 131.5 
(2×ArCH), 152.3 (C8), 153.5 (C4), 154.0 (C2), 155.5 (C6O), 162.9 (ArC), 191.9 (CO). 
MS m/z (ESI+); calculated for (C13H11N5O3S) [M+H]+; 318.0655 found 318.0650. IR 
max /cm-1: 3115 (NH), 2915 (CH), 1651 (CO), 1578 (CO). 
3-(((2-amino-6-oxo-6,9-dihydro-1H-purin-8-yl)thio)methyl)benzonitrile (76p). 
 
Following procedure (A) outlined above, the product (76p) was isolated as solid (71 
mg, 44%, Table 4, Entry 16). 1H NMR (400 MHz, DMSO-d6)H: 4.40 (s, 2H, CH2), 6.33 
(2H, NH2), 7.35-7.94 (4H, ArCH), 10.67 (s, br, 1H, NH), 12.53 (s, br, 1H, NH). 13C NMR 
(100 MHz, DMSO-d6) C: 35.19 (CH2), 110.2 (C5) 111.7, (ArCCN), 119.1 (ArCN), 
128.7 (ArCH), 130.1 (ArCH), 132.8 (ArCH), 134.2 (ArCH), 138.2 (ArC), 140.42 (C8), 
153.7 (C4), 155.8 (C2) 156.0 (C6O). MS m/z (ESI+); calculated for (C13H10N6OS) 
[M+H]+; 299.071 found 299.0719. IR max /cm-1:  3320 (NH), 3090 (CH), 2873 (CH), 
2228 (CN), 1650 (CO). 
2-amino-8-((4-isopropylbenzyl)thio)-1,9-dihydro-6H-purin-6-one (76q). 
 
Following procedure (A) outlined above, the product (76q) was isolated as solid (22 
mg, 13%, Table 4, Entry 17). m.p.= 291 °C. 1H NMR (400 MHz, DMSO-d6)H: 1.15 
(d, J 6.6 Hz, 6H, 2×CH3), 2.82 (m, 1H, CH), 4.31 (s, 2H, CH2), 6.30 (2H, NH2), 7.14-




7.35 (4H, ArCH), 10.17 (s, 1H, NH), 12.49 (s, 1H, NH). 13C NMR (100 MHz, DMSO-
d6) C: 24.3 (2×CH3), 33.5 (CH), 35.8 (SCH2), 117.6 (C5), 125.1 (2×ArCH), 129.2 
(ArCH), 129.2 ((2×ArCH), 135.4 (ArC), 141.1 (C8), 147.9 (ArC), 153.6 (C4), 154.5 
(C2), 156.2 (C6O). MS m/z (ESI+); calculated for (C15H17 N5OS) [M+H]+; 316.1227 
found 316.1224. IR max /cm-1: 3301 (NH), 3147 (CH), 2957 (CH), 2868 (CH), 1666 
(CO). 
 8-(([1,1'-biphenyl]-4-ylmethyl)thio)-2-amino-1,9-dihydro-6H-purin-6-one (76r). 
 
Following procedure (B) outlined above, the product (76r) was isolated as solid (105 
mg, 58%, Table 4, Entry 18). m.p.>300 °C. 1H NMR (400 MHz, DMSO-d6)H: 4.42 (s, 
2H, CH2Ar), 6.34 (2H, NH2), 7.30-7.62 (9H, ArCH), 10.68 (s, br, 1H, NH), 12.57 (s, br, 
1H, NH). 13C NMR (100 MHz, DMSO-d6) C: 35.7 (SCH2), 117.3 (C5), 127.0 (2×ArCH), 
127.2 (2×ArCH), 127.8 (ArCH), 129.3 (2×ArCH), 129.8 (ArCH), 137.5 (ArC), 139.5 
(ArC), 140.3 (ArC), 144.3 (C8), 153.6 (C4 and C2), 155.84 (C6). MS m/z (ESI+); 
calculated for (C18H15N5OS) [M+H]+; 350.107 found 350.1073. IR max /cm-1: 3317 
(NH), 3150 (CH), 2871 (CH), 1651 (CO). 
2-amino-8-((3,3-dimethoxypropyl)thio)-1,9-dihydro-6H-purin-6-one (76u). 
 
Following procedure (A) outlined above, the product (76u) was isolated as solid (89 
mg, 58%, Table 4, Entry 19). 1H NMR (400 MHz, DMSO-d6)H: 1.86 (q, 2H, 
SCH2CH2), 3.06 (t, J 7.2 Hz, 1H, CH), 3.20 (s, 6H, 2 × CH3), 4.43 (t, J 5.5 Hz, 2H, 
SCH2), 6.28 (s, 2H, NH2), 10.58 (s, 1H, NH). 12.45 (s, 1H, NH). 13C NMR (100 MHz, 
DMSO-d6) C: 27.5 (CH2S), 32.9 (SCH2CH2), 53.1 (2×OCH3), 103.5 (CH), 116.5 (C5), 
143.9 (C8), 154.0 (C4), 155.6 (C2), 156.4 (C6O). MS m/z (ESI+); calculated for 
(C10H15N5O3S) [M+H]+; 286.0968 found 286.0982. IR max /cm-1: 3305 (NH), 3142 
(CH), 2934 (CH). 
 
 






Following procedure (A) outlined above, the product (76v) was isolated as solid (95 
mg, 73%, Table 4, Entry 20). 1H NMR (400 MHz, DMSO-d6)H: 3.23 (s, 3H, CH3O), 
3.25 (t, J 6.4 Hz, 2H, CH2), 3.54 (t, J 6.4 Hz, 2H, SCH2), 6.67 (2H, NH2), 11.61 (s, br, 
1H, NH). MS m/z (ESI+); calculated for (C8H11N5O2S) [M+H]+; 242.0706 found 
242.0711. IR max /cm-1: 3330 (NH), 3099 (CH), 1674 (CO), 1098 (OMe). 
2-amino-8-((2-ethylbutyl)thio)-1,9-dihydro-6H-purin-6-one (76w). 
 
Following procedure (C) outlined above, the product (76w) was isolated as solid (137 
mg, 95%, Table 4, Entry 21). m.p.>300 °C. 1H NMR (400 MHz, DMSO-d6)H: 0.82 (t, 
J 7.3 Hz, 6H, 2× CH3), 1.35 (m, 4H, 2 × CH2), 1.49 (m, 1H, CH), 3.12 (d, J 4.8 Hz, 2H, 
SCH2), 6.24 (s, 2H, NH2), 10.49 (s, 1H, NH), 12.47 (s, 1H, NH). MS m/z (ESI+); 
calculated for (C11H17N5OS) [M+H]+; 268.1227 found 268.1231. IR max /cm-1: 3325 
(NH), 3089 (CH), 2960 (CH), 2870 (CH), 1650 (CO). 
 2-amino-8-(isopentylthio)-1,9-dihydro-6H-purin-6-one (76x).        
 
Following procedure (A) outlined above, the product (76x) was isolated as solid (112 
mg, 82%, Table 4, Entry 22). m.p.= 293 °C (dec). 1H NMR (400 MHz, DMSO-d6)H: 
0.85 (d, J 6.6 Hz, 6H, 2×CH3), 1.48 (m, 2H, CH2), 1.63 (m, 1H, CH), 3.09 (2H, SCH2), 
6.31 (s, 2H, NH2), 10.63 (s, 1H, NH). 12.47 (s, 1H, NH). 13C NMR (100 MHz, DMSO-
d6) C: 22.5 (2×CH3), 27.2 (CH), 30.1 (CHCH2), 38.6 (SCH2), 117.6 (C5), 141.5 (C8), 
153.5 (C4 and C2), 156.1 (C6O). MS m/z (ESI+); calculated for (C10H15N5OS) [M+H]+; 
254.107 found 254.1076. IR max /cm-1: 3306 (NH), 3122 (CH), 2934 (CH), 2867 (CH), 
1657 (CO). 






Following procedure (A) outlined above, the product (76y) was isolated as solid (59 
mg, 37%, Table 4, Entry 23). m.p.= 286 °C (dec). 1H NMR (400 MHz, DMSO-d6)H: 
0.81-2.06 (13H, 6 × CH2 and 1× CH), 3.08 (t, J 7.6 Hz, 2H, SCH2), 6.23 (s,4.8 2H, 
NH2), 10.69 (s,1H, NH). 12.46 (s,  1H, NH). 13C NMR (100 MHz, DMSO-d6) C: 26.1 
(2×CH2), 26.5 (CH2), 29.7 (CH2), 32.8 (2×CH2), 36.6 (CH), 37.1 (SCH2), 116.0 (C5), 
144.1 (C8), 153.7 (C4 and C2), 155.8 (C6O). MS m/z (ESI+); calculated for 
(C13H19N5OS) [M+H]+; 294.1383 found 294.1384. IR max /cm-1: 3318 (NH), 3155 (CH), 
2918 (CH), 1657 (CO). 
2-amino-8-((2-bromobenzyl)thio)-1,9-dihydro-6H-purin-6-one (76z). 
 
Following procedure (B) outlined above, the product (76z) was isolated as solid (114 
mg, 60%, Table 4, Entry 24). m.p.= 284 °C (dec). 1H NMR (400 MHz, DMSO-d6)H: 
4.44 (s, 2H, CH2), 6.31 (s, br, 2H, NH2), 7.18-7.62 (4H, ArCH), 10.71 (s, br, 1H, NH), 
12.59 (s, br, 1H, NH). 13C NMR (100 MHz, DMSO-d6) C: 36.8 (SCH2), 116.1 (C5), 
124.4 (C-Br), 128.3 (ArCH), 130.0 (ArCH), 131.5 (ArCH), 133.1 (ArCH), 137.4 (ArC), 
143.2 (C8), 153.8 (C4 and C2), 156.1 (C6O). MS m/z (ESI+); calculated for 
(C12H10BrN5OS) [M+H]+; 351.9862 found 351.9878. IR max /cm-1: 3305 (NH), 3098 
(CH), 2900 (CH), 1657 (CO). 
S-(2-amino-6-oxo-6, 9-dihydro-1H-purin-8-yl) diphenylcarbamothioate (76aa). 
 
Following procedure (C) outlined above, the product (76aa) was isolated as solid (47 
mg, 23%, Table 4, Entry 25). m.p >300 °C. 1H NMR (400 MHz, DMSO-d6)H: 6.39 (s, 




br, 2H, NH2), 7.38-7.46 (10H, ArCH), 10.59 (s, br, 1H, NH), 12.81 (s, br, 1H, NH). 13C 
NMR (100 MHz, DMSO-d6) C: 118.7 (C5), 128.58 (2×ArC), 130.07 (10×ArCH), 141.3 
(C8), 154.1 (C4), 154.8 (C2), 156.7 (C6O), 165.0 (CO). MS m/z (ESI+); calculated for 
(C18H14N6O2S) [M+H]+; 379.0972 found 379.0982. IR max /cm-1: 3323 (NH), 3158 
(CH), 1673 (CO), 1659 (CO). 
2-amino-8-((2-oxopropyl)thio)-1,9-dihydro-6H-purin-6-one (76ab). 
 
Following procedure (C) outlined above, the product (76ab) was isolated as solid (48 
mg, 37%, Table 4, Entry 26). m.p.>300 °C. 1H NMR (400 MHz, DMSO-d6)H: 2.22 (s, 
3H, CH3), 4.15 (s, 2H, CH2), 6.34 (s, br, 2H, NH2), 10.58 (s, br, 1H, NH), 12.51 (s, br, 
1H, NH). 13C NMR (100 MHz, DMSO-d6) C: 29.1 (CH3), 42.2 (CH2), 114.8 (C5), 142.8 
(C8), 153.6 (C4), 155.0 (C2), 155.8 (C6O), 202.7 (CO). MS m/z (ESI+); calculated for 
(C8H9 N5O2S) [M+H]+; 240.055 found 240.0571. IR max /cm-1: 3308 (NH), 3111 (CH), 






Following procedure (A) outlined above, the product (76ac) was isolated as solid (61 
mg, 30%, Table 4, Entry 27). 1H NMR (400 MHz, DMSO-d6)H:  4.47 (s, 2H, SCH2), 
6.30 (s, 2H, NH2), 7.51-7.55 (m, 4H, ArCH), 7.63-7.70 (m, 5H, ArCH), 10.53 (s, br, 1H, 
NH), 12.55 (s, br, 1H, NH). 13C NMR (100 MHz, DMSO-d6) c: 35.8 (SCH2), 117.7 (C5), 
129.0 (2×ArCH), 129.3 (2×ArCH), 130.0 (2×ArCH), 130.3 (2×ArCH), 133.0 (ArCH), 
136.2 (ArC), 137.4 (ArC), 140.5 (ArC), 143.4 (C8), 153.8 (C4), 154.0 (C2), 156.2 (CO), 
195.7 (CO). MS m/z (ESI+); calculated for (C19H15N5O2S) [M+H]+; 378.1019 found 











In 250 mL round bottomed flask, which immersed in crushed ice bath, was placed 50 
mL of ammonium hydroxide NH4OH. A solution of (1S)-(+)-10-Camphorsulfonyl 
chloride (5 g, 19.7 mmol) in 50 mL dichloromethane (DCM) was added dropwise over 
2 hours to NH4OH. After this time, the mixture was transferred to separating funnel 
and shaking many times then the lower dichloromethane layer was separated, and the 
aqueous layer was extracted (2×50 mL) with dichloromethane. The organic layers 
dried over MgSO4 and solvent was removed in vacuo to give (3.8 g, 85%) of (304). 
m.p.= 123-124 °C. 1H NMR (400 MHz, CDCl3)H: 0.93 (s, 3H, (CH3)2CR2), 1.00 (s, 
3H, (CH3)2CR2), 1.44-2.26 (m, 7H, CH2CH2CHCH2), 3.11 (d, J 15.0 Hz, 1H, CH2SO2), 
3.45 (d, J 15.0 Hz, 1H, CH2SO2), 5.36 (br, 2H, NH2). 13C NMR (100 MHz, CDCl3) C: 
19.3 ((CH3)2CR2), 19.9 ((CH3)2CR2), 26.8 (CH2CH2CHCH2), 27.0 (CH2CH2CHCH2), 
42.8 (CH2CH2CHCH2), 43.0 (CH2CH2CHCH2), 49.1 (C (CH3)2), 54.0 (CH2SO2), 59.3 
(CCH2SO2), 217.7 (CO). IR max /cm-1: 3301(NH), 2962 (CH), 1729 (CO), 1151, 1334 
(SO2). MS m/z (ESI+); calculated for (C10H17NO3S) [M+Na]+; 254.0821 found 
254.0817.  
(3aR,6R)-8,8-dimethyl-4,5,6,7-tetrahydro-3H-3a,6-methanobenzo[c]isothiazole         
2,2-dioxide (305).82 
 
In round -bottomed flask placed 0.7 g of Amberlyst 15 ion - exchange resin, (5 g, 21.6 
mmol) of camphorsulfonamide (304) and 200 mL toluene. Dean- Stark trap and reflux 
condenser were fitted with the flask. The mixture was stirred and reflux for 5 hours. 
After this time, the heat was stopped, and 100 mL dichloromethane was added. 
Solvents were removed in vacuo to give 95 % of (305). m.p.= 229 230 °C. 1H NMR 
(400 MHz, CDCl3)H: 0.87 (s, 3H, (CH3)2CR2), 1.08 (s, 3H, (CH3)2CR2), 1.45-2.80 




(7H, CH2CH2CHCH2), 2.95 (d, J 13.2 Hz, 1H, CH2SO2), 3.06 (d, J 13.2 Hz, 1H, 
CH2SO2). 13C NMR (100 MHz, CDCl3) C: 18.9 ((CH3)2C), 19.4 ((CH3)2C), 26.6 
(CH2CH2CHCH2), 28.3 (CH2CH2CHCH2), 35.9 (CH2CH2CHCH2), 44.5 
(CH2CH2CHCH2), 47.9 (C(CH3)2), 49.4 (CH2SO2), 64.4 (CCH2SO2), 195.3 (C=N). IR 
max /cm-1: 2964 (CH), 1731 (C=N), 1133, 1318 (SO2). MS m/z (ESI+); calculated for 




(0.88 g, 23.5 mmol) of LiALH4 and 250 mL dry THF were placed in round -bottomed 
flask, which was fitted with Soxlet extraction apparatus and condenser with nitrogen. 
(5.0 g, 23.5 mmol) of camphorsulfonimine (305) was placed into the Soxlet extraction 
apparatus. The reaction mixture was heated (100 °C) overnight.  After this time, the 
reaction mixture allowed to cool. (1N) HCl was added to react with the unreacted 
LiALH4. The contents were transferred to separation funnel, the lower aqueous silver 
layer was separated and washed by (3×100) dichloromethane then the organic layers 
were dried over MgSO4. The solvents were removed in vacuo to afford of (306). m.p.= 
165-166 °C. 1H NMR (400 MHz, CDCl3)H: 0.93 (s, 3H, (CH3)2CR2), 1.13 (s, 3H, 
(CH3)2CR2), 1.25-2.00 (7H, CH2CH2CHCH2), 3.07 (d, J 13.4 Hz, 1H, CH2SO2), 3.11 
(d, J 13.4 Hz, 1H, CH2SO2), 3.40 (q, J 7.0 Hz,  1H, NCH), 4.01 (br, 1H, NH). 13C NMR 
(100 MHz, CDCl3) C: 20.4 ((CH3)2CR2), 20.5 ((CH3)2CR2), 26.8 (CH2CH2CHCH2), 
31.8 (CH2CH2CHCH2), 36.0 (CH2CH2CHCH2), 44.7 (CH2CH2CHCH2), 47.4 (C(CH3)2), 
50.3 (CH2SO2), 55.0 (CCH2SO2), 62.8 (CHN). IR max /cm-1: 3287 (NH), 2955 (CH), 













Camphorsultam (306) (2.5 g, 11.6 mmol) in dry toluene (20 mL) was added to a 
solution of Sodium hydride (0.5 g, 12.76 mmol) in dry toluene (20 mL) at 0 °C. After 
the addition was completed, the reaction was stirred for 1 hour at room temperature. 
Next, Bromoacetyl (1.1 eq.) was added dropwise over 2 hours at 0 °C. The reaction 
mixture was allowed to warm to room temperature and stirred for 72 hours. After this 
time, the reaction was quenched by careful addition of water (25 mL) and extracted 
with ethyl acetate (25 mL). The organic layer was washed with brine (15 mL), dried 
over sodium sulfate and filtered. The solvent was removed in vacuo to yield crude 
which was subjected to column chromatography to give (2.0 g, 52%) of (307). 1H NMR 
(400 MHz, CDCl3)H: 0.98 (s, 3H, (CH3)2CR2), 1.16 (s, 3H, (CH3)2CR2), 1.33-2.18 
(7H, CH2CH2CHCH2), 3.44 (d, J 13.8 Hz, 1H, CH2SO2), 3.51 (d, J 13.8 Hz, 1H, 
CH2SO2), 3.90 (q, J 5.0 Hz, 1H, NCH), 4.19 (d, J 13.0 Hz, 1H, COCH2), 4.32 (d, J 13.0 
Hz, 1H, COCH2). 13C NMR (100 MHz, CDCl3) C: 19.8 ((CH3)2CR2), 20.7 ((CH3)2 CR2), 
26.4 (CH2CH2CHCH2), 27.5 (CH2CH2CHCH2), 32.8 (CH2CH2CHCH2), 37.9 (COCH2), 
44.5 (CH2CH2CHCH2), 47.8 (C(CH3)2), 49.0 (CCH2SO2), 57.7 (CH2SO2), 65.4 (CHN), 
164.5 (NCOCH2). MS m/z (ESI+); calculated for (C12H18BrNO3S) [M+H]+; 336.0264 




To a solution of (307) (1.34 g, 4 mmol) in THF (20 mL) at 0 °C was added in three 
portions dimethylamine hydrochloride (12 mmol) and triethylamine (20 mmol) over a 
period of 10 minutes. The reaction was allowed to stir for 12 hours, then was allowed 




to warm to room temperature. It was filtered through a celite plug, washed with THF 
(30 mL) and concentrated under reduced pressure to give crude (1.6 g, 94%) of (308), 
which was purified by flash column chromatography. m.p.= 121-122 °C. 1H NMR (400 
MHz, CDCl3)H: 0.95 (s, 3H, (CH3)2CR2), 1.13 (s, 3H, (CH3)2CR2), 1.31-1.42 (m, 2H, 
C(R)2HCH2CH2), 1.83-2.15 (m, 5H, CH2C(R)HCH2CH2), 2.36 (s, 6H, 2×N(CH3)2), 3.40 
(d, J 13.7 Hz, 1H, CH2SO2), 3.46 (d, J 13.7 Hz, 1H, CH2SO2), 3.55 (s, 2H, NCH2CO), 
3.88 (t, J 5.2 Hz, 1H, NCH). 13C NMR (100 MHz, CDCl3) C: 19.8 ((CH3)2CR2), 20.8 
((CH3)2 CR2), 26.4 (CH2CH2CHCH2), 32.8 (CH2CH2CHCH2), 38.4 (CH2CH2CHCH2), 
44.6 (CH2CH2CHCH2), 45.5 (2× N(CH3)2), 47.8 (C(CH3)2), 48.8 (CCH2SO2), 52.9 
(CCH2SO2), 61.2 (COCH2N), 65.2 (CHN), 169.3 (CO). IR max /cm-1: 2956 (CH), 1706 
(CO), 1306, 1131 (SO2). MS m/z (ESI+) calculated for C14H24N2O3S [M+H]+; 301.158 
found 301.1581. 
Preparation of 4-(Bromomethyl)acetophenone. 
 
 A suspension of methyl p-tolyl ketone (2.5 g, 18.6 mmol, 1 eq.), NBS (3.64 g, 20.5 
mmol, 1.1 eq.) and AIBN (0.15 g, 0.93 mmol, 0.05 eq.) in CH3CN (30 mL) was reflux 
for 3 hours. The solvent was removed in in vacuo then toluene (15 mL) was added to 
the residue, filtered and concentrated in vacuo to give 4-(Bromomethyl) acetophenone 
(3.5 g, 90%). 1H NMR (400 MHz, CDCl3)H: 2.60 (s, 3H, ArCOCH3), 4.50 (s, 2H, 
ArCH2Br),7.47 (d, J 8.3 Hz, 2H, ArCH), 7.47 (d, J 8.3 Hz, 2H, ArCH). 
General procedure (D) for synthesis of ammonium bromide salts (309a-m). 
(0.2 g, 0.66 mmol, 1 eq.) of (308), aryl bromide (1.9 mmol, 3 eq.) and toluene (10 mL) 
were heated to 50 °C for 3 days. The formed precipitate was collected over a glass 
sinter, washed with hexane, and dried in vacuo to give the crude salt, which was used 












Following procedure (D) outlined above, the product (309a) was isolated as solid 
(0.297 g, 95%, Table 19, Entry 1).  m.p.= 124-126 °C. 1H NMR (400 MHz, CDCl3)H: 
0.88 (s, 3H, (CH3)2CR2), 1.03 (s, 3H, (CH3)2CR2), 1.32-1.45 (m, 2H, C(R)2HCH2CH2), 
1.75-1.88 and 2.13 (m, 5H, CH2CH2C(R)HCH2), 3.46 (m, 8H, 2×N(CH3)2 and CH2SO2), 
4.10 (br, m, 1H, NCH), 4.66 (d, J 16.5 Hz, NCH2Ar), 5.02-5.12 (br, m, 1H, NCH2Ar), 
5.17 (d, J 13.4 Hz, 1H, COCH2N), 5.20 (d, J 13.4 Hz, 1H, COCH2N), 7.32-7.42 ((m, 
3H, ArCH), 7.54 (d, J 7.2 Hz, 2H, ArCH). 13C NMR (100 MHz, CDCl3) C: 19.8 
((CH3)2CR2), 21.0 ((CH3)2CR2), 26.0 (CH2CH2CHCH2), 32.8 (CH2CH2CHCH2), 38.2 
(CH2CH2CHCH2), 44.9 (CH2CH2CHCH2), 48.0 (C(CH3)2), 49.4 (CCH2SO2), 50.7 
(N(CH3)2), 51.1 (N(CH3)2), 52.6 (CH2SO2), 60.9 (NCH2Ar), 64.6 (NCH), 67.9 
(COCH2N), 126.9 (ArC), 129.2 (2 x ArCH), 130.9 (ArCH), 133.2 (2 x ArCH), 163.4 
(CO). IR max /cm-1: 2958 (CH), 1692 (CO), 1336, 1136 (SO2). 
2-((3aR,6R)-8,8-dimethyl-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo 
[c]isothiazol-1(4H)-yl)-N-(4-methoxybenzyl)-N,N-dimethyl-2-oxoethan-1-
aminium bromide (309b). 
 
Following procedure (D) outlined above, the product (309b) was isolated as solid 
(0.328 g, 98%, Table 19, Entry 2). m.p.= 130-132 °C. 1H NMR (400 MHz, CDCl3)H: 
0.95 (s, 3H, (CH3)2CR2), 1.11 (s, 3H, (CH3)2CR2), 1.41-1.52 (m, 2H, C(R)2HCH2CH2), 
1.84-1.96 and 2.17 (m, 5H, CH2C(R)HCH2CH2), 3.49 (s, 3H, N(CH3)2), 3.51 (app s, 
5H, N(CH3)2 and CH2SO2), 3.80 (s, 3H, OCH3), 4.17 (br, m, 1H, NCH), 4.53 (d, J 16.8 
Hz, 1H, NCH2Ar), 5.02-5.11 (br, m, 1H, NCH2Ar), 5.16 (d, J 12.6 Hz , 1H, COCH2N), 




5.21 (d, J 12.6 Hz, 1H, COCH2N), 6.90 (d, J 8.6 Hz, 2H, ArCH), 7.52(d, J 8.6 Hz, 2H, 
ArCH). 13C NMR (100 MHz, CDCl3) C: 19.8 ((CH3)2CR2), 21.0 ((CH3)2CR2), 26.1 
(CH2CH2CHCH2), 32.8 (CH2CH2CHCH2), 38.2 (CH2CH2CHCH2), 44.9 
(CH2CH2CHCH2), 48.1 (C(CH3)2), 49.4 (CCH2SO2), 50.6 (N(CH3)2), 51.0 (N(CH3)2), 
52.6 (CH2SO2), 55.4 (OCH3), 60.6 (NCH2Ar), 64.7 (NCH), 68.2 (COCH2N), 114.7 
(2×ArCH), 118.6 (ArC), 134.7 (2×ArCH), 161.5 (ArC), 163.3 (CO). IR max /cm-1: 2942 
(CH), 1697 (CO), 1341, 1140 (SO2), 1026 (OMe). MS m/z (ESI+) calculated for 





Following procedure (D) outlined above, the product (309c) was isolated as solid 
(0.255 g, 75%, Table 19, Entry 3). m.p.= 140-143 °C. 1H NMR (400 MHz, CDCl3)H: 
0.96 (s, 3H, (CH3)2CR2), 1.10 (s, 3H, (CH3)2CR2), 1.40-1.51 (m, 2H, CHCH2CH2), 1.88-
1.96 (m, 3H, CH2CHCH2CH2), 2.18 (br, 2H, CH2CHCH2CH2), 2.61 (s, 3H, ArCOCH3) 
3.45 (d, J 8.4 Hz, 1H, CH2SO2), 3.53 (d, J 8.4 Hz, 1H, CH2SO2),  3.57 (s, 3H, N(CH3)2), 
3.63 (s, 3H, N(CH3)2), 4.12-4.21 (br m, 1H, NCH), 4.65 (d, J 16.7 Hz, 1H, NCH2Ar), 
5.05-5.14 (br m, 1H, NCH2Ar), 5.39 (d, J 12.5 Hz, 1H, COCH2N), 5.44 (d, J 12.5 Hz, 
1H, COCH2N), 7.79 (d, J 8.0 Hz, 2H, ArCH), 7.97 (d, J 8.0 Hz, 2H, ArCH). 13C NMR 
(100 MHz, CDCl3) C: 19.8 ((CH3)2CR2), 21.0 ((CH3)2CR2), 26.1 (CH2CH2CHCH2), 
26.8 (ArCOCH3), 32.8 (CH2CH2CHCH2), 38.2 (CH2CH2CHCH2), 44.8 
(CH2CH2CHCH2), 48.1 (C(CH3)2), 49.5 (CCH2SO2), 51.1 (N(CH3)2), 51.5 (N(CH3)2), 
52.7 (CH2SO2), 61.1 (NCH2Ar), 64.9 (NCH), 67.3 (COCH2N), 129.0 (2 x ArCH), 131.6 
(ArC), 133.7 (2×ArCH), 138.8 (ArCCOCH3), 163.0 (CO), 197.3 (ArCOCH3). IR max 
/cm-1: 2948 (CH), 1685 (CO), 1341, 1140 (SO2). MS m/z (ESI+) calculated for 
C23H33N2O4S [M-Br]+; 433.2156 found 433.2158. 








Following procedure (D) outlined above, the product (309d) was isolated as solid (0.33 
g, 98%, Table 19, Entry 4). 1H NMR (400 MHz, CDCl3)H: 0.99 (s, 3H, (CH3)2CR2), 
1.15 (s, 3H, (CH3)2CR2), 1.41-1.52 (m, 2H, CHCH2CH2), 1.94-1.96 (m, 3H, 
CH2CHCH2CH2), 2.19 (br, 2H, CH2CHCH2CH2), 3.48 (d, J 14.4 Hz, 1H, CH2SO2), 3.50 
(d, J 14.4 Hz, 1H, CH2SO2), 3.58 (s, 3H, N(CH3)2), 3.71 (s, 3H, N(CH3)2), 4.09 (br, 1H, 
NCH), 4.46 (d, J 16.8 Hz, 1H, NCH2Ar), 5.02 (br, 1H, NCH2Ar), 5.44 (d, J 14.4 Hz, 1H, 
COCH2N), 5.51 (d, J 14.4 Hz, 1H, COCH2N), 7.14-7.26 (3H, ArCH). 13C NMR (100 
MHz, CDCl3) C: 19.8 ((CH3)2CR2), 20.1 ((CH3)2CR2), 26.1 (CH2CH2CHCH2), 32.8 
(CH2CH2CHCH2), 38.1 (CH2CH2CHCH2), 44.9 (CH2CH2CHCH2), 48.0 (C(CH3)2), 49.5 
(CCH2SO2), 51.5 (N(CH3)2), 51.9 (N(CH3)2), 52.6 (CH2SO2), 60.5 (NCH2Ar), 61.4 
(NCH), 64.8 (COCH2N), 116.1 (dd, JCF 16.2, 7.5, ArC), 117.7 (dd, JCF 24.8, 8.3, ArCH), 
120.3 (dd, JCF 23.7, 8.9, ArCH), 122.0 (dd, JCF 24.5, 2.1, ArCH), 157.1 (dd, JCF 35.5, 
2.5, ArCF), 159.5 (dd, JCF 36.9, 2.1, ArCF), 162.9 (CO). 19F NMR (376.5 MHz, CDCl3): 
 -117.62 – -118.35 (m, 1F, ArCF), -115.26 – -116.00 (m, 1F, ArCF). IR max /cm-1: 
2943 (CH), 1692 (CO), 1336, 1136 (SO2). MS m/z (ESI+) calculated for C21H29F2N2O3S 









Following procedure (D) outlined above, the product (309e) was isolated as solid 
(0.371 g, 97%, Table 19, Entry 5). m.p.= 121-123 °C. 1H NMR (400 MHz, CDCl3)H: 
0.94 (s, 3H, (CH3)2CR2), 1.10 (s, 3H, (CH3)2CR2), 1.40-1.51 (m, 2H, CHCH2CH2), 1.86-
1.95 (m, 5H, CH2CHCH2CH2), 3.49 (d, J 14.2 Hz, 1H, CH2SO2), 3.54 (d, J 14.2 Hz, 
1H, CH2SO2),  3.61 (s, 3H, N(CH3)2), 3.66 (s, 3H, N(CH3)2), 4.14 (br, 1H, NCH), 4.70 
(d, J 16.7 Hz, 1H, NCH2Ar), 5.09-5.15 (br, m, 1H, NCH2Ar),  5.42 (d, J 12.4 Hz, 1H, 
COCH2N), 5.47 (d, J 12.4 Hz, 1H, COCH2N), 7.45 (t, J 7.4 Hz, 2H, ArCH), 7.58 (t, J 
7.4 Hz, 1H, ArCH), 7.75 (d, J 7.8 Hz, 2H, ArCH), 7.80 (d, J 7.8 Hz, 2H, ArCH), 7.82 
(d, J 8.4 Hz, 2H, ArCH). 13C NMR (100 MHz, CDCl3) C: 19.8 ((CH3)2CR2), 21.0 
((CH3)2CR2), 26.1 (CH2CH2CHCH2), 32.8 (CH2CH2CHCH2), 38.2 (CH2CH2CHCH2), 
44.9 (CH2CH2CHCH2), 48.0 (C(CH3)2), 49.5 (CCH2SO2), 51.1 (N(CH3)2), 51.5 
(N(CH3)2), 52.7 (CH2SO2), 61.1 (NCH2Ar), 64.8 (NCH), 67.4 (COCH2N), 128.5 (2 x 
ArCH), 130.1 (2 x ArCH), 130.5 (ArCH), 130.9 (ArC), 133.1 (ArCH), 133.4 (ArCH), 
136.6 (ArCH), 139.8 (2 x ArC), 163.2 (CO), 195.7 (ArCO). IR max /cm-1: 2959 (CH), 
1690 (CO), 1655 (CO), 1335, 1136 (SO2). MS m/z (ESI+) calculated for C28H35N2O4S 
[M-Br]+; 495.2318 found 495.2312. 
2-((3aR,6R)-8,8-dimethyl-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo 
[c]isothiazol-1(4H)-yl)-N-(4-(methoxycarbonyl)benzyl)-N,N-dimethyl-2-
oxoethan-1-aminium bromide (309f). 
 
Following procedure (D) outlined above, the product (309f) was isolated as solid 
(0.281 g, 95%, Table 19, Entry 6). 1H NMR (400 MHz, CDCl3)H: 0.98 (s, 3H, 
(CH3)2CR2), 1.13 (s, 3H, (CH3)2CR2), 1.41-1.53 (m, 2H, CHCH2CH2), 1.88-2.09 (m, 
5H, CH2CHCH2CH2) 3.48 (d, J 12.3 Hz, 1H, CH2SO2), 3.55 (d, J 12.3 Hz, 1H, 
CH2SO2),  3.57 (s, 3H, N(CH3)2), 3.66 (s, 3H, N(CH3)2), 3.94 (s, 3H, ArCOOCH3), 4.12 
(br, 1H, NCH), 4.47 (d, J 16.8 Hz, 1H, NCH2Ar), 4.89-5.26 (br, m, 1H, NCH2Ar),  5.41 
(d, J 11.6 Hz, 1H, COCH2N), 5.48 (d, J 11.6 Hz, 1H, COCH2N), 7.75 (d, J 8.2 Hz, 2H, 
ArCH), 8.09 (d, J 8.2 Hz, 2H, ArCH).  13C NMR (100 MHz, CDCl3) C: 19.8 ((CH3)2CR2), 
21.0 ((CH3)2CR2), 26.1 (CH2CH2CHCH2), 32.8 (CH2CH2CHCH2), 38.2 




(CH2CH2CHCH2), 44.8 (CH2CH2CHCH2), 48.1 (C(CH3)2), 49.5 (CCH2SO2), 51.2 
(N(CH3)2), 51.6 (N(CH3)2), 52.5 (ArCOOCH3) 52.6 (CH2SO2), 61.1 (NCH2Ar), 64.7 
(NCH), 67.3 (COCH2N), 130.3 (2 x ArCH), 131.4 (ArCCOOCH3), 132.5 (ArC), 133.4 





Following procedure (D) outlined above, the product (309g) was isolated as solid 
(0.324 g, 96%, Table 19, Entry 7). 1H NMR (400 MHz, CDCl3)H: 0.98 (s, 3H, 
(CH3)2CR2), 1.14 (s, 3H, (CH3)2CR2), 1.40-1.52 (m, 2H, C(R)2HCH2CH2), 1.88-1.98 
and 2.19 (m, 5H, CH2C(R)HCH2CH2), 3.35 (s, 3H, N(CH3)2), 3.45-3.58 (m, 5H, N(CH3)2 
and CH2SO2), 3.67 (s, 3H, N(CH3)2), 4.10 (br, m, 1H, NCH), 4.52 (d, J 16.8 Hz, 1H, 
NCH2Ar), 4.49-5.20 (br, m, 1H, NCH2Ar), 5.29-5.48 (m, 2H, COCH2N), 6.93 (td, J 9.3 
Hz, 2.2 Hz, 1H, ArCH), 7.05 (td, J 8.3 Hz, 2.1 Hz, 1H, ArCH), 8.13-8.19 (m, 1H, ArCH). 
13C NMR (100 MHz, CDCl3) C: 19.8 ((CH3)2CR2), 20.9 ((CH3)2CR2), 26.1 
(CH2CH2CHCH2), 32.8 (CH2CH2CHCH2), 38.1 (CH2CH2CHCH2), 44.8 
(CH2CH2CHCH2), 48.0 (C(CH3)2), 49.4 (CCH2SO2), 51.2 (N(CH3)2), 51.6 (N(CH3)2), 
52.6 (CH2SO2), 60.6 (NCH2Ar), 61.1 (NCH), 64.8 (COCH2N), 104.8 (t, JCF 25.5, ArCH), 
110.9 (dd, JCF 14.5, 4.0, ArC), 113.0 (dd, JCF 20.3, 2.1, ArCH), 137.4 (dd, JCF 9.3, 3.1, 
ArCH), 162.3 (dd, JCF 223.7, 2.2, ArCF), 164.7 (CO), 164.8 (dd, JCF 225.8, 12.0, ArCF). 
19F NMR (376.5MHz, CDCl3):  -103.0 – -103.8 (m, 1F, ArCF), -106.8 – -108.2 (m, 1F, 
ArCF). IR max /cm-1: 2960 (CH), 1692 (CO), 1337, 1137 (SO2). MS m/z (ESI+) 













Following procedure (D) outlined above, the product (309h) was isolated as solid 
(0.276 g, 96%, Table 19, Entry 8). 1H NMR (400 MHz, CDCl3)H: 0.97 (s, 3H, 
(CH3)2CR2), 1.12 (s, 3H, (CH3)2CR2), 1.42-1.50 (m, 2H, CHCH2CH2), 1.90-1.96 (m, 
3H, CH2CHCH2CH2), 2.19 (br, 2H, CH2CHCH2CH2),  3.53 (d, J 12.8 Hz, 1H, CH2SO2), 
3.59 (d, J 12.8 Hz, 1H, CH2SO2),  3.60 (s, 3H, N(CH3)2), 3.68 (s, 3H, N(CH3)2), 4.09 
(br, 1H, NCH), 4.65 (d, J 16.8 Hz, 1H, NCH2Ar), 5.08 (br, 1H, NCH2Ar), 5.42 (d,  J 12.4 
Hz, 1H, COCH2N), 5.49 (d, J 12.4 Hz, 1H, COCH2N), 6.96 (t, JHF 8.6, 2.2 Hz, 1H, 
ArCH), 7.15-7.30 (m, 2H, ArCH). 13C NMR (100 MHz, CDCl3) C: 19.8 ((CH3)2CR2), 
20.9 ((CH3)2CR2), 26.1 (CH2CH2CHCH2), 32.8 (CH2CH2CHCH2), 38.1 
(CH2CH2CHCH2), 44.8 (CH2CH2CHCH2), 48.0 (C(CH3)2), 49.5 (CCH2SO2), 51.2 
(N(CH3)2), 51.6 (N(CH3)2), 52.6 (CH2SO2), 61.1 (NCH2Ar), 64.9 (NCH), 66.3 
(COCH2N), 106.8 (t, JCF 24.5, ArCH), 116.4 (dd, JCF 19.8, 7.4, 2 x ArCH), 130.3 (t, JCF 
9.8, ArC), 163.0 (dd, JCF 250.6, 12.4, 2 x ArCF). 19F NMR (376.5MHz, CDCl3):  -
106.61 (br s, 2F, ArCF). IR max /cm-1: 2962 (CH), 1689 (CO), 1320, 1136 (SO2). MS 
m/z (ESI+) calculated for C21H29F2N2O3S [M-Br]+; 427.1861 found 427.1862. 
2-((6R,7aR)-8,8-dimethyl-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo 
[c]isothiazol-1(4H)-yl)-N,N-dimethyl-2-oxo-N-(2,4,6-trifluorobenzyl)ethan-1-
aminium bromide (309i). 
 
Following procedure (D) outlined above, the product (309i) was isolated as solid 
(0.332 g, 95%, Table 19, Entry 9). 1H NMR (400 MHz, CDCl3)H: 0.97 (s, 3H, 




(CH3)2CR2), 1.16 (s, 3H, (CH3)2CR2), 1.44-1.54 (m, 2H, CHCH2CH2), 1.89-1.98 (m, 
3H, CH2CHCH2CH2), 2.25 (br, 2H, CH2CHCH2CH2), 3.48 (d, J 13.7 Hz, 1H, CH2SO2), 
3.55 (d, J 13.7 Hz, 1H, CH2SO2), 3.63 (s, 3H, N(CH3)2), 3.64 (s, 3H, N(CH3)2), 4.21 
(br, 1H, NCH), 4.71 (d, J 16.9 Hz, 1H, NCH2Ar), 5.12 (d, J 13.6 Hz, 1H, COCH2N), 
5.22 (d, J 13.6 Hz, 1H, COCH2N), 5.50 (br, 1H, NCH2Ar), 6.86 (t, JHF 8.2 Hz, 2H, 
ArCH). 13C NMR (100 MHz, CDCl3) C: 19.8 ((CH3)2CR2), 21.0 ((CH3)2CR2), 26.1 
(CH2CH2CHCH2), 32.9 (CH2CH2CHCH2), 38.1 (CH2CH2CHCH2), 44.9 
(CH2CH2CHCH2), 48.1 (C(CH3)2), 49.4 (CCH2SO2), 51.7 (N(CH3)2), 52.3 (N(CH3)2), 
52.7 (CH2SO2), 56.0 (NCH2Ar), 61.6 (NCH), 64.8 (COCH2N), 100.9 (d, JCF 21.6 Hz, 
ArC), 101.8 (td, JCF 25.9, 3.4, 2xArCH), 163.1 (dt, JCF 127.8, 11.8, 3xArCF), 163.8 
(CO). 19F NMR (376.5MHz, CDCl3): -98.8 (br s, 1F, ArCF), -103.2 (s, 2F, ArCF). IR 
max /cm-1: 2960 (CH), 1689 (CO), 1338, 1138 (SO2). MS m/z (ESI+) calculated for 





Following procedure (D) outlined above, the product (309j) was isolated as solid 
(0.319 g, 98%, Table 19, Entry 10). 1H NMR (400 MHz, CDCl3)H: 0.98 (s, 3H, 
(CH3)2CR2), 1.13 (s, 3H, (CH3)2CR2), 1.41-1.53 (m, 2H, C(R)2HCH2CH2), 1.88-1.98 
and 2.19 (m, 5H, CH2C(R)HCH2CH2), 3.51 (d, J 11.8 Hz, 1H, CH2SO2), 3.55 (d, J 11.8 
Hz, 1H, CH2SO2), 3.58 (s, 3H, N(CH3)2), 3.65 (s, 3H, N(CH3)2), 4.13 (br, 1H, NCH), 
4.54 (d, J 16.8 Hz, 1H, NCH2Ar), 4.97 (br, 1H, NCH2Ar), 5.36 (d, J 12.5 Hz, 1H, 
COCH2N), 5.42 (d, J 12.5 Hz, 1H, COCH2N), 7.16-7.23 (m, 4H, ArCH). 13C NMR (100 
MHz, CDCl3) C: 19.8 ((CH3)2CR2), 21.0 ((CH3)2CR2), 26.1 (CH2CH2CHCH2), 32.8 
(CH2CH2CHCH2), 38.2 (CH2CH2CHCH2), 44.8 (CH2CH2CHCH2), 48.1 (C(CH3)2), 49.5 
(CCH2SO2), 51.2 (N(CH3)2), 51.6 (N(CH3)2), 52.6 (CH2SO2), 61.0 (NCH2Ar), 64.9 
(NCH), 67.2 (COCH2N), 118.3 (d, JCF 21.3 Hz, ArCH), 120.0 (d, JCF 22.1 Hz, ArCH), 
129.0 (d, JCF 6.9 Hz, ArCH), 129.2 (d, JCF 3.1 Hz, ArCH), 131.1 (d, JCF 8.3 Hz, ArC), 








aminium bromide (309k). 
 
Following procedure (D) outlined above, the product (309k) was isolated as solid 
(0.262 g, 72%, Table 19, Entry 11). 1H NMR (400 MHz, CDCl3)H: 0.99 (s, 3H, 
(CH3)2CR2), 1.15 (s, 3H, (CH3)2CR2), 1.43-1.58 (m, 2H, C(R)2HCH2CH2), 1.94-1.96 
and 2.17 (m, 5H, CH2C(R)HCH2CH2), 3.49 (d, J 13.8 Hz, 1H, CH2SO2), 3.56 (d, J 13.8 
Hz, 1H, CH2SO2), 3.59 (s, 3H, N(CH3)2), 3.66 (s, 3H, N(CH3)2), 4.16 (br, 1H, NCH), 
4.38 (d, J 16.8 Hz, 1H, NCH2Ar), 5.04 (br, 1H, NCH2Ar), 5.33 (d, J 12.3 Hz, 1H, 





Following procedure (D) outlined above, the product (309l) was isolated as solid 
(0.286 g, 96%, Table 19, Entry 12). 1H NMR (400 MHz, CDCl3)H: 0.98 (s, 3H, 
(CH3)2CR2), 1.14 (s, 3H, (CH3)2CR2), 1.397-1.512 (m, 2H, C(R)2HCH2CH2), 1.88-1.99 
(m, 3H, CH2CH2CHCH2), 2.18 (d, 2H, J 5.8, CH2CH2CHCH2), 3.47 (d, J 13.9 Hz, 1H, 
CH2SO2), 3.53 (d, J 13.9 Hz, 1H, CH2SO2), 3.58 (s, 3H, N(CH3)2), 3.69 (s, 3H, 
N(CH3)2), 4.10 (br, 1H, NCH), 4.59 (d, J 16.6, 1H, NCH2Ar), 5.23-5.44 (br, 1H, 
NCH2Ar), 5.50 (d, J 12.9 Hz, 1H, COCH2N), 5.81 (d, J 12.9 Hz, 1H, COCH2N), 7.66 
(td, J 7.1, 8.2, 1H, ArCH), 7.81-7.86 (m, 2H, ArCH), 8.47 ( d, J 8.0 Hz, 1H, ArCH).  13C 
NMR (100 MHz, CDCl3) C: 19.8 ((CH3)2CR2), 21.0 ((CH3)2CR2), 26.2 
(CH2CH2CHCH2), 32.9 (CH2CH2CHCH2), 38.0 (CH2CH2CHCH2), 46.0 




(CH2CH2CHCH2), 48.0 ((C(CH3)2), 49.4 (CCH2SO2), 51.0 (N(CH3)2), 51.9 (N(CH3)2), 
52.7 (CH2SO2), 61.9 (NCH2Ar), 65.1 (NCH camphor), 65.3 (COCH2N), 115.7 (ArCN), 
117.4 (ArCCN), 130.0 (ArC), 131.7 (ArCH), 134.0 (ArCH), 134.1 (ArCH), 136.4 
(ArCH), 167.0 (CO). IR max /cm-1: 2950 (CH), 2223 (CN), 1689 (CO), 1335, 1136 
(SO2). MS m/z (ESI+) calculated for C22H30N3O3S [M-Br]+; 416.2002 found 416.2006. 
General procedure (E) for [1,2]-Stevens rearrangement.  
To a solution benzylic ammonium bromide salt (309a-m) (100 mg, 1 eq.) in DMSO (3 
mL) at room temperature with 5Å molecular sieves was added phosphazene bases 
(BTPP) (1.05 eq.). The reaction mixture was allowed to stir overnight. The crude 
mixture was filtered through a small pad of Celite and washed with Et2O. The organic 
layer was extracted with water (10 mL) and aqueous layer extracted with Et2O (3×15 
mL). The combined organic layers were washed with brine (10 mL), dried (Na2SO4), 
filtered and concentrated in vacuo to give the crude rearranged product, which was 






Following General procedure (E) outlined above, it was isolated as solid (46 mg, 54%, 
Table 21, Entry 1). m.p.= 190-191 °C. 1H NMR (400 MHz, CDCl3)H  0.66 (s, 3H, 
(CH3)2CR2), 0.87 (s, 3H, (CH3)2CR2), 1.26-1.36 (m, 2H, C(R)2HCH2CH2), 1.75-1.86 
(m, 4H, CH2C(R)HCH2CH2), 1.99 (dd, J 13.7 Hz, 7.8 Hz, 1H, CH2C(R)HCH2CH2), 2.50 
(s, 6H, 2×N(CH3)2), 2.97 (dd, J 13.2 Hz, 7.5 Hz, 1H, Ar-CH2), 3.08 (dd, J 13.3 Hz, 7.5 
Hz, 1H, Ar-CH2), 3.37 (s, 2H, CH2SO2), 3.81 (b m, 1H, NCH camphor), 4.19 (t, J 7.5 
Hz, 1H, CHCH2Ar) 7.14-7.18 (m, 1H, ArCH), 7.22-7.26 (m, 4H, ArCH).                                     
13C NMR (100 MHz, CDCl3) C 19.8 ((CH3)2CR2), 20.4 ((CH3)2CR2), 26.4 
(CR2HCH2CH2CR3), 32.8 (CR2HCH2CH2CR3), 34.2 (CH2Ar), 38.2 (CR2HCH2C(R)HN), 
41.6 (2×N(CH3)2), 44.5 (CH2CH2CHCH2), 47.5 (C(CH3)2), 48.0 (CCH2SO2), 53.0 
(CH2SO2), 65.0 (NCH camphor), 67.1 (NCHCH2Ar), 126.5 (ArCH), 128.3 (2×ArCH), 
129.5 (2×ArCH), 137.3 (ArC), 172.2 (CO). IR max (thin film, cm-1): 2947 (CH), 1686 




(CO), 1323, 1137 (SO2). MS m/z (ESI+) calculated for C21H30N2O3 S [M+H]+; 391.205 
found 391.2051. TLC Rf = 0.5 (Toluene:EtOAc, 4:1). HPLC tR = 7.84 min.  






Following General procedure (E) outlined above, it was impure includes 
camphorsultam product. Partial characterisation was only possible, as the product was 
not isolated pure (11%, Table 21, Entry 1). 1H NMR (400 MHz, CDCl3)H 0.96 (s, 3H, 
(CH3)2CR2), 1.18 (s, 3H, (CH3)2CR2), 1.25-1.51 (m, 2H, C(R)2HCH2CH2), 1.84-2.13 
(m, 5H, CH2C(R)HCH2CH2), 2.38 (s, 6H, 2×N(CH3)2), 2.88 (dd, J 14.0 Hz, 7.2 Hz, 1H, 
Ar-CH2), 3.04 (dd, J 14.0 Hz, 7.2 Hz, 1H, Ar-CH2), 3.37 (d, J 13.7 Hz, 1H, CH2SO2), 
3.46 (d, J 13.7 Hz, 1H, CH2SO2), 3.89 (dd, J 7.4 Hz, 5.2 Hz, 1H, NCH camphor), 4.17 
(t, J 7.0 Hz, 1H, CHCH2Ar) 7.16-7.29 (m, 5H, ArCH). 
N-[(2S)-N,N-dimethylamino-4-methoxyphenylphenylalanine]bornane-10,2-
sultam (313b).  
 
                                                                                                                                     
Following General procedure (E) outlined above, it was isolated as solid (41 mg, 50%, 
Table 21, Entry 2). m.p.= 120-121 °C. 1H NMR (400 MHz, CDCl3)H 0.66 (s, 3H, 
(CH3)2CR2), 0.87 (s, 3H, (CH3)2CR2), 1.25-1.35 (m, 2H, C(R)2HCH2CH2), 1.74-1.92 
(m, 4H, CH2C(R)HCH2CH2), 1.99 (dd, J 13.7 Hz, 7.7 Hz, 1H, CH2C(R)HCH2CH2), 2.49 
(s, 6H, 2×N(CH3)2), 2.92 (dd, J 13.3 Hz, 7.6 Hz, 1H, Ar-CH2), 3.01 (dd, J 13.3 Hz, 7.6 
Hz, 1H, Ar-CH2), 3.37 (s, 2H, CH2SO2), 3.75 (s, 3H, ArOCH3), 3.80 (b m, 1H, NCH 
camphor), 4.13 (t, J 7.5 Hz, 1H, CHCH2Ar), 6.78 (d, J 8.5 Hz, 2H, ArCH), 7.16 (d, J 
8.5 Hz, 2H, ArCH). 13C NMR (100 MHz, CDCl3) C 19.8 ((CH3)2CR2), 20.3 ((CH3)2CR2), 
26.4 (CR2HCH2CH2CR3), 32.8 (CR2HCH2CH2CR3), 33.6 (CH2Ar), 38.2 




(CR2HCH2C(R)HN), 41.7 (2×N(CH3)2), 44.5 (CH2CH2CHCH2), 47.5 (C(CH3)2), 48.0 
(CCH2SO2), 53.0 (CH2SO2), 55.2 (ArOCH3), 65.0 (NCH camphor), 67.3 (NCHCH2Ar), 
113.7 (2×ArCH), 129.2 (ArC), 130.5 (2×ArCH), 158.3 (ArC), 172.4 (CO).                                                                                                                            
IR max (thin film, cm-1): 2939 (CH), 1686 (CO), 1325, 1136 (SO2), 1035 (OMe). MS 
m/z (ESI+) calculated for C22H32N2O4S [M+H]+; 421.2156 found 421.2160. TLC Rf = 






Following General procedure (E) outlined above, it was isolated as solid (12 mg, 15%, 
Table 21, Entry 2). m.p.= 139-141 °C. 1H NMR (400 MHz, CDCl3) H 0.96 (s, 3H, 
(CH3)2CR2), 1.18 (s, 3H, (CH3)2CR2), 1.32-1.47 (m, 2H, C(R)2HCH2CH2), 1.84-2.13 
(m, 5H, CH2C(R)HCH2CH2), 2.38 (s, 6H, 2×N(CH3)2), 2.83 (dd, J 14.1 Hz, 7.2 Hz, 1H, 
Ar-CH2), 2.97 (dd, J 14.1 Hz, 7.2 Hz, 1H, Ar-CH2), 3.38 (d, J 13.7 Hz, 1H, CH2SO2), 
3.47 (d, J 13.7 Hz, 1H, CH2SO2), 3.77 (s, 3H, ArOCH3), 3.90 (dd, J 7.2 Hz, 5.3 Hz, 1H, 
NCH camphor), 4.12 (t, 7.5 Hz, 1H, CHCH2Ar), 6.81 (d, J 8.5 Hz, 2H, ArCH), 7.17 (d, 
J 8.5 Hz, 2H, ArCH). 13C NMR (100 MHz, CDCl3) C 19.9 ((CH3)2CR2), 21.0 
((CH3)2CR2), 26.4 (CR2HCH2CH2CR3), 32.4 (CR2HCH2CH2CR3), 33.0 (CH2Ar), 39.1 
(CR2HCH2C(R)HN), 41.3 (2×N(CH3)2), 44.9 (CH2CH2CHCH2), 47.7 (C(CH3)2), 48.2 
(CCH2SO2), 53.2 (CH2SO2), 55.1 (ArOCH3), 65.4 (NCH camphor), 67.4 (NCHCH2Ar), 
113.7 (2×ArCH), 130.2 (ArC), 130.3 (2×ArCH), 158.0 (ArC), 171.6 (CO). IR max (thin 
film, cm-1): 2960 (CH), 1682 (CO), 1326, 1176 (SO2), 1032 (OMe). MS m/z (ESI+) 
calculated for C22H32N2O4S [M+H]+; 421.2156 found 421.2160. TLC Rf = 0.20 










Following General procedure (E) outlined above, it was isolated as solid (48 mg, 57%, 
Table 21, Entry 3). m.p.= 136-137 °C. 1H NMR (400 MHz, CDCl3)H 0.62 (s, 3H, 
(CH3)2CR2), 0.86(s, 3H, (CH3)2CR2), 1.25-1.37 (m, 2H, C(R)2HCH2CH2), 1.75-1.89 (m, 
4H, CH2C(R)HCH2CH2), 2.00 (dd, J 13.7 Hz, 7.8 Hz, 1H, CH2C(R)HCH2CH2), 2.49 (s, 
6H, 2×N(CH3)2), 2.56 (s, 3H, ArCOCH3), 3.02 (dd, J 13.2 Hz, 7.5 Hz, 1H, Ar-CH2), 3.13 
(dd, J 13.2 Hz, 7.5 Hz, 1H, Ar-CH2), 3.38 (s, 2H, CH2SO2), 3.84 (dd, J 7.0 Hz, 4.9 Hz, 
1H, NCH camphor), 4.21 (t, J 7.5 Hz, 1H, CHCH2Ar), 7.35 (d, J 8.2 Hz, 2H, ArCH), 
7.85 (d, J 8.2 Hz, 2H,ArCH). 13C NMR (100 MHz, CDCl3) C 19.7 ((CH3)2CR2), 20.2 
((CH3)2CR2), 26.3 (CR2HCH2CH2CR3), 26.6 (COCH3), 32.8 (CR2HCH2CH2CR3), 34.2 
(CH2Ar), 38.2 (CR2HCH2C(R)HN), 41.6 (2×N(CH3)2), 44.4 (CH2CH2CHCH2), 47.5 
(C(CH3)2), 48.1 (CCH2SO2), 53.0 (CH2SO2), 65.1 (NCH camphor), 66.8 (NCHCH2Ar), 
128.4 (2×ArCH), 129.7 (2×ArCH), 135.5 (ArC), 143.3 (ArC), 171.0 (CO), 197.8 (ArCO).     
IR max (thin film, cm-1): 2954 (CH), 1681 (CO), 1605 (CO), 1324, 1136 (SO2). MS m/z 
(ESI+) calculated for C22H32N2O4S [M+H]+; 433.2156 found 433.2158. TLC Rf = 0.07 






Following General procedure (E) outlined above, it was isolated as solid (10 mg, 11%, 
Table 21, Entry 3). m.p.= 144-146 °C. 1H NMR (400 MHz, CDCl3)H 0.96 (s, 3H, 
(CH3)2CR2), 1.18 (s, 3H, (CH3)2CR2), 1.31-1.41 (m, 2H, C(R)2HCH2CH2), 1.86-2.16 
(m, 5H, CH2C(R)HCH2CH2), 2.38 (s, 6H, 2×N(CH3)2), 2.56 (s, 3H, ArCOCH3), 2.94 
(dd, J 14.0 Hz, 7.2 Hz, 1H, Ar-CH2), 3.07 (dd, J 14.0 Hz, 7.2 Hz, 1H, Ar-CH2), 3.38 (d, 
J 13.7 Hz, 1H, CH2SO2), 3.48 (d, J 13.7 Hz, 1H, CH2SO2), 3.89 (dd, J 7.4 Hz, 5.2 Hz, 
1H, NCH camphor), 4.19 (t, J 7.2 Hz, 1H, CHCH2Ar), 7.33 (d, J 8.1 Hz, 2H, ArCH), 
7.86 (d, J 8.1 Hz, 2H, ArCH). 13C NMR (100 MHz, CDCl3) C 19.9 ((CH3)2CR2), 21.0 
((CH3)2CR2), 26.4 (CR2HCH2CH2CR3), 26.5 (COCH3), 33.0 (CR2HCH2CH2CR3), 33.2 
(CH2Ar), 39.0 (CR2HCH2C(R)HN), 41.2 (2×N(CH3)2), 44.8 (CH2CH2CHCH2), 47.7 
(C(CH3)2), 48.2 (CCH2SO2), 53.1 (CH2SO2), 65.4 (NCH camphor), 66.9 (NCHCH2Ar), 
128.4 (2×ArCH), 129.6 (2×ArCH), 135.3 (ArC), 144.2 (ArC), 171.1 (CO), 197.9 (ArCO). 




IR max (thin film, cm-1): 2933 (CH), 1679 (CO), 1603 (CO), 1330, 1149 (SO2). MS m/z 
(ESI+) calculated for C22H32N2O4S [M+H]+; 433.2156 found 433.2152. TLC Rf = 0.15 






Following General procedure (E) outlined above, it was isolated as solid (50 mg, 60%, 
Table 21, Entry 4). m.p.= 133-135 °C. 1H NMR (400 MHz, CDCl3)H 0.71 (s, 3H, 
(CH3)2CR2), 0.88 (s, 3H, (CH3)2CR2), 1.24-1.42 (m, 2H, C(R)2HCH2CH2), 1.79-1.94 
(m, 4H, CH2C(R)HCH2CH2), 2.04 (dd, J 13.6 Hz, 7.8 Hz, 1H, CH2C(R)HCH2CH2), 2.49 
(s, 6H, 2×N(CH3)2), 2.96 (dd, J 13.4 Hz, 7.3 Hz, 1H, Ar-CH2), 3.11 (dd, J 13.4 Hz, 7.3 
Hz, 1H, Ar-CH2), 3.38 (s, 2H, CH2SO2), 3.86 (dd, J 7.4 Hz, 5.2 Hz, 1H, NCH camphor), 
4.17 (dd, J 7.8 Hz, 7.0 Hz, 1H, CHCH2Ar), 6.79-6.85 (m, 1H, ArCH), 6.91-6.98 (m, 2H, 
ArCH). 13C NMR (100 MHz, CDCl3) C 19.7 ((CH3)2CR2), 20.2 ((CH3)2CR2), 26.3 
(CR2HCH2CH2CR3), 27.0 (CR2HCH2CH2CR3), 32.9 (CH2Ar), 38.2 (CR2HCH2C(R)HN), 
41.5 (N(CH3)2), 42.8 (N(CH3)2), 44.5 (CH2CH2CHCH2), 47.5 (C(CH3)2), 48.1 
(CCH2SO2), 52.9 (CH2SO2), 65.2 (NCH camphor), 65.5 (NCHCH2Ar), 114.5 (dd, JCF 
23.8 Hz, 8.5 Hz, ArCH), 116.2 (dd, JCF 25.1Hz, 8.7 Hz, ArCH), 117.7 (dd, JCF 23.8 Hz, 
4.6 Hz, ArCH), 126.2 (dd, JCF 18.2 Hz, 8.0 Hz, ArC), 156.7 (dd, JCF 110.5 Hz, 2.4 Hz, 
ArCF), 159.1 (dd, JCF 110.4 Hz, 2.3 Hz, ArCF), 170.5 (CO). 19F NMR (376.5 MHz, 
CDCl3) F119.571F, ArCF), 123.53 (1F, ArCF). IR max (thin film, cm-1): 2946 (CH), 
1682 (CO), 1327, 1135 (SO2). MS m/z (ESI+) calculated for C21H28N2O3F2S [M+H]+; 










Following General procedure (E) outlined above, it was isolated as solid (27 mg, 29%, 
Table 21, Entry 4). m.p.= 100-101 °C. 1H NMR (400 MHz, CDCl3)H 0.96 (s, 3H, 
(CH3)2CR2), 1.18 (s, 3H, (CH3)2CR2), 1.31-1.41 (m, 2H, C(R)2HCH2CH2), 1.86-2.05 
(m, 4H, CH2C(R)HCH2CH2), 2.11 (dd, J 13.6 Hz, 7.6 Hz, 1H, CH2C(R)HCH2CH2), 2.38 
(s, 6H, 2×N(CH3)2), 2.93 (dd, J 14.0 Hz, 7.2 Hz, 1H, Ar-CH2), 3.02 (dd, J 14.0 Hz, 7.2 
Hz, 1H, Ar-CH2), 3.36 (d, J 13.6 Hz, 1H, CH2SO2), 3.46 (d, J 13.6 Hz, 1H, CH2SO2), 
3.89 (dd, J 7.3 Hz, 5.3 Hz, 1H, NCH camphor), 4.18 (t, J 7.0 Hz, 1H, CHCH2Ar), 6.81-
6.87 (m, 1H, ArCH), 6.91-7.00 (m, 2H, ArCH). 13C NMR (100 MHz, CDCl3) C 19.9 
((CH3)2CR2), 21.0 ((CH3)2CR2), 26.4 (CR2HCH2CH2CR3) and (CR2HCH2CH2CR3), 
33.0 (CH2Ar), 39.0 (CR2HCH2C(R)HN), 41.2 (2×N(CH3)2), 44.9 (CH2CH2CHCH2), 47.7 
(C(CH3)2), 48.1 (CCH2SO2), 53.1 (CH2SO2), 65.3 (NCH camphor), 65.8 (NCHCH2Ar), 
114.2 (dd, JCF 23.7 Hz, 8.7 Hz, ArCH), 115.9 (dd, JCF 25.3 Hz, 8.4 Hz, ArCH), 118.0 
(dd, JCF 23.8 Hz, 4.4 Hz, ArCH), 126.9 (d, J CF 8.0 Hz, ArC), 156.7 (dd, JCF 87.0 Hz, 
2.0 Hz, ArCF), 159.1 (d, JCF 87.2, 2.2 Hz, ArCF), 170.8 (CO). 19F NMR (376.5 MHz, 
CDCl3) F119.69(s, 1F, ArCF), 123.71 (s, 1F, ArCF). IR max (thin film, cm-1): 2942 
(CH), 1686 (CO), 1327, 1131 (SO2). MS m/z (ESI+) calculated for C21H28N2O3F2S 





Following General procedure (E) outlined above, it was isolated as solid (37 mg, 43%, 
Table 21, Entry 5). m.p.= 179-181 °C. 1H NMR (400 MHz, CDCl3)H 0.69 (s, 3H, 
(CH3)2CR2), 0.87 (s, 3H, (CH3)2CR2), 1.25-1.38 (m, 2H, C(R)2HCH2CH2), 1.77-1.89 
(m, 4H, CH2C(R)HCH2CH2), 2.02 (dd, J 13.7 Hz, 7.8 Hz, 1H, CH2C(R)HCH2CH2), 2.52 
(s, 6H, 2×N(CH3)2), 3.07 (dd, J 13.2 Hz, 7.4 Hz, 1H, Ar-CH2), 3.17 (dd, J 13.2 Hz, 7.4 
Hz, 1H, Ar-CH2), 3.39 (s, 2H, CH2SO2), 3.85 (dd, J 6.9 Hz, 7.0 Hz, 1H, NCH camphor), 
4.25 (t, J 7.4 Hz, 1H, CHCH2Ar), 7.38 (d, J 8.0 Hz, 2H, ArCH), 7.47 (t, J 7.4 Hz, 1H, 




ArCH), 7.57 (t, J 7.3 Hz, 1H, ArCH), 7.72 (d, J 8.0 Hz, 2H, ArCH), 7.77 (d, J 7.2 Hz, 
2H, ArCH). 13C NMR (100 MHz, CDCl3) C 19.7 ((CH3)2CR2), 20.4 ((CH3)2CR2), 26.3 
(CR2HCH2CH2CR3), 32.8 (CR2HCH2CH2CR3), 34.1 (CH2Ar), 38.2 (CR2HCH2C(R)HN), 
41.6 (2×N(CH3)2), 44.4 (CH2CH2CHCH2), 47.6 (C(CH3)2), 48.1 (CCH2SO2), 53.0 
(CH2SO2), 65.1 (NCH camphor), 66.8 (NCHCH2Ar), 128.2 (2×ArCH), 129.5 (2×ArCH), 
129.9 ((2×ArCH), 130.3 (2×ArCH), 132.2 (ArCH), 135.8 (ArC), 137.7 (ArC), 143.5 
(ArC), 171.5 (CO), 196.2 (ArCO). IR max (thin film, cm-1): 2948 (CH), 1683 (CO), 1655 
(CO), 1324, 1135 (SO2). MS m/z (ESI+) calculated for C28H34N2O4S [M+H]+; 495.2312 





Following General procedure (E) outlined above, it was isolated as solid (14.5 mg, 
17%, Table 21, Entry 5). m.p.= 124-126 °C. 1H NMR (400 MHz, CDCl3)H 0.97 (s, 
3H, (CH3)2CR2), 1.19 (s, 3H, (CH3)2CR2), 1.33-1.47 (m, 2H, C(R)2HCH2CH2), 1.84-
2.17 (m, 5H, CH2C(R)HCH2CH2), 2.40 (s, 6H, 2×N(CH3)2), 2.98 (dd, J 13.9 Hz, 7.2 Hz, 
1H, Ar-CH2), 3.10 (dd, J  13.7 Hz, 7.2 Hz, 1H, Ar-CH2), 3.38 (d, J 13.6, 1H, CH2SO2), 
3.49 (d, J 13.6, 1H, CH2SO2), 3.91 (dd, J 7.2 Hz, 5.4 Hz, 1H, NCH camphor), 4.22 (t, 
J 6.8 Hz, 1H, CHCH2Ar), 7.37 (d, J 7.8 Hz, 2H, ArCH), 7.48 (t, J 7.8 Hz, 1H, ArCH), 
7.56 (t, J 7.4 Hz, 1H, ArCH), 7.73 (d, J 7.6 Hz, 2H, ArCH), 7.78 (d, J 7.6 Hz, 2H, ArCH). 
13C NMR (100 MHz, CDCl3) C 19.9 ((CH3)2CR2), 21.0 ((CH3)2CR2), 26.4 
(CR2HCH2CH2CR3), 33.0 (CR2HCH2CH2CR3), 33.3 (CH2Ar), 39.1 (CR2HCH2C(R)HN), 
41.2 (2×N(CH3)2), 44.9 (CH2CH2CHCH2), 47.7 (C(CH3)2), 48.2 (CCH2SO2), 53.1 
(CH2SO2), 65.4 (NCH camphor), 67.0 (NCHCH2Ar), 128.1 (2×ArCH), 129.3 (2×ArCH), 
130 ((2×ArCH), 130.2 ((2×ArCH), 132.1 (ArCH), 135.5 (ArC), 137.9 (ArC), 143.6 (ArC), 
171.1 (CO), 196.5 (ArCO).IR max (thin film, cm-1): 2957 (CH), 1684 (CO), 1654 (CO), 
1326, 1131 (SO2). MS m/z (ESI+) calculated for C28H34N2O4S [M+H]+; 495.2312 found 
495.2319. TLC Rf = 0.18 (PE:EtOAc, 7:3). HPLC tR = 6.31 min. 
 









Following General procedure (E) outlined above, it was isolated as solid (32 mg, 41%, 
Table 21, Entry 6). m.p.= 133-134 °C. 1H NMR (400 MHz, CDCl3)H 0.62 (s, 3H, 
(CH3)2CR2), 0.86 (s, 3H, (CH3)2CR2), 1.24-1.36 (m, 2H, C(R)2HCH2CH2), 1.75-1.85 
(m, 4H, CH2C(R)HCH2CH2), 2.00 (dd, J 13.8 Hz, 7.8 Hz, 1H, CH2C(R)HCH2CH2), 2.48 
(s, 6H, 2×N(CH3)2), 3.01 (dd, J 13.2 Hz, 7.5 Hz, 1H, Ar-CH2), 3.12 (dd, J 13.2 Hz, 7.5 
Hz, 1H, Ar-CH2), 3.37 (s, 2H, CH2SO2),  3.83 (br dd, J 7.8 Hz, 4.9 Hz, 1H, NCH 
camphor), 3.89 (s, 3H, COOCH3), 4.20 (t, J 7.5 Hz, 1H, CHCH2Ar), 7.33 (d, J 8.2 Hz, 
2H, ArCH), 7.92 (d, J 8.2 Hz, 2H, ArCH). 13C NMR (100 MHz, CDCl3) C 19.7 
((CH3)2CR2), 20.2 ((CH3)2CR2), 26.3 (CR2HCH2CH2CR3), 32.8 (CR2HCH2CH2CR3), 
34.1 (CH2Ar), 38.2 (CR2HCH2C(R)HN), 41.6 (2×N(CH3)2), 44.4 (CH2CH2CHCH2), 47.5 
(C(CH3)2), 48.1 (CCH2SO2), 52.0 (COOCH3), 53.0 (CH2SO2), 65.1 (NCH camphor), 
66.8 (NCHCH2Ar), 128.4 (ArC), 129.6 (2×ArCH), 129.6 ((2×ArCH), 143.0 (ArC), 167.0 
(ArCO), 171.7 (CO). IR max (thin film, cm-1): 2948 (CH), 1715 (CO), 1683 (CO), 1324, 
1136 (SO2). MS m/z (ESI+) calculated for C23H32N2O5S [M+H]+; 449.2105 found 






Following General procedure (E) outlined above, it was isolated as solid (16 mg, 22%, 
Table 21, Entry 6). m.p.= 161-162 °C. 1H NMR (400 MHz, CDCl3)H 0.96 (s, 3H, 
(CH3)2CR2), 1.18 (s, 3H, (CH3)2CR2), 1.25-1.46 (m, 2H, C(R)2HCH2CH2), 1.86-2.17 
(m, 5H, CH2C(R)HCH2CH2), 2.38 (s, 6H, 2×N(CH3)2), 2.93 (dd, J 13.9 Hz, 7.2 Hz, 1H, 
Ar-CH2), 3.07 (dd, J 13.9 Hz, 7.2 Hz, 1H, Ar-CH2), 3.37 (d, J 13.7, 1H, CH2SO2), 3.47 




(d, J 13.7, 1H, CH2SO2), 3.87 (dd, J 12.1 Hz, 6.2 Hz, 1H, NCH camphor), 3.88 (s, 3H, 
COOCH3), 4.18 (t, J 6.8 Hz, 1H, CHCH2Ar), 7.32 (d, J 8.1 Hz, 2H, ArCH), 7.94 (d, J 
8.1 Hz, 2H, ArCH). 13C NMR (100 MHz, CDCl3) C 19.9 ((CH3)2CR2), 21.0 ((CH3)2CR2), 
26.4 (CR2HCH2CH2CR3), 31.8 (CR2HCH2CH2CR3), 33.0 (CH2Ar), 39.0 
(CR2HCH2C(R)HN), 41.2 (2×N(CH3)2), 44.9 (CH2CH2CHCH2), 47.7 (C(CH3)2), 48.2 
(CCH2SO2), 51.9 (COOCH3), 53.1 (CH2SO2), 65.4 (NCH camphor), 67.0 
(NCHCH2Ar), 128.1 (ArC), 129.4 (2×ArCH), 129.5 (2×ArCH), 143.9 (ArC), 167.1 
(ArCO), 171.1 (CO). IR max (thin film, cm-1): 2953 (CH), 1718 (CO), 1688 (CO), 1327, 
1133 (SO2). MS m/z (ESI+) calculated for C23H32N2O5S [M+H]+; 449.2105 found 






Following General procedure (E) outlined above, it was isolated as solid (35.9 mg, 
42%, Table 21, Entry 7). m.p.= 129-130 °C. 1H NMR (400 MHz, CDCl3)H 0.67 (s, 
3H, (CH3)2CR2), 0.88 (s, 3H, (CH3)2CR2), 1.24-1.37 (m, 2H, C(R)2HCH2CH2), 1.77-
1.87 (m, 4H, CH2C(R)HCH2CH2), 2.02 (dd, J 13.7 Hz, 7.8 Hz, 1H, CH2C(R)HCH2CH2), 
2.49 (s, 6H, 2×N(CH3)2), 2.97 (dd, J 13.3 Hz, 7.6 Hz, 1H, Ar-CH2), 3.09 (dd, J 13.3 Hz, 
7.6 Hz, 1H, Ar-CH2), 3.37 (s, 2H, CH2SO2), 3.84 (dd, J 7.6 Hz, 4.8 Hz, 1H, NCH 
camphor), 4.16 (dd, J 8.2 Hz, 6.6 Hz, 1H, CHCH2Ar), 6.71-6.77 (m, 2H, 2×ArCH), 7.18-
7.24 (m, 1H, ArCH). 13C NMR (100 MHz, CDCl3) C 19.7 ((CH3)2CR2), 20.2 
((CH3)2CR2), 26.3 (CR2HCH2CH2CR3), 26.7 (CR2HCH2CH2CR3), 32.9 (CH2Ar), 38.2 
(CR2HCH2C(R)HN), 41.60 (2×N(CH3)2), 44.5 (CH2CH2CHCH2), 47.5 (C(CH3)2), 48.0 
(CCH2SO2), 52.9 (CH2SO2), 65.1 (NCH camphor), 65.6 (NCHCH2Ar), 103.7 (t, JCF 25.5 
Hz, ArCH), 111.0 (dd, JCF 20.2 Hz, 4.1 Hz, ArCH), 120.2 (dd, JCF 15.5 Hz, 4.0 Hz, 
ArC), 132.1 (dd, JCF 9.3 Hz, 6.4 Hz, ArCH), 160.4 (dd, JCF 59.2 Hz, 12.6 Hz, ArCF), 
162.9 (dd, JCF 57.0 Hz, 12.1 Hz, ArCF), 171.6 (CO). 19F NMR (376.5 MHz, CDCl3) F 
112.86- 112.74 (m, 2F, ArCF). IR max (thin film, cm-1): 2948 (CH), 1685 (CO), 




1330, 1138 (SO2). MS m/z (ESI+) calculated for C21H28N2O3F2S [M+H]+; 427.1861 






Following General procedure (E) outlined above, it was isolated as solid (14.77mg, 
19%, Table 21, Entry 7). m.p.= 125-126 °C. 1H NMR (400 MHz, CDCl3)H 0.96 (s, 
3H, (CH3)2CR2), 1.17(s, 3H, (CH3)2CR2), 1.25-1.41 (m, 2H, C(R)2HCH2CH2), 1.86-2.04 
(m, 4H, CH2C(R)HCH2CH2), 2.10 (dd, J 13.6 Hz, 7.7 Hz, 1H, CH2C(R)HCH2CH2), 2.38 
(s, 6H, 2×N(CH3)2), 2.93 (dd, J 14.0 Hz, 7.2 Hz, 1H, Ar-CH2), 3.00 (dd, J 14.0 Hz, 7.2 
Hz, 1H, Ar-CH2), 3.36 (d, J 13.7 Hz, 1H, CH2SO2), 3.46 (d, J 13.7 Hz, 1H, CH2SO2), 
3.87 (dd, J 7.2 Hz, 5.2 Hz, 1H, NCH camphor), 4.15 (t, J 7.1 Hz, 1H, CHCH2Ar), 6.72 
(m, 2H, 2×ArCH), 7.19-7.25 (m, 1H, ArCH). 13C NMR (100 MHz, CDCl3) C 19.9 
((CH3)2CR2), 21.0 ((CH3)2CR2), 26.4 (CR2HCH2CH2CR3), 33.0 (CH2Ar and 
(CR2HCH2CH2CR3), 39.0 (CR2HCH2C(R)HN), 41.2 (2×N(CH3)2), 44.9 
(CH2CH2CHCH2), 47.7 (C(CH3)2), 48.1 (CCH2SO2), 53.1 (CH2SO2), 65.3 (NCH 
camphor), 66.0 (NCHCH2Ar), 103.2 (t, JCF 25.2 Hz, ArCH), 110.9 (dd, JCF 20.6 Hz, 3.6 
Hz, ArCH), 120.8 (dd, JCF 15.6 Hz, 3.9 Hz, ArC), 132.3 (dd, JCF 9.1 Hz, 6.4 Hz, ArCH), 
160.3 (dd, JCF 20.0 Hz, 12.6 Hz, ArCF), 162.9 (dd, JCF 35.5 Hz, 23.1 Hz, ArCF), 170.9 
(CO). 19F NMR (376.5 MHz, CDCl3) F 113.01 (m, 1F, ArCF), 113.29 (br, m, 1F, 
ArCF). IR max (thin film, cm-1): 2956 (CH), 1686 (CO), 1329, 1133 (SO2). MS m/z (ESI+) 
calculated for C21H28N2O3F2S [M+H]+; 427.1861 found 427.1866. TLC Rf = 0.37 










Following General procedure (E) outlined above, it was isolated as solid (46.6 mg, 
55%, Table 21, Entry 8). m.p.= 173-175 °C. 1H NMR (400 MHz, CDCl3) H 0.78 (s, 3H, 
(CH3)2CR2), 0.90 (s, 3H, (CH3)2CR2), 1.25-1.39 (m, 2H, C(R)2HCH2CH2), 1.80-1.91 
(m, 4H, CH2C(R)HCH2CH2), 2.04 (dd, J 13.8 Hz, 7.8 Hz, 1H, CH2C(R)HCH2CH2), 2.48 
(s, 6H, 2×N(CH3)2), 2.93 (dd, J 13.4 Hz, 7.5 Hz, 1H, Ar-CH2), 3.05 (dd, J 13.4 Hz, 7.5 
Hz, 1H, Ar-CH2), 3.37 (d, J 14.0 Hz, 1H, CH2SO2), 3.41 (d, J 14.0 Hz, 1H, CH2SO2),  
3.86 (dd, J 7.6 Hz, 5.0 Hz, 1H, NCH camphor), 4.15 (t, J 7.5 Hz, 1H, CHCH2Ar), 6.59 
(app t, JHF 9.0, 1H, ArCH), 6.78 (app d, JHF 6.2, 2H, ArCH). 13C NMR (100 MHz, CDCl3) 
C 19.7 ((CH3)2CR2), 20.2 ((CH3)2CR2), 26.3 (CR2HCH2CH2CR3), 32.8 
(CR2HCH2CH2CR3), 33.9 (CH2Ar), 38.2 (CR2HCH2C(R)HN), 41.5 (2×N(CH3)2), 44.5 
(CH2CH2CHCH2), 47.6 (C(CH3)2), 48.1 (CCH2SO2), 52.9 (CH2SO2), 65.1 (NCH 
camphor), 66.6 (NCHCH2Ar), 102.0 (t, JCF 25.1 Hz, ArCH), 112.3 (dd, JCF 18.2 Hz, 6.5 
Hz, ArCH), 141.4 (t, JCF 9.2 Hz, ArC), 161.6 (d, JCF 12.7 Hz, ArCF), 164.1 (d, JCF 12.9 
Hz, ArCF), 171.6 (CO). 19F NMR (376.5 MHz, CDCl3) F 110.55 (t, JHF 8.6 Hz, 2F, 
ArCF). IR max (thin film, cm-1): 2950 (CH), 1685 (CO), 1321, 1135 (SO2). MS m/z (ESI+) 
calculated for C21H28N2O3F2S [M+H]+; 427.1861 found 427.1861. TLC Rf = 0.04 






Following General procedure (E) outlined above, it was isolated as solid (27.4 mg, 
32%, Table 21, Entry 8). m.p.= 136-137 °C. 1H NMR (400 MHz, CDCl3)H 0.97 (s, 
3H, (CH3)2CR2), 1.19 (s, 3H, (CH3)2CR2), 1.25-1.42 (m, 2H, C(R)2HCH2CH2), 1.87-
2.07 (m, 4H, CH2C(R)HCH2CH2), 2.11 (dd, J 13.7 Hz, 7.6 Hz, 1H, CH2C(R)HCH2CH2), 
2.37 (s, 6H, 2×N(CH3)2), 2.86 (dd, J 14.1 Hz, 6.6 Hz, 1H, Ar-CH2), 2.98 (dd, J 14.1 Hz, 
6.6 Hz, 1H, Ar-CH2), 3.39 (d, J 13.7 Hz, 1H, CH2SO2), 3.49 (d, J 13.7 Hz, 1H, CH2SO2), 
3.89 (dd, J 7.4 Hz, 5.2 Hz, 1H, NCH camphor), 4.13 (t, J 6.7 Hz, 1H, CHCH2Ar), 6.62 
(app t, JHF 9.0, 1H, ArCH), 6.78 (app d, JHF 6.4, 2H, ArCH). 13C NMR (100 MHz, CDCl3) 
C 19.9 ((CH3)2CR2), 21.0 ((CH3)2CR2), 26.4 (CR2HCH2CH2CR3), 33.0 




(CR2HCH2CH2CR3), 33.1 (CH2Ar), 39.0 (CR2HCH2C(R)HN), 41.2 (2×N(CH3)2), 44.8 
(CH2CH2CHCH2), 47.7 (C(CH3)2), 48.2 (CCH2SO2), 53.1 (CH2SO2), 65.4 (NCH 
camphor), 66.7 (NCHCH2Ar), 101.7 (t, JCF 25.1 Hz, ArCH), 112.2 (dd, JCF 18.0 Hz, 6.4 
Hz, ArCH), 142.2 (t, JCF 9.3 Hz, ArC), 161.5 (d, JCF 12.8 Hz, ArCF), 164.0 (d, JCF 12.8 
Hz, ArCF), 170.9 (CO). 19F NMR (376.5 MHz, CDCl3) F 112.86 (t, JHF 8.2 Hz, 2F, 
ArCF). IR max (thin film, cm-1): 2954 (CH), 1686 (CO), 1325, 1132(SO2). MS m/z (ESI+) 
calculated for C21H28N2O3F2S [M+H]+; 427.1861 found 427.1860. TLC Rf = 0.14 






Following General procedure (E) outlined above, it was isolated as solid (35 mg, 41%, 
Table 21, Entry 9). m.p.= 135-136 °C. 1H NMR (400 MHz, CDCl3) H 0.69 (s, 3H, 
(CH3)2CR2), 0.88 (s, 3H, (CH3)2CR2), 1.23-1.41 (m, 2H, C(R)2HCH2CH2), 1.79-1.95 
(m, 4H, CH2C(R)HCH2CH2), 2.05 (dd, J 13.8 Hz, 7.8 Hz, 1H, CH2C(R)HCH2CH2), 2.50 
(s, 6H, 2×N(CH3)2), 2.96 (dd, J 13.3 Hz, 7.3 Hz, 1H, Ar-CH2), 3.17 (dd, J 13.3 Hz, 7.3 
Hz, 1H, Ar-CH2), 3.36 (s, 2H, CH2SO2), 3.86 (dd, J 7.7 Hz, 5.1 Hz, 1H, NCH camphor), 
4.17 (dd, J 9.5 Hz, 5.2 Hz, 1H, CHCH2Ar), 6.55-6.62 (m, 2H, 2×ArCH). 13C NMR (100 
MHz, CDCl3) C 19.7 ((CH3)2CR2), 20.3 (CH2Ar), 21.4 ((CH3)2CR2), 26.3 
(CR2HCH2CH2CR3), 32.9 (CR2HCH2CH2CR3), 38.2 (CR2HCH2C(R)HN), 41.6 
(2×N(CH3)2), 44.5 (CH2CH2CHCH2), 47.5 (C(CH3)2), 47.9 (CCH2SO2), 53.0 (CH2SO2), 
64.4 (NCH camphor), 65.3 (NCHCH2Ar), 99.7 -100.2 (m, 2×ArCH), 109.2 (td, JCF 20.3 
Hz, 5.0 Hz, ArC), 160.4 (dd, JCF 14.2 Hz, 3.5 Hz, ArCF), 162.9 (dd, JCF 15.4 Hz, 4.0 
Hz, 2× ArCF), 170.6 (CO). 19F NMR (376.5 MHz, CDCl3) F 110.72(t, JHF 6.7, 2F, 
ArCF), 110.54- 110.58 (br m, 1F, ArCF). IR max (thin film, cm-1): 2960 (CH), 1694 
(CO), 1329, 1135 (SO2). MS m/z (ESI+) calculated for C21H27N2O3F3S [M+H]+; 
445.1767 found 445.1767. TLC Rf = 0.31 (PE:EtOAc, 1:1). HPLC tR = 6.8 min. 
 
 









Following General procedure (E) outlined above, it was isolated as solid (20 mg, 24%, 
Table 21, Entry 9). m.p.= 145-146 °C. 1H NMR (400 MHz, CDCl3)H 0.96 (s, 3H, 
(CH3)2CR2), 1.19 (s, 3H, (CH3)2CR2), 1.25-1.43 (m, 2H, C(R)2HCH2CH2), 1.86-2.04 
(m, 4H, CH2C(R)HCH2CH2), 2.12 (dd, J 13.7 Hz, 7.7 Hz, 1H, CH2C(R)HCH2CH2), 2.36 
(s, 6H, 2×N(CH3)2), 2.96 (dd, J 14.1 Hz, 7.4 Hz, 1H, Ar-CH2), 3.03 (dd, J  14.1 Hz, 7.4 
Hz, 1H, Ar-CH2), 3.36 (d, J 13.6 Hz, 1H, CH2SO2), 3.46 (d, J 13.6 Hz, 1H, CH2SO2), 
3.89 (dd, J 7.6 Hz, 5.0 Hz, 1H, NCH camphor), 4.24 (t, J 7.3 Hz, 1H, CHCH2Ar), 6.60 
(t, JHF 8.0, 2H, 2×ArCH). 13C NMR (100 MHz, CDCl3) C 19.9 ((CH3)2CR2), 20.7 
(CH2Ar), 21.0 ((CH3)2CR2), 26.4 (CR2HCH2CH2CR3), 33.0 (CR2HCH2CH2CR3), 39.0 
(CR2HCH2C(R)HN), 41.3 (2×N(CH3)2), 44.8 (CH2CH2CHCH2), 47.7 (C(CH3)2), 48.0 
(CCH2SO2), 53.2 (CH2SO2), 64.7 (NCH camphor), 65.4 (NCHCH2Ar), 99.6 -100.1 (m, 
2×ArCH), 110.1 (dd, JCF 20.2 Hz, 4.6 Hz, ArC), 160.6 (d, JCF 11.3 Hz, ArCF), 163.1 (t, 
JCF 14.7 Hz, 2× ArCF), 170.6 (CO). 19F NMR (376.5 MHz, CDCl3) F 110.70 (t, JHF 
6.8, 2F, ArCF), 110.85- 110.93 (br m, 1F, ArCF). IR max (thin film, cm-1): 2953 
(CH), 1683 (CO), 1322, 1134 (SO2). MS m/z (ESI+) calculated for C21H27N2O3 F3S 








Following General procedure (E) outlined above, it was isolated as solid (52.6 mg, 
65%, Table 21, Entry 10). m.p.= 197-199 °C. 1H NMR (400 MHz, CDCl3)H 0.71 (s, 




3H, (CH3)2CR2), 0.88 (s, 3H, (CH3)2CR2), 1.25-1.38 (m, 2H, C(R)2HCH2CH2), 1.77-
1.89 (m, 4H, CH2C(R)HCH2CH2), 2.02 (dd, J 13.7 Hz, 7.8 Hz, 1H, CH2C(R)HCH2CH2), 
2.49 (s, 6H, 2×N(CH3)2), 2.96 (dd, J 13.3 Hz, 7.5 Hz, 1H, Ar-CH2), 3.07 (dd, J 13.3 Hz, 
7.5 Hz, 1H, Ar-CH2), 3.39 (s, 2H, CH2SO2), 3.84 (dd, J 6.8 Hz, 5.1 Hz, 1H, NCH 
camphor), 4.17 (t, J 7.5 Hz, 1H, CHCH2Ar), 6.86 (app d, J 2.3 Hz, 1H, ArCH), 6.94 (d, 
J 11.4 Hz, 1H, ArCH), 7.03 (d, J 7.6 Hz, 1H, ArCH), 7.18-7.23 (m, 1H, ArCH). 13C NMR 
(100 MHz, CDCl3) C 19.8 ((CH3)2CR2), 20.3 ((CH3)2CR2), 26.3 (CR2HCH2CH2CR3), 
32.8 (CR2HCH2CH2CR3), 33.9 (CH2Ar), 38.2 (CR2HCH2C(R)HN), 41.6 (2×N(CH3)2), 
44.5 (CH2CH2CHCH2), 47.5 (C(CH3)2), 48.1 (CCH2SO2), 53.0 (CH2SO2), 65.1 (NCH 
camphor), 66.9 (NCHCH2Ar), 113.4 (d, J 20.8 Hz, ArCH), 116.4 (d, J 21.1 Hz, ArCH), 
125.2 (d, J 2.7 Hz, ArCH), 129.7 (d, J 8.2 Hz, ArCH), 139.9 (d, J 7.3 Hz, ArC), 162.75 
(dd, J 243.8 Hz, ArCF), 171.8 (CO). 19F NMR (376.5 MHz, CDCl3) F 113.72 (1F, 
ArCF). IR max (thin film, cm-1): 2952 (CH), 1686(CO), 1323, 1136 (SO2). MS m/z (ESI+) 
calculated for C21H29FN2O3S [M+H]+; 409.1956 found 409.1957. HPLC tR = 11.50 min. 







Following General procedure (E) outlined above, it was impure includes 
camphorsultam product. Partial characterisation was only possible, as the product was 
not isolated pure (23%, Table 21, Entry 10). 1H NMR (400 MHz, CDCl3)H 0.94 (s, 
3H, (CH3)2CR2), 1.13 (s, 3H, (CH3)2CR2), 1.25-1.48 (m, 2H, C(R)2HCH2CH2), 1.84-
2.10 (m, 5H, CH2C(R)HCH2CH2), 2.38 (s, 6H, 2×N(CH3)2), 2.87 (dd, J 14.1 Hz, 7.2 Hz, 
1H, Ar-CH2), 3.02 (dd, J 14.1 Hz, 7.2 Hz, 1H, Ar-CH2), 3.38 (d, J 13.7 Hz, 1H, CH2SO2), 
3.48 (d, J 13.7 Hz, 1H, CH2SO2), 3.89 (dd, J 7.3 Hz, 5.1 Hz, 1H, NCH camphor), 4.15 
(t, J 7.1 Hz, 1H, CHCH2Ar), 6.88 (app d, J 2.0 Hz, 1H, ArCH), 6.96 (d, J 9.9 Hz, 1H, 
ArCH), 7.03 (d, J 7.5 Hz, 1H, ArCH), 7.19-7.23 (m, 1H, ArCH). 
 
 








Following General procedure (E) outlined above, it was isolated as solid (35.4 mg, 
41%, Table 21, Entry 11). m.p.= 142-143 °C. 1H NMR (400 MHz, CDCl3)H 0.61 (s, 
3H, (CH3)2CR2), 0.84 (s, 3H, (CH3)2CR2), 1.25-1.35 (m, 2H, C(R)2HCH2CH2), 1.72-
1.85 (m, 4H, CH2C(R)HCH2CH2), 1.97 (dd, J 13.8 Hz, 7.8 Hz, 1H, CH2C(R)HCH2CH2), 
2.53 (s, 6H, 2×N(CH3)2), 3.00 (dd, J 13.2 Hz, 7.6 Hz, 1H, ArCH2), 3.09 (dd, J 13.2 Hz, 
7.6 Hz, 1H, ArCH2), 3.37 (s, 2H, CH2SO2), 3.82 (b, 1H, NCH camphor), 4.21 (dd, J 7.5 
Hz, 7.4 Hz, 1H, CHCH2Ar), 7.32-7.34 (m, 3H, ArCH), 7.44 (t, J 7.7 Hz, 2H, ArCH), 7.48 
(d, J 7.7 Hz, 2H, ArCH), 7.54 (d, J 7.7 Hz, 2H, ArCH). 13C NMR (100 MHz, CDCl3) C 
19.8 ((CH3)2CR2), 20.2 ((CH3)2CR2), 26.3 (CR2HCH2CH2CR3), 32.8 
(CR2HCH2CH2CR3), 34.0 (CH2Ar), 38.2 (CR2HCH2C(R)HN), 41.7 (2×N(CH3)2), 44.5 
(CH2CH2CHCH2), 47.5 (C(CH3)2), 48.06(CCH2SO2), 53.0 (CH2SO2), 65.1 (NCH 
camphor), 67.0 (NCHCH2Ar), 127.0 (5×ArCH), 128.7 (2×ArCH), 130.0 (2×ArCH), 
136.3 (ArC), 139.4 (ArC), 141.1 (ArC), 172.1 (CO). IR max (thin film, cm-1): 2958 (CH), 
1692 (CO), 1328, 1132 (SO2). MS m/z (ESI+) calculated for C27H34N2O3S [M+H]+; 






Following General procedure (E) outlined above, it was impure includes 
camphorsultam. Partial characterisation was only possible, as the product was not 
isolated pure (22%, Table 21, Entry 11). 1H NMR (400 MHz, CDCl3)H 0.97 (s, 3H, 
(CH3)2CR2), 1.19 (s, 3H, (CH3)2CR2), 1.30-1.40 (m, 2H, C(R)2HCH2CH2), 1.84-2.14 
(m, 5H, CH2C(R)HCH2CH2), 2.41 (s, 6H, 2×N(CH3)2), 2.94 (dd, J 14.1 Hz, 7.2 Hz, 2H, 
ArCH2), 3.06 (dd, J 14.1 Hz, 7.2 Hz, 2H, ArCH2), 3.40 (d, J 13.6 Hz, 1H, CH2SO2), 




3.49 (d, J 13.6 Hz, 1H, CH2SO2), 3.92 (dd, J 7.4 Hz, 5.2 Hz, 1H, NCH camphor), 4.22 
(t, J 6.5 Hz, 1H, CHCH2Ar), 7.29-7.35 (m, 3H, ArCH), 7.41 (t, J 7.8 Hz, 2H, ArCH), 






Following General procedure (E) outlined above, it was impure includes [2,3]-product. 
Partial characterisation was only possible, as the product was not isolated pure (47%, 
Table 21, Entry 12). 1H NMR (400 MHz, CDCl3)H  0.67 (s, 3H, (CH3)2CR2), 0.87 (s, 
3H, (CH3)2CR2), 1.21-1.37 (m, 2H, C(R)2HCH2CH2), 1.71-1.97 (m, 4H, 
CH2C(R)HCH2CH2), 2.04 (dd, J 13.7 Hz, 7.8 Hz, 1H, CH2C(R)HCH2CH2), 2.52 (s, 6H, 
2×N(CH3)2), 3.23 (dd, J 13.6 Hz, 7.4 Hz, 2H, ArCH2), 3.30 (dd, J 13.6 Hz, 7.4 Hz, 2H, 
ArCH2), 3.37 (s, 2H, CH2SO2), 3.84 (dd, J 7.4 Hz, 5.1 Hz, 1H, NCH camphor), 4.27 (t, 
J 6.9 Hz, 1H, CHCH2Ar), 7.28 (dd, J 7.0 Hz, 1.1 Hz, 1H, ArCH), 7.43-7.49 (m, 2H, 






Following General procedure (E) outlined above, it was isolated as solid (20 mg, 30%, 
Table 21, Entry 12). m.p.= 128-130 °C. 1H NMR (400 MHz, CDCl3)H 0.96 (s, 3H, 
(CH3)2CR2), 1.17 (s, 3H, (CH3)2CR2), 1.24-1.40 (m, 2H, C(R)2HCH2CH2), 1.86-2.04 
(m, 4H, CH2C(R)HCH2CH2), 2.08 (dd, J 13.6 Hz, 7.7 Hz, 1H, CH2C(R)HCH2CH2), 2.42 
(s, 6H, 2×N(CH3)2), 3.15 (dd, J 14.1 Hz, 7.0 Hz, 1H, ArCH2), 3.21 (dd, J 14.1 Hz, 7.0 
Hz, 1H, ArCH2), 3.34 (d, J 13.7 Hz, 1H, CH2SO2), 3.44 (d, J 13.7 Hz, 1H, CH2SO2), 
3.88 (dd, J 7.4 Hz, 5.2 Hz, 1H, NCH camphor), 4.19 (t, J 7.0 Hz, 1H, CHCH2Ar), 7.29 
(dd, J 7.4 Hz, 1.2, 1H, ArCH), 7.44 (br d, J 7.0 Hz, 1H, ArCH), 7.49 (td, J 7.3 Hz, 1.2 




Hz, 1.3 Hz, 1H, ArCH), 7.59 (dd, J 7.6 Hz, 0.8 Hz, 1H, ArCH). 13C NMR (100 MHz, 
CDCl3) C 19.9 ((CH3)2CR2), 21.0 ((CH3)2CR2), 26.4 (CR2HCH2CH2CR3), 33.0 
(CR2HCH2CH2CR3 and CH2Ar), 39.0 (CR2HCH2C(R)HN), 41.4 (2×N(CH3)2), 44.9 
(CH2CH2CHCH2), 47.7 (C(CH3)2), 48.2 (CCH2SO2), 53.1 (CH2SO2), 65.2 (NCH 
camphor), 66.8 (NCHCH2Ar), 113.3 (ArCN), 118.1 (ArCCN), 126.7 (ArCH), 130.7 
(ArCH), 132.6 (ArCH), 132.7 (ArCH), 142.3 (ArC), 170.3 (CO). IR max (thin film, cm-1): 
2956 (CH), 1686 (CO), 2223 (CN), 1327, 1132 (SO2). MS m/z (ESI+) calculated for 
C22H29N3O3S [M+H]+; 416.2002 found 416.2005. TLC Rf = 0.45 (PE:EtOAc, 1:1). 






Following General procedure (E) outlined above, it was impure includes [1,2]- (2S) 
product. Partial characterisation was only possible, as the product was not isolated 
pure (Table 21, Entry 12). 1H NMR (400 MHz, CDCl3)H 0.69 (s, 3H, (CH3)2CR2), 
0.88(s, 3H, (CH3)2CR2), 1.25-1.37 (m, 2H, C(R)2HCH2CH2), 1.71-1.97 (m, 4H, 
CH2C(R)HCH2CH2), 2.02 (dd, J 13.7 Hz, 7.8 Hz, 1H, CH2C(R)HCH2CH2), 2.25 (s, 6H, 
2×N(CH3)2), 2.52 (s, 3H, ArCH3), 3.46 (d, J 2.6 Hz, 2H, CH2SO2), 3.93 (dd, J 7.5 Hz, 
4.6 Hz, 1H, NCH camphor), 4.53 (s,1H, CHAr), 7.28 (dd, J 7.0 Hz, 1.1 Hz, 1H, ArCH), 
7.67 (dd, J 8.0 Hz, 1.8 Hz, 1H, ArCH), 7.80 (d, J 1.7 Hz, 1H, ArCH).  
General procedure (F) for sultam hydrolysis.  
The substituted sulfonamide (0.13 - 0.16 mmol, 1 eq.) was dissolved in THF/H2O (4:1 
3.25 ml) and lithium hydroxide monohydrate (2 eq.) was added in one portion. The 
reaction mixture was allowed to stir for 22 hours. The organic solvent was removed by 
concentration under reduced pressure and the residue dissolved in sat. aq. sodium 
bicarbonate (19 ml) and extracted with chloroform (3 x 15 ml). The combined organics 
were dried (MgSO4) and concentrated under reduced pressure to yield recovered 
sultam. The aqueous layer was neutralised to pH7 with 6M hydrochloric acid and then 
extracted with n-butanol (3 x 10 ml). The combined organics were dried (Na2SO4) and 




concentrated under reduced pressure. The residue was triturated with acetone (10 
ml), filtered and concentrated under reduced pressure to yield desired product. 
N,N-Dimethyl-L-phenylalanine (311a). 
 
Following the general procedure (F) N-[(2S)-N,N-Dimethylphenylalanine]bornane-
10,2-sultam (313a) (50.0 mg, 0.13 mmol) was hydrolysed to yield the product (8.0 mg, 
32 %, Table 22, Entry 1) as a colourless solid. m.p.= 229 - 231 °C. 1H NMR (400 MHz, 
D2O) H 2.67 (s, 6H, 2NCH3), 2.96 (dd J 13.6, 9.7 Hz, 1H, CH2Ar), 3.13 (dd J 13.6, 5.8 
Hz, 1H, CH2Ar), 3.57 (dd J 9.7, 5.8 Hz, 1H, CHCH2Ar), 7.19 - 7.32 (m, 5H, 5×ArCH). 
13C NMR (100 MHz, D2O) C 34.6 (2NCH3), 41.5 (CH2Ar), 72.4 (CH), 127.2 (ArCH), 
128.9 (ArCH), 129.2 (ArCH), 136.2 (ArC), 173.9 (CO). IR max / cm-1: 3352 (OH), 1621 
(CO). MS m/z (ESI+) calculated for C11H16NO2 [M+H]+; 194.1136, found 194.1176. 
N,N-Dimethyl-2,4-difluoro-L-phenylalanine (311b). 
 
Following the general procedure (F) N-[(2S)-N,N-Dimethylamino-2,4-
difluorophenylalanine]bornane-10,2-sultam (313g) (58.0 mg, 0.14 mmol) was 
hydrolysed to yield the product (12.0 mg, 39 %, Table 22, Entry 2) as a colourless 
hygroscopic solid.  
1H NMR (400 MHz, D2O) H 2.82 (s, 6H, 2NCH3), 2.92 (dd J 10.3, 13.4 Hz, 1H, CH2Ar), 
3.26 (dd J 13.4, 5.2 Hz, 1H, CH2Ar), 3.65 (dd J 10.3, 5.2 Hz, 1H, CHCH2Ar), 6.80 - 
6.90 (m, 2H, 2×ArCH), 7.18 (m, 1H, ArCH). 13C NMR (100 MHz, D2O) C 27.5 (2NCH3), 
41.5 (CH2Ar), 72.4 (CH), 103.7 (t, J 25.8 Hz, CFCHCF), 111.5 (dd, J 21.3, 3.6 Hz, 
CFCHCFCH), 118.3 (dd, J 15.5, 3.6 Hz, CFCCH), 132.2 (dd, J 9.8, 5.9 Hz, CCHCH), 
160.9 (dd, J 245, 12.3 Hz, CCFCHCF), 162.2 (dd, J 244, 12.3 Hz, CCF), 172.3 (CO). 
19F NMR (376 MHz, D2O) F -111.9 (d, J 7.4 Hz CF), -113.8 (d, J 7.4 Hz CF). IR max 




/cm-1: 3357 (OH), 1632 (CO). MS m/z (ESI+) calculated for C11H13F2NO2 [M+H]+; 
230.0987, found 230.0987. 
N,N-Dimethyl-2phenyl-L-phenylalanine (311c). 
 
Following the general procedure (F) N-[(2S)-N,N-Dimethylamino-biphenyl 
phenylalanine]bornane-10,2-sultam (313k) (75.0 mg, 0.16 mmol) was hydrolysed to 
yield the product (15.0 mg, 35 %, Table 22, Entry 3) as a colourless solid. m.p.= 220 
- 222 °C. 1H NMR (400 MHz, D2O) H 2.25 (s, 6H, 2NCH3), 2.78 - 2.93 (m, 2H, CH2Ar), 
3.17 (dd J 6.3, 9.1 Hz, 1H, CHCH2Ar), 7.21 - 7.30 (m, 3H, 3ArCH), 7.37 (t J 7.6 Hz, 
2H, 2ArCH), 7.49 (d J 8.0 Hz, 2H, 2ArCH), 7.56 (t J 8.0 Hz, 2H, 2ArCH). 13C NMR 
(100 MHz, D2O) C 35.7 (2NCH3), 41.1 (CH2Ar), 72.7 (CH), 126.8 (2×ArCH), 126.9 
(2×ArCH), 127.5 (ArCH), 129.1 (2×ArCH), 129.7 (2×ArCH), 137.9 (ArC), 138.6 (ArC), 
140.3 (ArC), 177.7 (CO). IR max /cm-1: 3371 (OH), 1607 (CO). 
MS m/z (ESI+) calculated for C17H19NO2 [M+H]+; 270.1489, found 270.1487 
Glyoxylic acid p-toluenesulfonyl hydrazone (329).84 
 
A mixture of glyoxylic acid (2.5 g, 27.2 mmol) and p-toluenesulfonyl hydrazide (5.11g, 
27.2 mmol) in 50 mL of dry THF was stirred overnight at room temperature. The 
solvent was removed under reduced pressure and 150 mL cold water was added to 
the residue. The precipitated solid was filtered and washed by cold water, acetone and 
dried for 2 days in oven at 45 °C to give (6.4 g, 98%). The yield was used without any 
purifications. 1H NMR (400 MHz, DMSO, d6)H 2.36 (s, 3H, ArCH3), 7.17 (s, 1H, 
CHCOOH), 7.40 (d, J 8.1 Hz, 2H, ArCH), 7.68 (d, J 8.2 Hz, 2H, ArCH), 12.28 (s, 1H, 
COOH). 1C NMR (100 MHz, CDCl3)C 21.4 (ArCH3), 127.5 (ArCH), 130.3 (ArCH), 
136.1 (ArC), 137.9 (ArC), 144.5 (CHCOOH), 164.0 (CO). IR max /cm-1: 3168 (OH), 
1694 (CO), 1348, 1081 (SO2). MS m/z (ESI+) calculated for C9H10N2O4S [M+H]+; 
243.0434 found 243.1434. 
 




Glyoxylic acid chloride p-toluenesulfonyl hydrazine (330).84  
 
A mixture of glyoxylic acid p-toluenesulfonyl hydrazone (1.0 g, 4.12 mmol) and thionyl 
chloride (0.5 mL, 6.89 mmol) in 20 mL of dry toluene was stirred and heated to 90 °C 
overnight. The solvent was removed under reduced pressure to give (0.48 g, 50%). 
The yield was used immediately without any purifications. 1H NMR (400 MHz, 
CDCl3)H 2.46 (s, 3H, ArCH3), 7.22 (s, 1H, CHCOCl), 7.38 (d, J 8.2 Hz, 2H, ArCH), 
7.87 (d, J 8.2 Hz, 2H, ArCH), 8.86 (s, 1H, NH). IR max (thin film, cm-1): 1744 (CO), 
1353, 1079 (SO2). 
Diazo Camphorsultam (297).58  
 
(1S)- camphorsultam (306) (0.84 g, 3.8 mmol, 1eq) in 10 mL CHCl3 was added to 
cooled glyoxylic acid chloride p-toluenesulfonylhydrazone (1.0 g, 7.6 mmol, 2 eq) in 
CHCl3 (10 mL). Dimethylaniline (0.98 mL, 7.8 mmol, 2.1 eq) was added dropwise over 
3 hours. Triethylamine (2.72 mL, 19 mmol, 5 eq) was added dropwise. After 
completing the addition, the mixture was stirred for 1 hour at room temperature before 
water (16 mL) was added and the mixture concentrated in vacuo. Saturated citric acid 
(32 mL) and EtOAc-hexane (3:2) v/v, 32 mL) were added and the layers were 
separated. The organic layers were dried over MgSO4 and filtered and the solvents 
were removed in vacuo. The crude was purified via column chromatography (4:1, 
PE:EtOAc) to give yellow solid (0.64 g, 60%). m.p.= 159-161 °C. 1H NMR (400 MHz, 
CDCl3)H 0.95 (s, 3H, C(CH3)2), 1.12 (s, 3H, C(CH3)2), 1.33-1.48 (m, 2H, 
CH2CH2CHCH2), 1.85-1.94 (m, 3H, CH2CH2CHCH2), 3.40 (d, 1H, J 13.8 Hz, CH2SO2), 
3.44 (d, 1H, J 13.8 Hz, CH2SO2), 3.89 (dd, 1H, J 7.6 Hz, 4.8 Hz, CHN), 5.72 (s, 1H, 
CHN2). 13C NMR (100 MHz, CDCl3)C 19.9 (CCH3)2, 20.4 (CCH3)2, 26.5 
(CH2CH2CHCH2), 32.4 (CH2CH2CHCH2), 38.1 (CH2CH2CHCH2), 44.4 
(CH2CH2CHCH2), 47.9 (C(CH3)2), 48.7 (CCH2SO2), 49.8 (CHN2), 52.5 (CH2SO2), 64.8 
(NCH), 162.9 (CO). MS m/z (ESI+) calculated for C12H17N3O3S [M+Na]+; 306.0883 




found 206.0882. IR max /cm-1: 3124 (CH), 2956 (CH), 2127 (NΞN), 1637(CO), 1394, 
1126 (SO2). TLC Rf = 0.15 (PE:EtOAc, 4:1). 
Diazoacyl phthalimide (332).86,87  
 
To a solution of N-hydroxyphthalimide (2.0 g, 12.4 mmol, 1eq) and glyoxylic acid p-
toluenesulfonyl hydrazone (3.0 g, 12.4 mmol, 1eq) in dry THF (100 mL). At 0 °C was 
added dropwise a solution of DCC in 20 mL THF. The mixture was allowed to warm 
to room temperature and stirring was continued overnight. DCU was filtered off and 
filtrate was concentrated under reduced pressure. The crude was purified by flash 
chromatography (PE:EtOAc, 7:3) to give (2.0 g, 71%). 1H NMR (400 MHz, CDCl3)H: 
5.18 (s br, 1H, COCH), 7.77-7.81 (m, 2H, ArCH), 7.87-7.91 (m, 2H, ArCH). 13C NMR 
(100 MHz, CDCl3) C 45.0 (COCHN2), 124.0 (2×ArCH), 128.8 (2×ArCH), 134.8 
(2×ArC), 162.1 (3×CO). IR max /cm-1: 3099 (CH), 2145 (NΞN), 1796, 1704 (CO). MS 
m/z (ESI+) calculated for C10H5N3O4 [M+Na]+; 254.0172 found 254.0172. TLC Rf = 
0.22 (PE:EtOAc, 7:3). 
General procedure (G) for synthesis of N--diazoacyl oxazolidinones.87 
To a solution of oxazolinone or oxazolinone derivatives (1.0 eq) in THF (50 mL) was 
added n-BuLi (1.6 M in hexane, 1.1 eq) dropwise at 0 °C. After stirring hour, a solution 
of diazoacyl phthalimide (1.0 eq) was added. The mixture was stirred at room 
temperature overnight. The resulting mixture was quenched with saturated NaHCO3, 
and extracted with EtOAc. The combined organic layers were dried over MgSO4 and 
evaporated under reduced pressure. The crude was purified by flash chromatography. 
3-(2-diazoacetyl)oxazolidin-2-one (339). 
 
Following General procedure (G) outlined above, it was isolated as solid (0.25 g, 75%, 
Table 23, Entry 1). 1H NMR (400 MHz, CDCl3)H 4.06 (t, J 7.8 Hz, 2H, CH2N), 4.42 
(t, J 8.3 Hz, 2H, CH2O), 6.56 (s, 1H, COCHN2). 13C NMR (100 MHz, CDCl3) C 42.5 
(NCH2), 49.6 (CHN2), 62.3 (CH2O), 153.7 (CO), 164.1 (CO). IR max /cm-1: 3131 (CH), 




2109 (NΞN), 1764, 1739 (CO). MS m/z (ESI+) calculated for C5H5N3O3 [M+Na]+; 
178.0223 found 178.0223. TLC Rf = 0.21 (PE:EtOAc, 7:3). 
(R)-4-benzyl-3-(2-diazoacetyl) oxazolidin-2-one (341). 
 
Following General procedure (G) outlined above, it was isolated as solid (0.8 g, 57%, 
Table 23, Entry 2). 1H NMR (400 MHz, CDCl3)H 2.83 (dd, J 13.3 Hz, 6.2 Hz, 1H, 
ArCH2), 3.34 (dd, J 13.3 Hz, 6.2 Hz, 1H, ArCH2), 4.17-4.25 (m, 2H, CHCH2O), 4.72-
4.78 (m, 1H, CHCH2), 6.62 (s, 1H, CHN2), 7.21-7.34 (5H, ArCH). 13C NMR (100 MHz, 
CDCl3) C 38.2 (ArCH2), 49.9 (CHN2), 55.2 (CHCH2), 66.4 (CH2O), 127.4 (ArCH), 
128.9 (2×ArCH), 129.4 (2×ArCH), 135.1 (ArC), 153.5 (CO), 164.0 (CO). IR max /cm-1: 
3116 (CH), 2114 (NΞN), 1772, 1754 (CO). MS m/z (ESI+) calculated for C12H11N3O3 
[M+Na]+; 268.0693 found 268.0694. TLC Rf = 0.25 (PE:EtOAc, 7:3). 
(R)-3-(2-diazoacetyl)-4-isopropyloxazolidin-2-one (341a) 
 
Following General procedure (G) outlined above, it was isolated as solid (0.165 g, 
55%, Table 23, Entry 2). 1H NMR (400 MHz, CDCl3)H 0.88 (d, J 6.8 Hz, 3H, CHCH3), 
0.93 (d, J 7.0 Hz, 3H, CHCH3), 2.34-2.48 (m, 1H, CH(CH3)2, 4.23 (dd, J 9.0 Hz, 5.7 Hz, 
1H, OCH2), 4.29 (dd, J 9.0 Hz, 5.7 Hz, 1H, OCH2), 4.48-4.52 (m, 1H, CH2CHCH), 6.62 
(s, 1H, CHN2). 13C NMR (100 MHz, CDCl3) C 14.6 (CHCH3), 17.9 (CHCH3), 28.7 
(CH(CH3)2), 49.8 CHN2), 58.6 (CH2CHCH) 63.6 (OCH2). IR max (thin film, cm-1): 2963 
(CH), 2111 (NΞN), 1762, 1732 (CO). MS m/z (ESI+) calculated for C8H11N3O3 [M+Na]+; 
220.0693 found 220.0693. TLC Rf = 0.31 (PE:EtOAc, 7:3). 
General procedure (H) for reaction of allyl tertiary amines with diazo compounds 
A solution of diazo (100 mg, 1 eq) and allyl tertiary amines (1eq) in CH2Cl2 or CHCl3 
(1 mL) was added in a single portion to a solution of the catalyst (iron(III) porphyrins) 




(0.2-40 mol%), in 1.5 mL CH2Cl2 or CHCl3. The solvent was removed to produce crude, 
which was subjected to column chromatography. 
(2R)-1-((6R,7aR)-8,8-dimethyl-2,2-dioxidotetrahydro-3H-3a,6 methanobenzo 
[c]isothiazol-1(4H)-yl)-2-(dimethylamino)pent-4-en-1-one (338a)  and (2S)-1-
((6R,7aR)-8,8-dimethyl-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c] 




Following procedure (H) above the major diastereoisomer was isolated as solid (14 
mg, 25%) and the second was impure with camphorsultam.   
The first diastereoisomer  
m.p.= 129-131 °C. 1H NMR (400 MHz, CDCl3)H 0.96 (s, 3H, C(CH3)2), 1.13 (s, 3H, 
C(CH3)2), 1.23-1.42 (m, 2H, CH2CH2CHCH2), 1.84-2.08 (m, 5H, CH2CH2CHCH2), 2.43 
(s, 6H, 2×N(CH3)2, 2.47-2.61 (m, 2H, NCHCH2), 3.42 (d, 1H, J 13.7 Hz, CH2SO2), 3.48 
(d, 1H, J 13.7 Hz, CH2SO2), 3.87-3.94 (m, 2H, N(CH3)2CH, CHN), 5.05 (d, J 13.0 Hz, 
1H, CH2=CH), 5.12 (d, J 13.0 Hz, 1H, CH2=CH), 5.85 (ddt, J 17.0, 10.1, 7.0, 1H, 
CH=CH2). 13C NMR (100 MHz, CDCl3)C 19.9 (CCH3)2, 20.8 (CCH3)2, 26.4 
(CH2CH2CHCH2), 32.9 (CH2CH2CHCH2), 34.5 (CH2CH=CH2), 38.3 (CH2CH2CHCH2), 
41.8 (2×N(CH3)2), 44.5 (CH2CH2CHCH2), 47.7 (C(CH3)2), 48.2 (CCH2SO2), 53.2 
(CH2SO2), 65.2 (NCH), 66.1 (N(CH3)2CH), 117.8 (CH2CH=CH2), 133.9 (CH2CH=CH2), 
172.8 (CO). IR max (thin film, cm-1): 2765 (CH), 1683 (CO). MS m/z (ESI+) calculated 
for C17H28N2O3S [M+H]+; 341.1893 found 341.1892. Rf = 0.35 (PE: EtOAc, 2:1). 
3-(2-(dimethylamino)pent-4-enoyl)oxazolidin-2-one (340). 
 
Following procedure (H) above, the product was isolated as oil (96 mg, 70%, Scheme 
87). 1H NMR (400 MHz, CDCl3)H 2.38 (s, 6H, N(CH3))2, 2.42 (m, 1H, CHCH2CH), 
2.56 (m, 1H, CHCH2CH), 4.00-4.04 (m, 2H, NCH2), 4.40 (t, J 8.0 Hz, 2H, COOCH2), 




4.75 (dd, J 8.9 Hz, 5.6 Hz, 1H, COCHN(CH3)2), 5.05 (d, J 10.0 Hz, 1H, CH=CH2), 5.11 
(dd, J 17.0 Hz, 1.3 Hz, 1H, CH=CH2), 5.77 (ddt, J 17.3 Hz, 10.2 Hz, 7.5 Hz, 1H, 
CH=CH2). 13C NMR (100 MHz, CDCl3) C 30.8 (CHCH2CH), 41.3 (N(CH3)2), 42.4 
(NCH2CH2O), 61.8 (NCH2CH2O), 62.7 (COCHN(CH3)2), 117.6 (CH=CH2), 134.4 
(CH=CH2), 153.1 (OCON), 172.1 (NCOCH). IR max (thin film, cm-1): 2923 (CH), 1750 
(CO), 1694 (CO). MS m/z (ESI+) calculated for C10H16N2O3 [M+H]+; 213.1234 found 
213.1234. TLC Rf = 0.21 (EtOAc). 
(R)-4-benzyl-3-((S)-2-(dimethylamino)pent-4-enoyl)oxazolidin-2-one (342a) and 
(R)-4-benzyl-3-((R)-2-(dimethylamino)pent-4-enoyl)oxazolidin-2-one (342b).  
                      
Following procedure (H) above, the combined yield was isolated as oil (342a+342b 
=106 mg, 86%, Scheme 88, Table 25, Entry 1). 
The first diastereoisomer  
1H NMR (400 MHz, CDCl3)H 2.35-2.41 (m, 1H, CHCH2CH), 2.43 (s, 6H, N(CH3))2, 
2.53-2.60 (m, 1H, CHCH2CH), 2.71 (dd, J 13.2 Hz, 6.6 Hz, 1H, CHCH2Ar), 3.37 (dd, J 
13.2 Hz, 6.6 Hz, 1H, CHCH2Ar), 4.12-4.18 (m, 2H, COOCH2), 4.67-4.79 (m, 1H, 
COOCH2CH), 4.78 (dd, J 8.9 Hz, 5.7 Hz, 1H, COCHN), 5.05 (d, J 13.4 Hz, 1H, 
CH=CH2), 5.12 (d, J 13.4 Hz, 1H, CH=CH2), 5.78 (ddt, J 17.2 Hz, 10.1 Hz, 7.1 Hz, 1H, 
CH=CH2). 13C NMR (100 MHz, CDCl3) C 31.1 (CHCH2CH), 38.4 (CH2Ar) 41.3 
(N(CH3)2), 55.8 (NCHCH2O), 62.8 (COCHN(CH3)2), 66.1 (NCH2CH2O), 117.6 
(CH=CH2), 127.3 ArCH), 128.9 (2×ArCH), 129.4 (2×ArCH), 134.4 (CH=CH2), 135.3 
(ArC),153.1 (OCON), 172.0 (NCOCH). IR max (thin film, cm-1): 2785 (CH), 1773 (CO), 
1693 (CO). MS m/z (ESI+) calculated for C17H22N2O3 [M+H]+; 303.1703 found 
303.1703. TLC Rf = 0.38 (PE:EtOAc, 1:1). HPLC tR = 4.9 min (50:50, Hex:IPA). 
The second diastereoisomer  
1H NMR (400 MHz, CDCl3)H 2.33-2.46 (m, 1H, CHCH2CH), 2.39(s, 6H, N(CH3))2, 
2.59-2.67 (m, 1H, CHCH2CH), 2.71 (dd, J 13.2 Hz, 6.4 Hz, 1H, CHCH2Ar), 3.27 (dd, J 
13.2 Hz, 6.4 Hz, 1H, CHCH2Ar), 4.13-4.22 (m, 2H, COOCH2), 4.66-4.72 (m, 1H, 




COOCH2CH), 4.77 (dd, J 5.5 Hz, 8.9 Hz, 1H, COCHN), 5.09 (d, J 10.0 Hz, 1H, 
CH=CH2), 5.16 (dd, J 17.1 Hz, 1.3 Hz, 1H, CH=CH2), 5.84 (ddt, J 17.1 Hz, 10.1 Hz, 
6.9 Hz, 1H, CH=CH2). 13C NMR (100 MHz, CDCl3) C 30.8 (CHCH2CH), 37.8 (CH2Ar) 
41.3 (N(CH3)2), 55.4 (NCHCH2O), 62.7 (COCHN(CH3)2), 66.0 (NCH2CH2O), 117.7 
(CH=CH2), 127.3 ArCH), 128.9 (2×ArCH), 129.4 (2×ArCH), 134.4 (CH=CH2), 135.3 
(ArC),153.1 (OCON), 172.0 (NCOCH). IR max (thin film, cm-1): 2783 (CH), 1772 (CO), 
1696(CO). MS m/z (ESI+) calculated for C17H22N2O3 [M+H]+; 303.1703 found 
303.1704. TLC Rf = 0.14 (PE:EtOAc, 1:1). HPLC tR = 5.6 min (50:50, Hex:IPA). 
(R)-4-benzyl-3-((S)-2-(piperidin-1-yl)pent-4-enoyl)oxazolidin-2-one (346a) and 
(R)-4-benzyl-3-((R)-2-(piperidin-1-yl)pent-4-enoyl)oxazolidin-2-one (346b).                 
 
Following procedure (H) above, the combined yield was isolated as oil (346a+346b = 
86.5 mg, 62%, Scheme 89, Table 25, Entry 3). 
The first diastereoisomer  
1H NMR (400 MHz, CDCl3)H 1.43-1.44 (m, 2H, NCH2CH2CH2), 1.53-1.57 (m, 4H, 
NCH2CH2CH2), 2.42 (ddd, J 12 Hz, 6.0 Hz, 6.0 Hz, 1H, CH2=CHCH2), 2.55-2.71 (m, 
1H, CH2=CHCH2 and 4H, 2×NCH2), 2.75 (dd, J 13.3 Hz, 6.3 Hz, 1H, CH2Ph), 3.28 (dd, 
J 13.3 Hz, 6.3 Hz, 1H, CH2Ph), 4.10-4.17 (m, 2H, OCH2CH), 4.72 (m, 1H, CHCH2Ph), 
4.79 (dd, J 9.7 Hz, 5.1 Hz, 1H, COCHNR2), 5.02 (d, J 13.6 Hz, 1H, CH=CH2), 5.10 (d, 
J 13.6 Hz, 1H, CH=CH2), 5.77 (ddt, J 17.1 Hz, 10.1 Hz, 7.4 Hz, 1H, CH=CH2), 7.26-
7.35 (m, 5H, ArH). 13C NMR (100 MHz, CDCl3) C 24.6 (NCH2CH2CH2), 26.6 (2×CH2), 
30.9 (CH2CHN), 38.2 (CH2Ph), 50.4 (2×NCH2), 55.13 (NCHCH2Ph), 63.4 (COCHN), 
65.8 (CH2O), 117.42 (CH2=CH), 127.3 (ArCH), 128.9 (2×ArCH), 129.5 (2×ArCH), 
134.8 (ArC), 135.3 (CH2=CH), 153.0 (CO), 171.8 (CO). IR max (thin film, cm-1): 2928 
(CH), 1774 (CO), 1693(CO). MS m/z (ESI+) calculated for C20H26N2O3 [M+H]+; 








The second diastereoisomer  
1H NMR (400 MHz, CDCl3)H 1.39-1.41 (m, 2H, NCH2CH2CH2), 1.50-1.54 (m, 4H, 
NCH2CH2CH2), 2.44 (ddd, J 12.5 Hz, 6.1 Hz, 6.3 Hz, 1H, CH2=CHCH2), 2.56-2.66 (m, 
1H, CH2=CHCH2 and 4H, 2×NCH2), 2.69 (dd, J 13.3 Hz, 6.5 Hz, 1H, CH2Ph), 3.28 (dd, 
J 13.3 Hz, 6.5 Hz, 1H, CH2Ph), 4.12-4.19 (m, 2H, OCH2CH), 4.67 (m, 1H, CHCH2Ph), 
4.79 (dd, J 9.5 Hz, 5.2 Hz, 1H, COCHNR2), 5.06 (d, J 13.7 Hz, 1H, CH=CH2), 5.13 (d, 
J 13.7 Hz, 1H, CH=CH2), 5.84 (ddt, J 17.1 Hz, 10.1 Hz, 7.5 Hz, 1H, CH=CH2), 7.21-
7.34 (m, 5H, ArH). 13C NMR (100 MHz, CDCl3) C 24.4 (NCH2CH2CH2), 26.2 (2×CH2), 
31.5 (CH2CHN), 37.8 (CH2Ph), 50.6 (2×NCH2), 55.6 (NCHCH2Ph), 63.2 (COCHN), 
66.0 (CH2O), 117.8 (CH2=CH), 127.3 (ArCH), 128.9 (2×ArCH), 129.4 (2×ArCH), 135.4 
(ArC), 135.9 (CH2=CH), 153.1 (CO), 158.9 (CO). IR max (thin film, cm-1): 2927 (CH), 
1774 (CO), 1696(CO). MS m/z (ESI+) calculated for C20H26N2O3 [M+H]+; 343.2016 
found 343.2020. TLC Rf = 0.16 (PE:EtOAc, 4:1). HPLC tR = 10.2 min (95:5, Hex:IPA). 
(R)-4 benzyl-3-(dimethyl-L-phenylalanyl)oxazolidin-2-one (349a) and (R)-4-
benzyl-3-(dimethyl-D-phenylalanyl)oxazolidin-2-one (349b).  
 
Following procedure (H) above, the combined yield was isolated as oil (349a+349b = 
30 mg, 21%, Scheme 95). 
The first diastereoisomer  
1H NMR (400 MHz, CDCl3)H   2.50 (s, 6H, N(CH3)2), 2.67 (dd, J 13.1 Hz, 9.8 Hz, 1H, 
CH2Ph), 2.98 (dd, J 12.9 Hz, 5.1 Hz, 1H, CH2Ph), 3.09 (dd, J 12.8 Hz, 10.4 Hz, 1H, 
CH2Ph), 3.29 (dd, J 13.2 Hz, 3.2 Hz, 1H, CH2Ph), 3.78 (t, J 8.3 Hz, 1H, OCH2), 3.98 
(dd, J 8.9 Hz, 2.4 Hz, 1H, OCH2), 4.43 (td, J 10.1 Hz, 3.0 Hz, 1H, CH2CHNCO), 5.01 
(dd, J 10.3 Hz, 5.1 Hz, 1H, COCHN), 7.16-7.33 (m, 10H, ArCH). 13C NMR (100 MHz, 
CDCl3) C 33.3 (CH2Ar), 38.2 (CH2Ar), 41.6 (N(CH3)2), 55.3 CH2CHNCO), 64.7 
(COCHN), 65.8 (OCH2), 126.4 (2×ArCH), 127.3 (2×ArCH), 128.4 (2×ArCH), 128.9 
(2×ArCH), 129.3 (2×ArCH), 129.4 (2×ArCH), 135.3 (ArC), 137.8 (ArC), 152.8 (CO), 
172.2 (CO). TLC Rf = 0.35 (PE:EtOAc, 1:1). 




The second diastereoisomer  
1H NMR (400 MHz, CDCl3)H 2.48 (s, 6H, N(CH3)2), 2.94 (1H, CH2Ph and 2H, 
CH2Ph), 3.21 (dd, J 12.9 Hz, 10.6 Hz, 1H, CH2Ph), 4.06 (dd, J 9.0 Hz, 2.0 Hz, 1H, 
OCH2), 4.16 (dd, J 8.6 Hz, 8.2 Hz, 1H, OCH2), 4.66 (td, J 8.2 Hz, 8.0 Hz, 1H, 
CH2CHNCO), 5.12 (dd, J 10.3 Hz, 4.1 Hz, 1H, COCHN), 7.13-7.37 (m, 10H, ArCH). 
13C NMR (100 MHz, CDCl3) C 31.8 (CH2Ar), 37.2 (CH2Ar), 41.4 (N(CH3)2), 54.9 
CH2CHNCO), 64.4 (COCHN), 65.6 (OCH2), 126.5 (2×ArCH), 127.2 (2×ArCH), 128.4 
(2×ArCH), 128.8 (2×ArCH), 129.3 (2×ArCH), 129.6 (2×ArCH), 135.0 (ArC), 137.8 
(ArC), 152.8 (CO), 171.3 (CO). 
General procedure (I) for reaction of allyl iodide with diazo compounds. 
A solution of diazo (100 mg) in DME (10 mL) was added dropwise by syringe pump 
(0.397 mL.h-1) to solution of allyl iodide or allyl sulfide (5 eq) and Rh2(OAc)4 (5 mol%) 
in DME (3 mL). The solvent was removed to produce crude which was subjected to 
column chromatography. 
(2R)-1-((6R,7aR)-8,8-dimethyl-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo 
[c]isothiazol-1(4H)-yl)-2-iodopent-4-en-1-one (352a) and (2S)-1-((6R,7aR)-8,8-
dimethyl-2,2-dioxidotetrahydro-3H-3a,6 methanobenzo [c] isothiazol-1(4H)-yl)-
2-iodopent-4-en-1-one (352b).  
 
Following procedure (I) above, the combined yield was isolated as solid (352a+352b 
= 141 mg, 95%, Scheme 100, Table 29, Entry 6). 
The first diastereoisomer  
1H NMR (400 MHz, CDCl3)H 0.98 (s, 3H, C(CH3)2), 1.21 (s, 3H, C(CH3)2), 1.32-1.45 
(m, 2H, CH2CH2CHCH2), 1.85-2.21 (m, 5H, CH2CH2CHCH2), 2.75 (ddd, J 21.5 Hz, 
14.2 Hz, 7.2 Hz, 1H, CHCH2CH), 2.90 (ddd, J 21.5 Hz, 14.2 Hz, 7.2 Hz, 1H, 
CHCH2CH), 3.43 (d, J 13.7 Hz, 1H, CH2SO2), 3.51 (d, J 13.7 Hz, 1H, CH2SO2), 3.97 
(dd, J 7.4 Hz, 5.2 Hz, 1H, NCH), 4.99 (app t, J 7.3 Hz, 1H, CHI), 5.15 (d, J 1.8 Hz, 1H, 
CH2=CH), 5.18 (d, J 7.5 Hz, 1H, CH2=CH), 5.80 (ddt, J  16.8 Hz, 10.2 Hz, 6.7 Hz, 1H, 
CH=CH2). 13C NMR (100 MHz, CDCl3)C 19.9 (CCH3)2, 20.3 (CHI), 20.6 (CCH3)2, 




26.5 (CH2CH2CHCH2), 32.7 (CH2CH2CHCH2), 37.0 (CH2CH=CH2), 39.3 
(CH2CH2CHCH2), 44.3 (CH2CH2CHCH2), 47.8 (C(CH3)2), 48.7 (CCH2SO2), 53.0 
(CH2SO2), 64.8 (NCH), 118.8 (CH2CH=CH2), 134.5 (CH2CH=CH2), 169.5 (CO). IR max 
(thin film, cm-1): 2940 (CH), 1678 (CO), 1325, 1136 (SO2). MS m/z (ESI+) calculated 
for C15H22INO3S [M+H]+; 424.0438 found 424.0422. HPLC tR = 13.7 min (96:4, 
Hex:IPA). 
The second diastereoisomer  
1H NMR (400 MHz, CDCl3)H 0.96 (s, 3H, C(CH3)2), 1.12 (s, 3H, C(CH3)2), 1.32-1.43 
(m, 2H, CH2CH2CHCH2), 1.85-2.08 (m, 5H, CH2CH2CHCH2), 2.75 (ddd, J 21.5 Hz, 
14.2 Hz, 7.2 Hz, 1H, CHCH2CH), 2.90 (ddd, J 21.5 Hz, 14.2 Hz, 7.2 Hz, 1H, 
CHCH2CH), 3.47 (d, J 12.2 Hz, 1H, CH2SO2), 3.51 (d, J 12.2 Hz, 1H, CH2SO2), 3.86 
(app t, J 6.5 Hz, 1H, NCH), 4.94 (dd, J 9.2 Hz, 5.7 Hz, 1H, CHI), 5.15 (m, 2H, CH2=CH), 
5.71 (ddt, J 17.1 Hz, 10.1 Hz, 7.2 Hz, 1H, CH=CH2). 13C NMR (100 MHz, CDCl3)C 
19.1 (CCH3)2, 19.9 (CHI), 20.8 (CCH3)2, 26.3 (CH2CH2CHCH2), 32.9 
(CH2CH2CHCH2), 38.2 (CH2CH=CH2), 42.1 (CH2CH2CHCH2), 44.6 (CH2CH2CHCH2), 
47.8 (C(CH3)2), 48.6 (CCH2SO2), 52.6 (CH2SO2), 65.9 (NCH), 119.1 (CH2CH=CH2), 




isothiazol-1(4H)-yl)-2-iodo-4-methylpent-4-en-1-one (353b).  
 
Following procedure (I) above, the combined yield was isolated as solid (353a+353b 
= 135 mg, 90%, Scheme 101, Table 31, Entry 2). 
The first diastereoisomer  
1H NMR (400 MHz, CDCl3)H 0.97 (s, 3H, C(CH3)2), 1.21 (s, 3H, C(CH3)2), 1.31-1.48 
(m, 2H, CH2CH2CHCH2), 1.75 (s, 3H, CH2=C(CH3)CH2), 1.84-2.16 (m, 5H, 
CH2CH2CHCH2), 2.71 (dd, J 14.6 Hz, 7.4 Hz, 1H, CH2CHI), 2.91 (dd, J 14.6 Hz, 7.4 
Hz, 1H, CH2CHI), 3.43 (d, J 13.7 Hz, 1H, CH2SO2), 3.51 (d, J 13.7 Hz, 1H, CH2SO2), 




3.96 (dd, J 7.5 Hz, 5.0 Hz, 1H, NCH), 4.82 (s, 1H, CH2=CH), 4.88 (s, 1H, CH2=CH), 
5.14 (app t, J 7.2 Hz, 1H, CHI). 13C NMR (100 MHz, CDCl3)C 19.6 (CCH3)2, 19.9 
(CHI), 20.6 (CCH3)2, 22.1 CH2=C(CH3)CH2), 26.5 (CH2CH2CHCH2), 32.7 
(CH2CH2CHCH2), 37.0 (CH2CH=CH2), 43.2 (CH2CH2CHCH2), 44.3 (CH2CH2CHCH2), 
47.8 (C(CH3)2), 48.7 (CCH2SO2), 52.9 (CH2SO2), 64.8 (NCH), 114.42 
(CH2=C(CH3)CH2), 141.9 (CH2=C(CH3)CH2), 169.5 (CO). TLC Rf = 0.22 (PE:EtOAc, 
4:1). HPLC tR = 16.1 min (95:5, Hex:EtOH). 
The second diastereoisomer  
Partial characterisation was only possible, as the product was not isolated pure. 1H 
NMR (400 MHz, CDCl3)H 0.96 (s, 3H, C(CH3)2), 1.10 (s, 3H, C(CH3)2), 1.32-1.44 (m, 
2H, CH2CH2CHCH2), 1.76 (s, 3H, CH2=C(CH3)CH2), 1.84-2.07 (m, 5H, 
CH2CH2CHCH2), 2.71 (dd, J 13.8 Hz, 7.8 Hz, 1H, CH2CHI), 3.06 (dd, J 13.8 Hz, 7.8 
Hz, 1H, CH2CHI), 3.47 (d, J 4.4 Hz, 1H, CH2SO2), 3.49 (d, J 4.4 Hz, 1H, CH2SO2), 
3.86 (dd, J 6.5 Hz, 6.1 Hz, 1H, NCH), 4.79 (s, 1H, CH2=CH), 4.81 (s, 1H, CH2=CH), 
5.06 (dd, J 10.2 Hz, 5.2 Hz, 1H, CHI). HPLC tR = 21.1 min (95:5, Hex:EtOH). 
(2R)-2-azido-1-((6R,7aR)-8,8-dimethyl-2,2-dioxidotetrahydro-3H-3a,6-methan- 




The mixture of diastereoisomers of camphorsultam iodide (354) (0.295 g, 0.69 mmol) 
was dissolved in DMF (5 mL) and sodium azide (45.34 mg, 0.697 mmol) was added, 
the mixture was stirred at room temperature for 4 h, after which it was taken to the 
ethyl acetate and extracted with water (3×50 mL) and brine (1× 50 mL). The combined 
organic layers were dried using anhydrous MgSO4. The solvent was removed to 
produce crude which was subjected to column chromatography to afford (354a+354b 
= 0.165 g, 70%, Scheme 102, Table 32) total yield.  
 
 




The first diastereoisomer  
1H NMR (400 MHz, CDCl3)H 0.97 (s, 3H, C(CH3)2), 1.12 (s, 3H, C(CH3)2), 1.32-1.45 
(m, 2H, CH2CH2CHCH2), 1.87-2.12 (m, 5H, CH2CH2CHCH2), 2.59 (ddd, J 21.2 Hz, 
14.1 Hz, 7.2 Hz, 1H, CHCH2CHN3), 2.69 (ddd, J 21.2 Hz, 14.1 Hz, 7.2 Hz, 1H, 
CHCH2CHN3), 3.47 (d, J 13.8 Hz, 1H, CH2SO2), 3.52 (d, J 13.8 Hz, 1H, CH2SO2), 3.94 
(dd, J 7.6 Hz, 5.0 Hz, 1H, NCH), 4.42 (dd, J 7.1 Hz, 6.5 Hz, 1H, CHN3), 5.15 (d, J 10.0 
Hz, 1H, CH2=CH), 5.21 (d, J 17.0 Hz, 1H, CH2=CH), 5.80 (ddt, J  17.2 Hz, 10.0 Hz, 
7.0 Hz, 1H, CH=CH2). 13C NMR (100 MHz, CDCl3)C 19.8 (CCH3)2, 20.7 (CCH3)2, 
26.3 (CH2CH2CHCH2), 32.8 (CH2CH2CHCH2), 36.7 (CH2CH=CH2), 38.0 
(CH2CH2CHCH2), 44.5 (CH2CH2CHCH2), 47.8 (C(CH3)2), 48.7 (CCH2SO2), 52.9 
(CH2SO2), 60.3 (CHN3), 65.2 (NCH), 119.6 (CH2CH=CH2), 131.6 (CH2CH=CH2), 
169.5 (CO). IR max /cm-1: 2952 (CH), 2101 (C=N3), 1688 (CO), 1323, 1135 (SO2). MS 
m/z (ESI+) calculated for C15H22N4O3S [M+Na]+; 361.1305 found 361.1311. TLC Rf = 
0.17 (PE:EtOAc, 4:1). 
The second diastereoisomer  
1H NMR (400 MHz, CDCl3)H 0.97 (s, 3H, C(CH3)2), 1.12 (s, 3H, C(CH3)2), 1.32-1.45 
(m, 2H, CH2CH2CHCH2), 1.87-2.12 (m, 5H, CH2CH2CHCH2), 2.59 (ddd, J 21.2 Hz, 
14.1 Hz, 7.2 Hz, 1H, CHCH2CHN3), 2.69 (ddd, J 21.2 Hz, 14.1 Hz, 7.2 Hz, 1H, 
CHCH2CHN3), 3.48 (d, J 7.6 Hz, 1H, CH2SO2), 3.51 (d, J 7.6 Hz, 1H, CH2SO2), 3.86-
3.93 (m, 1H, NCH), 4.34 (dd, J 8.6 Hz, 5.4 Hz, 1H, CHN3), 5.15 (d, J 10.0 Hz, 1H, 
CH2=CH), 5.24 (d, J 15.5 Hz, 1H, CH2=CH), 5.80 (ddt, J  17.2 Hz, 10.0 Hz, 7.0 Hz, 
1H, CH=CH2). 13C NMR (100 MHz, CDCl3)C 20.8 (CCH3)2, 22.1 (CCH3)2, 26.4 
(CH2CH2CHCH2), 31.9 (CH2CH2CHCH2), 34.5 (CH2CH=CH2), 38.2 (CH2CH2CHCH2), 
44.7 (CH2CH2CHCH2), 47.8 (C(CH3)2), 48.8 (CCH2SO2), 53.0 (CH2SO2), 60.2 (CHN3), 

















Following procedure (I) above, the combined yield was isolated as solid (355a+355b 
= 114.5 mg, 80%, Scheme 103, Table 33). 
The first diastereoisomer  
1H NMR (400 MHz, CDCl3)H 0.93 (s, 3H, C(CH3)2), 1.00 (s, 3H, C(CH3)2), 1.33-1.41 
(m, 2H, CH2CH2CHCH2), 1.84-2.02 (m, 5H, CH2CH2CHCH2), 2.47 (ddd, J 21.5 Hz, 
14.3 Hz, 7.1 Hz, 1H, CHCH2CHSPh), 2.68 (ddd, J 21.5 Hz, 14.3 Hz, 7.1 Hz, 1H, 
CHCH2CHSPh), 3.40 (d, J 13.7 Hz, 1H, CH2SO2), 3.47 (d, J 13.7 Hz, 1H, CH2SO2), 
3.88 (dd, J 7.6 Hz, 5.0 Hz, 1H, NCH), 4.34 (dd, J 6.6 Hz, 6.2 Hz, 1H, CHSPh), 5.09 
(d, J 11.2 Hz, 1H, CH2=CH), 5.13 (d, J 17.1 Hz, 1H, CH2=CH), 5.83 (ddt, J  17.1 Hz, 
10.1 Hz, 7.0 Hz, 1H, CH=CH2), 7.28-7.30 (m, 3H, ArCH), 7.49-7.51 (m, 2H, ArCH). 
13C NMR (100 MHz, CDCl3)C 19.8 (CCH3)2, 20.7 (CCH3)2, 26.4 (CH2CH2CHCH2), 
32.8 (CH2CH2CHCH2), 35.4 (CH2CH=CH2), 38.2 (CH2CH2CHCH2), 44.6 
(CH2CH2CHCH2), 47.7 (C(CH3)2), 48.3 (CCH2SO2), 49.5 (CHSPh), 53.1 (CH2SO2), 
65.1 (NCH), 118.2 (CH2CH=CH2), 128.6 (ArCH), 128.8 (4×ArCH), 133.8 (ArC), 134.8 
(CH2CH=CH2), 170.3 (CO). IR max /cm-1: 2922 (CH), 1689 (CO), 1330, 1132 (SO2). 
MS m/z (ESI+) calculated for C21H27NO3S2 [M+H]+; 406.1505 found 406.1511. TLC Rf 
= 0.20 (PE:EtOAc, 4:1). 
The second diastereoisomer  
1H NMR (400 MHz, CDCl3)H 0.96 (s, 3H, C(CH3)2), 1.13 (s, 3H, C(CH3)2), 1.25-1.43 
(m, 2H, CH2CH2CHCH2), 1.84-2.09 (m, 5H, CH2CH2CHCH2), 2.61 (ddd, J 20.9 Hz, 
14.1 Hz, 6.8 Hz, 1H, CHCH2CHSPh), 2.68 (ddd, J 20.9 Hz, 14.1 Hz, 6.8 Hz, 1H, 
CHCH2CHSPh), 3.45 (d, J 13.8 Hz, 1H, CH2SO2), 3.50 (d, J 13.8 Hz, 1H, CH2SO2), 
3.93 (dd, J 6.7 Hz, 6.1 Hz, 1H, NCH), 4.45 (dd, J 7.8 Hz, 5.7 Hz, 1H, CHSPh), 5.04 
(d, J 10.2 Hz, 1H, CH2=CH), 5.10 (d, J 17.1 Hz, 1H, CH2=CH), 5.79 (ddt, J  16.8 Hz, 




10.1 Hz, 6.5 Hz, 1H, CH=CH2), 7.28-7.33 (m, 3H, ArCH), 7.53-7.55 (m, 2H, ArCH). 
13C NMR (100 MHz, CDCl3)C 19.9 (CCH3)2, 20.8 (CCH3)2, 26.3 (CH2CH2CHCH2), 
32.8 (CH2CH2CHCH2), 38.2 (CH2CH=CH2), 38.3 (CH2CH2CHCH2), 44.5 
(CH2CH2CHCH2), 47.7 (C(CH3)2), 48.4 (CCH2SO2), 50.6 (CHSPh),  53.0 (CH2SO2), 
65.6 (NCH), 118.5 (CH2CH=CH2), 128.1 (ArCH), 128.9 (2×ArCH), 132.6 (ArC),  133.4 
(CH2CH=CH2), 133.9 (2×ArCH), 169.9 (CO). IR max /cm-1: 2957 (CH), 1670 (CO), 
1356, 1137 (SO2). MS m/z (ESI+) calculated for C21H27NO3S2 [M+H]+; 406.1505 found 
406.1512. 
Ethyl 2-(((2R)-1-((6R,7aR)-8,8-dimethyl-2,2-dioxidotetrahydro-3H-3a,6-methano- 




Following procedure (I) above, the combined yield was isolated as solid (356a+356b 
= 41 mg, 28%, Scheme 103, Table 33). 
The first diastereoisomer  
m.p.= 97-99 °C. 1H NMR (400 MHz, CDCl3)H 0.97 (s, 3H, C(CH3)2), 1.20 (s, 3H, 
C(CH3)2), 1.27 (t, J 7.2 Hz, 3H, COOCH2CH3) 1.31-1.44 (m, 2H, CH2CH2CHCH2), 
1.85-2.16 (m, 5H, CH2CH2CHCH2), 2.53 (ddd, J 21.6 Hz, 14.1 Hz, 6.9 Hz, 1H, 
CHCH2CHSCH2), 2.74 (ddd, J 21.6 Hz, 14.1 Hz, 6.9 Hz, 1H, CHCH2CHSCH2), 3.33-
3.52 (2H, CH2SO2 and 2H, COCH2S), 3.91 (dd, J 7.6 Hz, 4.9 Hz, 1H, NCH), 4.02 (app 
t, J 7.0 Hz, 1H, COCHSCH2), 4.17 (q, J 7.1 Hz, 2H, COOCH2), 5.09 (d, J 10.1 Hz, 1H, 
CH2=CH), 5.15 (d, J 17.0 Hz, 1H, CH2=CH), 5.80 (ddt, J  17.0 Hz, 10.0 Hz, 6.8 Hz, 
1H, CH=CH2). 13C NMR (100 MHz, CDCl3)C 14.1 (COOCH2CH3), 19.9 (CCH3)2, 20.7 
(CCH3)2, 26.5 (CH2CH2CHCH2), 32.0 (SCH2COO), 32.7 (CH2CH2CHCH2), 35.1 
(CH2CH=CH2), 37.9 (CH2CH2CHCH2), 44.6 (CH2CH2CHCH2), 45.7 (COCHS), 47.8 
(C(CH3)2), 48.5 (CCH2SO2), 53.1 (CH2SO2), 61.5 (COOCH2CH3), 65.0 (NCH), 118.2 
(CH2CH=CH2), 133.6 (CH2CH=CH2), 169.7 (CO), 170.0 (CO). IR max /cm-1: 2942 
(CH), 1731 (CO), 1323, 1133 (SO2). MS m/z (ESI+) calculated for C19H29NO5S2 




[M+Na]+; 438.1379 found 438.1377. TLC Rf = 0.27 (PE:EtOAc, 7:3). HPLC tR = 11.5 
min (90:10, Hex:IPA). 
The second diastereoisomer  
m.p.= 72-74 °C. 1H NMR (400 MHz, CDCl3)H 0.95 (s, 3H, C(CH3)2), 1.12 (s, 3H, 
C(CH3)2), 1.27 (t, J 7.2 Hz, 3H, COOCH2CH3) 1.31-1.45 (m, 2H, CH2CH2CHCH2), 
1.84-2.08 (m, 5H, CH2CH2CHCH2), 2.63 (ddd, J 21.0 Hz, 14.0 Hz, 7.0 Hz, 1H, 
CHCH2CHSCH2), 2.70 (ddd, J 21.0 Hz, 14.0 Hz, 7.0 Hz, 1H, CHCH2CHSCH2), 3.38-
3.52 (2H, CH2SO2 and 2H, COCH2S), 3.92 (dd, J 6.5 Hz, 6.5 Hz, 1H, NCH), 4.17 (q, 
J 7.0 Hz, 2H, COOCH2), 4.23 (dd, J 8.3 Hz, 5.9 Hz, 1H, COCHSCH2), 5.04 (d, J 10.2 
Hz, 1H, CH2=CH), 5.12 (d, J 17.0 Hz, 1H, CH2=CH), 5.80 (ddt, J  16.8 Hz, 10.1 Hz, 
6.2 Hz, 1H, CH=CH2). 13C NMR (100 MHz, CDCl3)C 14.1 (COOCH2CH3), 19.9 
(CCH3)2, 20.8 (CCH3)2, 26.3 (CH2CH2CHCH2), 32.8 (SCH2COO), 32.9 
(CH2CH2CHCH2), 38.0 (CH2CH=CH2), 38.2 (CH2CH2CHCH2), 44.6 (CH2CH2CHCH2), 
46.6 (COCHS), 47.7 (C(CH3)2), 48.4 (CCH2SO2), 53.0 (CH2SO2), 61.5 (COOCH2CH3), 
65.6 (NCH), 118.5 (CH2CH=CH2), 133.3 (CH2CH=CH2), 170.0 (CO), 170.4 (CO). IR 
max /cm-1: 2941 (CH), 1731 (CO), 1327, 1133 (SO2). MS m/z (ESI+) calculated for 
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Ar (2S)-product (major)  (2R)-product (minor) 
313a/314a H 4.19 (t, J 7.5 Hz, 1H) 4.17 (t, J 7.0 Hz, 1H) 
313b/314b 4-OMe 4.13 (t, J 7.5 Hz, 1H) 4.12 (t, J 7.5 Hz, 1H)  
313c/314c 4-COMe 4.21 (t, J 7.5 Hz 1H) 4.19 (t, J 7.2 Hz, 1H) 
313d/314d 2,5-diF 4.17 (dd, J 7.0, 6.5, 1H) 4.18 (t, J 7.0 Hz, 1H) 
313e/314e 4-COPh 4.25 (t, J 7.4 Hz, 1H) 4.22 (t, J 6.8 Hz, 1H) 
313f/314f 4-COOMe 4.20 (t, J 7. Hz, 1H) 4.18 (t, J 6.8 Hz, 1H) 
313g/314g 2,4-diF 4.16 (dd, J 8.2, 6.6 Hz, 1H) 4.15 (t, J 7.1 Hz, 1H) 
313h/314h 3,5-diF 4.15 (t, J 7.5 Hz, 1H) 4.13 (t, J 6.7 Hz, 1H) 
313i/314i 2,4,6-triF 4.18 (dd, J 9.5, 5.1 Hz, 1H) 4.24 (t, J 7.3 Hz, 1H), 
313j/314j 3-F 4.17 (t, J 7.5 Hz, 1H) 4.15 (t, J 7.1 Hz, 1H) 
313k/314k 4-Ph 4.21 (t, J 7.5 Hz, 1H) 4.22 (t, J 6.5 Hz, 1H) 














Ar (2S)-product (major)  (2R)-product (minor) 
313a/314a 
H 
2.97 (dd, J 13.2, 7.5, 1H)  
3.08 (dd, J 13.2, 7.5, 1H) 
2.88 (dd, J 14.0, 7.2, 1H) 
3.04 (dd, J 14.0, 7.2, 1H) 
313b/314b 
4-OMe 
2.92 (dd, J 13.3, 7.6, 1H)  
3.01 (dd, J 13.3, 7.6, 1H) 
2.83 (dd, J 14.1, 7.2, 1H) 
2.97 (dd, J 14.1, 7.2, 1H) 
313c/314c 
4-COMe 
3.02 (dd, J 13.2, 7.5, 1H)  
3.13 (dd, J 13.2, 7.5, 1H) 
2.94 (dd, J 14.0, 7.2, 1H)  
3.07 (dd, J 14.0, 7.2, 1H) 
313d/314d 
2,5-diF 
2.96 (dd, J 13.4, 7.3, 1H) 
3.11 (dd, J 13.4, 7.3, 1H) 
2.93 (dd, J 14.0, 7.2, 1H)  
3.02 (dd, J 14.0, 7.2, 1H) 
313e/314e 
4-COPh 
3.07 (dd, J 13.2, 7.4, 1H) 
3.17 (dd, J 13.2, 7.4, 1H) 
2.98 (dd, J 13.8, 7.2, 1H)  
3.10 (dd, J 13.8, 7.2, 1H) 
313f/314f 
4-COOMe 
3.01 (dd, J 13.2, 7.5, 1H)  
3.12 (dd, J 13.2, 7.5, 1H) 
2.93 (dd, J 13.9, 7.2, 1H)  
3.07 (dd, J 13.9, 7.2, 1H) 
313g/314g 
2,4-diF 
2.97 (dd, J 13.3, 7.6, 1H) 
3.09 (dd, J 13.3, 7.6, 1H) 
2.93 (dd, J 14.0, 7.2, 1H)  
3.00 (dd, J 14.0, 7.2, 1H) 
313h/314h 
3,5-diF 
2.93 (dd, J 13.4, 7.5, 1H) 
3.05 (dd, J 13.4, 7.5, 1H) 
2.86 (dd, J 14.1, 6.6, 1H)  
2.98 (dd, J 14.1, 6.6, 1H) 
313i/314i 
2,4,6-triF 
2.96 (dd, J 13.4, 7.5, 1H)  
3.17 (dd, J 13.4, 7.5, 1H) 
2.96 (dd, J 14.1, 7.4, 1H) 
3.03 (dd, J 14.1, 7.4, 1H) 
313j/314j 
3-F 
2.96 (dd, J 13.3, 7.5, 1H) 
3.07 (dd, J 13.3, 7.5, 1H) 
2.87 (dd, J 14.1, 7.2, 1H)  
3.02 (dd, J 14.1, 7.2, 1H) 
313k/314k 
4-Ph 
3.00 (dd, J 13.2, 7.6, 1H)  
3.09 (dd, J 13.2, 7.6, 1H) 
2.94 (dd, J 14.1, 7.2, 2H)  
3.06 (dd, J 14.1, 7.2, 2H) 
313l/314l 
2-CN 
3.23 (dd, J 13.6, 7.4, 2H)  
3.30 (dd, J 13.6, 7.4, 2H) 
3.15 (dd, J 14.1, 7.0, 1H) 













Ar (2S)-product (major)  (2R)-product (minor) 
313a/314a 
H 3.37 (s, 2H) 
3.37 (d, J 13.7, 1H) 
3.46 (d, J 13.7, 1H) 
313b/314b 
4-OMe 3.37 (s, 2H) 
3.38 (d, J 13.7, 1H) 
3.47 (d, J 13.7, 1H) 
313c/314c 
4-COMe 3.38 (s, 2H) 
3.38 (d, J 13.7, 1H) 
3.468 (d, J 13.7, 1H) 
313d/314d 
2,5-diF 3.38 (s, 2H) 
3.36 (d, J 13.6, 1H) 
3.46 (d, J 13.7, 1H) 
313e/314e 
4-COPh 3.39 (s, 2H) 
3.38 (d, J 13.6, 1H) 
3.49 (d, J 13.7, 1H) 
313f/314f 
4-COOMe 3.37 (s, 2H) 
3.37 (d, J 13.7, 1H)  
3.47 (d, J 13.7, 1H) 
313g/314g 
2,4-diF 3.37 (s, 2H) 
3.36 (d, J 13.7, 1H) 
3.46 (d, J 13.7, 1H) 
313h/314h 
3,5-diF 3.37 (s, 2H) 
3.39 (d, J 13.7, 1H) 
3.49 (d, J 13.7, 1H) 
313i/314i 
2,4,6-triF 3.36 (s, 2H) 
3.36 (d, J 13.6, 1H) 
3.46 (d, J 13.6, 1H) 
313j/314j 
3-F 3.39 (s, 2H) 
3.38 (d, J 13.7, 1H) 
3.48 (d, J 13.7, 1H) 
313k/314k 
4-Ph 3.37 (s, 2H) 
3.40 (d, J 13.7, 1H) 
3.48 (d, J 13.6, 1H) 
313l/314l 
2-CN 3.37 (s, 2H) 
3.34 (d, J 13.7, 1H) 
3.44 (d, J 13.7, 1H) 





















































































































































































































































































































































































































































































































           





























































































































































































































































































































































































































































































































































































































































































































               
    
                   
       
















































































































































































































































































































               




















             





































































































































[ ] ppm  7   6   5   4   3   2   1  
Hm exp cam 12 R crude 












































































































































              




















              
